1	-LSB-	-lsb-	-LRB-	_	2	punct
2	Interaction	interaction	NN	_	0	ROOT
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-RSB-	-rsb-	-RRB-	_	2	punct
8	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interaction	interaction	NN	_	11	nsubj
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	11	aux
9	been	be	VBN	_	11	cop
10	the	the	DT	_	11	det
11	subject	subject	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	much	much	JJ	_	14	amod
14	study	study	NN	_	11	nmod
15	in	in	IN	_	17	case
16	recent	recent	JJ	_	17	amod
17	years	year	NNS	_	11	nmod
18	.	.	.	_	11	punct

1	Contradictory	contradictory	JJ	_	2	amod
2	results	result	NNS	_	0	ROOT
3	regarding	regard	VBG	_	5	case
4	the	the	DT	_	5	det
5	effect	effect	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	on	on	IN	_	10	case
9	platelet	platelet	NN	_	10	compound
10	reactivity	reactivity	NN	_	5	nmod
11	and	and	CC	_	5	cc
12	on	on	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	outcome	outcome	NN	_	5	conj
15	in	in	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	-	-	:	_	5	punct
18	treated	treated	JJ	_	19	amod
19	patients	patient	NNS	_	22	nsubjpass
20	have	have	VBP	_	22	aux
21	been	be	VBN	_	22	auxpass
22	reported	report	VBN	_	5	acl:relcl
23	in	in	IN	_	24	case
24	literature	literature	NN	_	22	nmod
25	.	.	.	_	2	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	was	be	VBD	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	decrease	decrease	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	exposure	exposure	NN	_	10	dobj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	AUC	auc	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	to	to	TO	_	20	case
17	clopidogrel	clopidogrel	NN	_	20	nmod:poss
18	's	's	POS	_	17	case
19	active	active	JJ	_	20	amod
20	metabolite	metabolite	NN	_	12	nmod
21	by	by	IN	_	23	case
22	50	50	CD	_	23	nummod
23	%	%	NN	_	10	nmod
24	and	and	CC	_	10	cc
25	to	to	TO	_	27	mark
26	sharply	sharply	RB	_	27	advmod
27	increase	increase	VB	_	10	conj
28	platelet	platelet	NN	_	29	compound
29	reactivity	reactivity	NN	_	27	dobj
30	,	,	,	_	10	punct
31	as	as	IN	_	33	case
32	a	a	DT	_	33	det
33	result	result	NN	_	10	nmod
34	of	of	IN	_	35	case
35	inhibition	inhibition	NN	_	33	nmod
36	by	by	IN	_	37	case
37	drug3	drug3	NN	_	35	nmod
38	of	of	IN	_	39	case
39	CYP2C19	cyp2c19	NN	_	37	nmod
40	,	,	,	_	39	punct
41	a	a	DT	_	43	det
42	cytochrome	cytochrome	NN	_	43	compound
43	P450	p450	NN	_	47	compound
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	CYP	cyp	NN	_	43	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	enzyme	enzyme	NN	_	39	appos
48	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	a	a	DT	_	6	det
4	much	much	JJ	_	6	amod
5	weaker	weaker	JJR	_	6	amod
6	effect	effect	NN	_	2	dobj
7	on	on	IN	_	10	case
8	drug2	drug2	NN	_	10	nmod:poss
9	's	's	POS	_	8	case
10	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
11	and	and	CC	_	10	cc
12	on	on	IN	_	14	case
13	platelet	platelet	NN	_	14	compound
14	reactivity	reactivity	NN	_	10	conj
15	during	during	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	use	use	NN	_	14	nmod
18	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	influence	influence	NN	_	16	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	2	nmod
7	when	when	WRB	_	8	advmod
8	used	use	VBN	_	2	acl:relcl
9	simultaneously	simultaneously	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	has	have	VBZ	_	16	aux
13	not	not	RB	_	16	neg
14	yet	yet	RB	_	16	advmod
15	been	be	VBN	_	16	auxpass
16	investigated	investigate	VBN	_	0	ROOT
17	in	in	IN	_	20	case
18	adequately	adequately	RB	_	19	advmod
19	randomized	randomize	VBN	_	20	amod
20	studies	study	NNS	_	16	nmod
21	.	.	.	_	16	punct

1	Regulatory	regulatory	JJ	_	2	amod
2	agencies	agency	NNS	_	3	nsubj
3	state	state	VBP	_	0	ROOT
4	that	that	IN	_	18	mark
5	the	the	DT	_	6	det
6	combination	combination	NN	_	18	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	CYP2C19	cyp2c19	NN	_	12	compound
12	inhibitors	inhibitor	NNS	_	8	conj
13	drug2	drug2	NN	_	12	dep
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	3	ccomp
19	.	.	.	_	3	punct

1	To	to	TO	_	2	case
2	date	date	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	is	be	VBZ	_	0	ROOT
6	no	no	DT	_	8	neg
7	conclusive	conclusive	JJ	_	8	amod
8	evidence	evidence	NN	_	5	nsubj
9	of	of	IN	_	12	case
10	a	a	DT	_	12	det
11	clinically-relevant	clinically-relevant	JJ	_	12	amod
12	interaction	interaction	NN	_	8	nmod
13	between	between	IN	_	14	case
14	any	any	DT	_	12	nmod
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	drug1	drug1	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	.	.	.	_	5	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	1	punct
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	9	advmod
9	and	and	CC	_	1	advmod
10	in	in	FW	_	11	compound
11	vivo	vivo	FW	_	9	advmod
12	,	,	,	_	1	punct
13	in	in	IN	_	17	case
14	human	human	JJ	_	17	amod
15	A375	a375	NN	_	17	compound
16	melanoma	melanoma	NN	_	17	compound
17	cells	cell	NNS	_	1	nmod
18	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	mechanisms	mechanism	NNS	_	2	dobj
4	of	of	IN	_	5	case
5	interaction	interaction	NN	_	3	nmod
6	between	between	IN	_	10	case
7	the	the	DT	_	10	det
8	alkyating	alkyating	JJ	_	10	amod
9	agent	agent	NN	_	10	compound
10	drug1	drug1	NN	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	and	and	CC	_	10	cc
15	the	the	DT	_	18	det
16	pro-oxidant	pro-oxidant	JJ	_	18	amod
17	,	,	,	_	18	punct
18	drug3	drug3	NN	_	10	conj
19	,	,	,	_	2	punct
20	in	in	IN	_	26	case
21	the	the	DT	_	26	det
22	human	human	JJ	_	26	amod
23	A375	a375	NN	_	26	compound
24	melanoma	melanoma	NN	_	26	compound
25	cell	cell	NN	_	26	compound
26	line	line	NN	_	2	nmod
27	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	alone	alone	RB	_	4	conj
9	and	and	CC	_	4	cc
10	in	in	IN	_	11	case
11	combination	combination	NN	_	4	conj
12	,	,	,	_	2	punct
13	was	be	VBD	_	14	auxpass
14	evaluated	evaluate	VBN	_	0	ROOT
15	for	for	IN	_	17	case
16	growth	growth	NN	_	17	compound
17	inhibition	inhibition	NN	_	14	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	MTT	mtt	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	17	punct
22	radiolabeled	radiolabele	VBN	_	24	amod
23	drug	drug	NN	_	24	compound
24	uptake	uptake	NN	_	17	conj
25	,	,	,	_	17	punct
26	cellular	cellular	JJ	_	28	amod
27	thiol	thiol	NN	_	28	compound
28	content	content	NN	_	17	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	HPLC	hplc	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	,	,	,	_	17	punct
33	and	and	CC	_	17	cc
34	DNA	dna	NN	_	36	compound
35	strand	strand	NN	_	36	compound
36	breaks	break	NNS	_	17	conj
37	-LRB-	-lrb-	-LRB-	_	39	punct
38	Comet	comet	NN	_	39	compound
39	assay	assay	NN	_	36	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	.	.	.	_	14	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	antitumor	antitumor	JJ	_	1	conj
4	effects	effect	NNS	_	1	dep
5	were	be	VBD	_	6	auxpass
6	evaluated	evaluate	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	mice	mouse	NNS	_	6	nmod
9	.	.	.	_	6	punct

1	Growth	growth	NN	_	2	compound
2	inhibition	inhibition	NN	_	6	nsubj
3	in	in	FW	_	4	compound
4	vitro	vitro	FW	_	2	advmod
5	was	be	VBD	_	6	cop
6	additive	additive	JJ	_	0	ROOT
7	with	with	IN	_	10	case
8	the	the	DT	_	10	det
9	two	two	CD	_	10	nummod
10	drugs	drug	NNS	_	6	nmod
11	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	on	on	IN	_	7	case
6	drug	drug	NN	_	7	compound
7	uptake	uptake	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	number	number	NN	_	7	conj
12	of	of	IN	_	15	case
13	DNA	dna	NN	_	15	compound
14	strand	strand	NN	_	15	compound
15	breaks	break	NNS	_	11	nmod
16	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	a	a	DT	_	7	det
4	>	>	JJR	_	5	advmod
5	75	75	CD	_	6	dep
6	%	%	NN	_	7	dep
7	reduction	reduction	NN	_	2	nsubj
8	in	in	IN	_	10	case
9	cellular	cellular	JJ	_	10	amod
10	glutathione	glutathione	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	cysteine	cysteine	NN	_	10	conj
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	7	nmod
15	but	but	CC	_	16	cc
16	not	not	RB	_	14	cc
17	drug2	drug2	NN	_	14	conj
18	.	.	.	_	2	punct

1	Co-administration	co-administration	NN	_	8	nsubj
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	two	two	CD	_	5	nummod
5	drugs	drug	NNS	_	1	nmod
6	in	in	IN	_	7	case
7	mice	mouse	NNS	_	5	nmod
8	caused	cause	VBD	_	0	ROOT
9	an	a	DT	_	10	det
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	area	area	NN	_	10	nmod
14	under	under	IN	_	16	case
15	the	the	DT	_	16	det
16	curve	curve	NN	_	10	nmod
17	of	of	IN	_	19	case
18	both	both	CC	_	19	det
19	drugs	drug	NNS	_	16	nmod
20	,	,	,	_	8	punct
21	but	but	CC	_	8	cc
22	the	the	DT	_	23	det
23	combination	combination	NN	_	26	nsubj
24	was	be	VBD	_	26	cop
25	not	not	RB	_	26	neg
26	effective	effective	JJ	_	8	conj
27	in	in	IN	_	28	mark
28	reducing	reduce	VBG	_	26	advcl
29	human	human	JJ	_	32	amod
30	A375	a375	NN	_	32	compound
31	melanoma	melanoma	NN	_	32	compound
32	tumors	tumor	NNS	_	28	dobj
33	in	in	FW	_	34	compound
34	vivo	vivo	FW	_	28	advmod
35	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	show	show	VBP	_	0	ROOT
5	additive	additive	JJ	_	6	amod
6	effects	effect	NNS	_	4	dobj
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	4	advmod
9	but	but	CC	_	10	cc
10	not	not	RB	_	8	cc
11	in	in	FW	_	12	compound
12	vivo	vivo	FW	_	8	conj
13	in	in	IN	_	17	case
14	human	human	JJ	_	17	amod
15	A375	a375	NN	_	17	compound
16	melanoma	melanoma	NN	_	17	compound
17	cells	cell	NNS	_	4	nmod
18	.	.	.	_	4	punct

1	Enhancement	enhancement	NN	_	0	ROOT
2	of	of	IN	_	5	case
3	humoral	humoral	JJ	_	5	amod
4	immune	immune	JJ	_	5	amod
5	responses	response	NNS	_	1	nmod
6	to	to	TO	_	9	case
7	inactivated	inactivate	VBN	_	9	amod
8	Newcastle	Newcastle	NNP	_	9	compound
9	disease	disease	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	drug1	drug1	NN	_	9	conj
12	by	by	IN	_	14	case
13	oral	oral	JJ	_	14	amod
14	administration	administration	NN	_	1	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	in	in	IN	_	18	case
18	chickens	chicken	NNS	_	14	nmod
19	.	.	.	_	1	punct

1	Newcastle	newcastle	JJ	_	2	amod
2	disease	disease	NN	_	13	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	ND	nd	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	and	and	CC	_	2	cc
7	avian	avian	JJ	_	8	amod
8	influenza	influenza	NN	_	2	conj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	AI	ai	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	are	be	VBP	_	13	cop
13	common	common	JJ	_	0	ROOT
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	poultry	poultry	NN	_	17	compound
17	industry	industry	NN	_	13	nmod
18	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	objective	objective	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	of	of	IN	_	13	case
12	oral	oral	JJ	_	13	amod
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug2	drug2	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	on	on	IN	_	23	case
20	the	the	DT	_	23	det
21	humoral	humoral	JJ	_	23	amod
22	immune	immune	JJ	_	23	amod
23	responses	response	NNS	_	10	nmod
24	of	of	IN	_	25	case
25	chickens	chicken	NNS	_	23	nmod
26	to	to	TO	_	27	case
27	drug3	drug3	NN	_	23	nmod
28	and	and	CC	_	27	cc
29	drug4	drug4	NN	_	30	compound
30	drug4	drug4	NN	_	27	conj
31	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	experiment	experiment	NN	_	31	nmod
3	1	1	CD	_	2	nummod
4	,	,	,	_	31	punct
5	oral	oral	JJ	_	6	amod
6	administration	administration	NN	_	31	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	at	at	IN	_	11	case
10	a	a	DT	_	11	det
11	dose	dose	NN	_	6	nmod
12	of	of	IN	_	14	case
13	5	5	CD	_	14	nummod
14	mg/kg	mg/kg	NN	_	11	nmod
15	of	of	IN	_	16	case
16	BW	bw	NN	_	14	nmod
17	for	for	IN	_	19	case
18	7	7	CD	_	19	nummod
19	d	d	NN	_	6	nmod
20	on	on	IN	_	23	case
21	the	the	DT	_	23	det
22	immune	immune	JJ	_	23	amod
23	response	response	NN	_	19	nmod
24	in	in	IN	_	25	case
25	chickens	chicken	NNS	_	23	nmod
26	intramuscularly	intramuscularly	RB	_	27	advmod
27	injected	inject	VBN	_	25	acl
28	with	with	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	was	be	VBD	_	31	auxpass
31	evaluated	evaluate	VBN	_	0	ROOT
32	.	.	.	_	31	punct

1	Results	result	NNS	_	2	nsubj
2	showed	show	VBD	_	0	ROOT
3	that	that	IN	_	6	mark
4	drug1	drug1	NN	_	6	nsubj
5	significantly	significantly	RB	_	6	advmod
6	increased	increase	VBD	_	2	ccomp
7	the	the	DT	_	9	det
8	antibody	antibody	NN	_	9	compound
9	level	level	NN	_	6	dobj
10	against	against	IN	_	11	case
11	ND	nd	NN	_	9	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	serum	serum	NN	_	9	nmod
15	of	of	IN	_	16	case
16	chickens	chicken	NNS	_	14	nmod
17	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	experiment	experiment	NN	_	11	nmod
3	2	2	CD	_	2	nummod
4	,	,	,	_	11	punct
5	the	the	DT	_	7	det
6	same	same	JJ	_	7	amod
7	regimen	regimen	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	0	ROOT
12	to	to	TO	_	13	case
13	chickens	chicken	NNS	_	11	nmod
14	inoculated	inoculate	VBN	_	13	acl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	11	punct
18	and	and	CC	_	11	cc
19	an	a	DT	_	23	det
20	enhanced	enhance	VBN	_	23	amod
21	serum	serum	NN	_	23	compound
22	antibody	antibody	NN	_	23	compound
23	response	response	NN	_	29	nsubjpass
24	to	to	TO	_	26	case
25	AI	AI	NNP	_	26	compound
26	vaccination	vaccination	NN	_	23	nmod
27	was	be	VBD	_	29	auxpass
28	also	also	RB	_	29	advmod
29	observed	observe	VBN	_	11	conj
30	.	.	.	_	11	punct

1	Considering	consider	VBG	_	23	advcl
2	the	the	DT	_	3	det
3	safety	safety	NN	_	1	dobj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	1	punct
7	because	because	IN	_	12	mark
8	no	no	DT	_	10	neg
9	adverse	adverse	JJ	_	10	amod
10	effect	effect	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	found	find	VBN	_	1	advcl
13	throughout	throughout	IN	_	15	case
14	the	the	DT	_	15	det
15	experiments	experiment	NNS	_	12	nmod
16	,	,	,	_	23	punct
17	drug2	drug2	NN	_	23	nsubj
18	may	may	MD	_	23	aux
19	be	be	VB	_	23	cop
20	a	a	DT	_	23	det
21	promising	promising	JJ	_	23	amod
22	oral	oral	JJ	_	23	amod
23	adjuvant	adjuvant	JJ	_	0	ROOT
24	to	to	TO	_	25	mark
25	improve	improve	VB	_	23	xcomp
26	immunization	immunization	NN	_	25	dobj
27	in	in	IN	_	28	case
28	poultry	poultry	NN	_	26	nmod
29	.	.	.	_	23	punct

1	Protective	protective	JJ	_	2	amod
2	effect	effect	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	against	against	IN	_	10	case
8	the	the	DT	_	10	det
9	acute	acute	JJ	_	10	amod
10	toxicity	toxicity	NN	_	2	nmod
11	of	of	IN	_	12	case
12	diepoxybutane	diepoxybutane	NN	_	10	nmod
13	to	to	TO	_	15	case
14	human	human	JJ	_	15	amod
15	lymphocytes	lymphocyte	NNS	_	10	nmod
16	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	biotransformation	biotransformation	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	oxidative	oxidative	JJ	_	5	amod
5	stress	stress	NN	_	2	conj
6	may	may	MD	_	7	aux
7	contribute	contribute	VB	_	0	ROOT
8	to	to	TO	_	9	case
9	1,2:3,4	1,2:3,4	CD	_	7	nmod
10	-	-	:	_	9	punct
11	diepoxybutane	diepoxybutane	NN	_	9	dep
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	DEB	deb	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	-	-	:	_	9	punct
16	induced	induce	VBN	_	17	amod
17	toxicity	toxicity	NN	_	9	dep
18	to	to	TO	_	20	case
19	human	human	JJ	_	20	amod
20	lymphocytes	lymphocyte	NNS	_	17	nmod
21	of	of	IN	_	23	case
22	Fanconi	Fanconi	NNP	_	23	compound
23	Anemia	Anemia	NNP	_	20	nmod
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	FA	FA	NNP	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	patients	patient	NNS	_	23	dep
28	.	.	.	_	7	punct

1	Thus	thus	RB	_	29	advmod
2	,	,	,	_	29	punct
3	the	the	DT	_	4	det
4	identification	identification	NN	_	29	nsubj
5	of	of	IN	_	7	case
6	putative	putative	JJ	_	7	amod
7	inhibitors	inhibitor	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	bioactivation	bioactivation	NN	_	7	nmod
10	,	,	,	_	7	punct
11	as	as	RB	_	7	cc
12	well	well	RB	_	11	mwe
13	as	as	IN	_	11	mwe
14	the	the	DT	_	15	det
15	determination	determination	NN	_	7	conj
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	protective	protective	JJ	_	19	amod
19	role	role	NN	_	15	nmod
20	of	of	IN	_	22	case
21	oxidant	oxidant	JJ	_	22	amod
22	defenses	defens	NNS	_	19	nmod
23	,	,	,	_	4	punct
24	on	on	IN	_	26	case
25	DEB-induced	deb-induced	JJ	_	26	amod
26	toxicity	toxicity	NN	_	4	nmod
27	,	,	,	_	4	punct
28	can	can	MD	_	29	aux
29	help	help	VB	_	0	ROOT
30	to	to	TO	_	31	mark
31	understand	understand	VB	_	29	xcomp
32	what	what	WP	_	34	nsubj
33	is	be	VBZ	_	34	aux
34	failing	fail	VBG	_	31	ccomp
35	in	in	IN	_	37	case
36	FA	fa	NN	_	37	compound
37	cells	cell	NNS	_	34	nmod
38	.	.	.	_	29	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	work	work	NN	_	6	nmod
5	we	we	PRP	_	6	nsubj
6	studied	study	VBD	_	0	ROOT
7	the	the	DT	_	8	det
8	contribution	contribution	NN	_	6	dobj
9	of	of	IN	_	12	case
10	several	several	JJ	_	12	amod
11	biochemical	biochemical	JJ	_	12	amod
12	pathways	pathway	NNS	_	8	nmod
13	for	for	IN	_	16	case
14	DEB-induced	deb-induced	JJ	_	16	amod
15	acute	acute	JJ	_	16	amod
16	toxicity	toxicity	NN	_	12	nmod
17	in	in	IN	_	20	case
18	human	human	JJ	_	20	amod
19	lymphocyte	lymphocyte	NN	_	20	compound
20	suspensions	suspension	NNS	_	16	nmod
21	,	,	,	_	6	punct
22	by	by	IN	_	23	mark
23	using	use	VBG	_	6	advcl
24	inhibitors	inhibitor	NNS	_	23	dobj
25	of	of	IN	_	27	case
26	epoxide	epoxide	NN	_	27	compound
27	hydrolases	hydrolase	NNS	_	24	nmod
28	,	,	,	_	24	punct
29	inhibitors	inhibitor	NNS	_	24	conj
30	of	of	IN	_	32	case
31	protective	protective	JJ	_	32	amod
32	enzymes	enzyme	NNS	_	29	nmod
33	as	as	IN	_	35	case
34	glutathione	glutathione	NN	_	35	compound
35	S-transferase	s-transferase	NN	_	29	nmod
36	and	and	CC	_	35	cc
37	catalase	catalase	NN	_	35	conj
38	,	,	,	_	24	punct
39	the	the	DT	_	40	det
40	depletion	depletion	NN	_	24	conj
41	of	of	IN	_	42	case
42	glutathione	glutathione	NN	_	40	nmod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	GSH	gsh	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	,	,	,	_	24	punct
47	and	and	CC	_	24	cc
48	the	the	DT	_	49	det
49	inhibition	inhibition	NN	_	24	conj
50	of	of	IN	_	52	case
51	protein	protein	NN	_	52	compound
52	synthesis	synthesis	NN	_	49	nmod
53	;	;	:	_	6	punct

1	and	and	CC	_	0	ROOT
2	a	a	DT	_	3	det
3	variety	variety	NN	_	1	dep
4	of	of	IN	_	7	case
5	putative	putative	JJ	_	7	amod
6	protective	protective	JJ	_	7	amod
7	compounds	compound	NNS	_	3	nmod
8	,	,	,	_	7	punct
9	including	include	VBG	_	10	case
10	antioxidants	antioxidant	NNS	_	7	nmod
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	mitochondrial	mitochondrial	JJ	_	15	amod
14	protective	protective	JJ	_	15	amod
15	agents	agent	NNS	_	7	conj
16	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	present	present	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	reports	report	VBZ	_	0	ROOT
5	two	two	CD	_	7	nummod
6	novel	novel	JJ	_	7	amod
7	findings	finding	NNS	_	4	dobj
8	:	:	:	_	7	punct
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	i	i	LS	_	15	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	it	it	PRP	_	15	nsubjpass
13	was	be	VBD	_	15	auxpass
14	clearly	clearly	RB	_	15	advmod
15	evidenced	evidence	VBN	_	7	dep
16	,	,	,	_	15	punct
17	for	for	IN	_	20	case
18	the	the	DT	_	20	det
19	first	first	JJ	_	20	amod
20	time	time	NN	_	15	nmod
21	,	,	,	_	15	punct
22	that	that	IN	_	33	mark
23	the	the	DT	_	25	det
24	acute	acute	JJ	_	25	amod
25	exposure	exposure	NN	_	33	nsubj
26	of	of	IN	_	30	case
27	freshly	freshly	RB	_	28	advmod
28	isolated	isolate	VBN	_	30	amod
29	human	human	JJ	_	30	amod
30	lymphocytes	lymphocyte	NNS	_	25	nmod
31	to	to	TO	_	32	case
32	DEB	DEB	NNP	_	25	nmod
33	results	result	VBZ	_	15	ccomp
34	in	in	IN	_	37	case
35	severe	severe	JJ	_	37	amod
36	GSH	gsh	NN	_	37	compound
37	depletion	depletion	NN	_	33	nmod
38	and	and	CC	_	37	cc
39	loss	loss	NN	_	37	conj
40	of	of	IN	_	41	case
41	ATP	atp	NN	_	39	nmod
42	,	,	,	_	33	punct
43	followed	follow	VBN	_	33	dep
44	by	by	IN	_	46	case
45	cell	cell	NN	_	46	compound
46	death	death	NN	_	43	nmod
47	;	;	:	_	15	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	ii	ii	LS	_	5	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	drug1	drug1	NN	_	5	nsubj
5	elicits	elicit	VBZ	_	0	ROOT
6	a	a	DT	_	9	det
7	significant	significant	JJ	_	9	amod
8	protective	protective	JJ	_	9	amod
9	effect	effect	NN	_	5	dobj
10	on	on	IN	_	13	case
11	DEB	deb	NN	_	13	compound
12	induced	induce	VBD	_	13	amod
13	toxicity	toxicity	NN	_	9	nmod
14	,	,	,	_	13	punct
15	which	which	WDT	_	17	nsubjpass
16	was	be	VBD	_	17	auxpass
17	potentiated	potentiate	VBN	_	13	acl:relcl
18	by	by	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	5	punct

1	Collectively	collectively	RB	_	5	advmod
2	,	,	,	_	5	punct
3	these	these	DT	_	4	det
4	findings	finding	NNS	_	5	nsubj
5	contribute	contribute	VBP	_	0	ROOT
6	to	to	TO	_	7	mark
7	increase	increase	VB	_	5	xcomp
8	our	we	PRP$	_	9	nmod:poss
9	knowledge	knowledge	NN	_	7	dobj
10	of	of	IN	_	12	case
11	DEB-induce	deb-induce	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	and	and	CC	_	5	cc
14	will	will	MD	_	17	aux
15	be	be	VB	_	17	cop
16	very	very	RB	_	17	advmod
17	useful	useful	JJ	_	5	conj
18	when	when	WRB	_	19	advmod
19	applied	apply	VBN	_	17	advcl
20	in	in	IN	_	21	case
21	studies	study	NNS	_	19	nmod
22	with	with	IN	_	23	case
23	lymphocytes	lymphocyte	NNS	_	21	nmod
24	from	from	IN	_	26	case
25	FA	fa	NN	_	26	compound
26	patients	patient	NNS	_	23	nmod
27	,	,	,	_	5	punct
28	in	in	IN	_	31	mark
29	order	order	NN	_	28	mwe
30	to	to	TO	_	31	mark
31	find	find	VB	_	5	advcl
32	out	out	RP	_	31	compound:prt
33	a	a	DT	_	35	det
34	protective	protective	JJ	_	35	amod
35	agent	agent	NN	_	31	dobj
36	against	against	IN	_	41	case
37	spontaneous	spontaneous	JJ	_	41	amod
38	and	and	CC	_	37	cc
39	DEB-induced	deb-induced	JJ	_	37	conj
40	chromosome	chromosome	NN	_	41	compound
41	instability	instability	NN	_	35	nmod
42	.	.	.	_	5	punct

1	Metabotropic	metabotropic	JJ	_	5	amod
2	glutamate	glutamate	NN	_	5	compound
3	receptor	receptor	NN	_	5	compound
4	5	5	CD	_	5	nummod
5	antagonist	antagonist	NN	_	6	nsubj
6	protects	protect	VBZ	_	0	ROOT
7	dopaminergic	dopaminergic	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	noradrenergic	noradrenergic	JJ	_	7	conj
10	neurons	neuron	NNS	_	6	dobj
11	from	from	IN	_	12	case
12	degeneration	degeneration	NN	_	6	nmod
13	in	in	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	-	-	:	_	6	punct
16	treated	treat	VBN	_	17	amod
17	monkeys	monkey	NNS	_	6	dobj
18	.	.	.	_	6	punct

1	Degeneration	Degeneration	NNP	_	18	nsubj
2	of	of	IN	_	6	case
3	the	the	DT	_	6	det
4	dopaminergic	dopaminergic	JJ	_	6	amod
5	nigrostriatal	nigrostriatal	JJ	_	6	amod
6	system	system	NN	_	1	nmod
7	and	and	CC	_	1	cc
8	of	of	IN	_	10	case
9	noradrenergic	noradrenergic	JJ	_	10	amod
10	neurons	neuron	NNS	_	1	conj
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	locus	locus	NN	_	14	compound
14	coeruleus	coeruleus	NN	_	10	nmod
15	are	be	VBP	_	18	cop
16	important	important	JJ	_	18	amod
17	pathological	pathological	JJ	_	18	amod
18	features	feature	NNS	_	0	ROOT
19	of	of	IN	_	22	case
20	Parkinson	Parkinson	NNP	_	22	nmod:poss
21	's	's	POS	_	20	case
22	disease	disease	NN	_	18	nmod
23	.	.	.	_	18	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	an	a	DT	_	5	det
4	urgent	urgent	JJ	_	5	amod
5	need	need	NN	_	2	nsubj
6	to	to	TO	_	7	mark
7	develop	develop	VB	_	5	acl
8	therapies	therapy	NNS	_	7	dobj
9	that	that	WDT	_	10	nsubj
10	slow	slow	VBP	_	8	acl:relcl
11	down	down	RP	_	10	compound:prt
12	the	the	DT	_	13	det
13	progression	progression	NN	_	10	dobj
14	of	of	IN	_	15	case
15	neurodegeneration	neurodegeneration	NN	_	13	nmod
16	in	in	IN	_	19	case
17	Parkinson	Parkinson	NNP	_	19	nmod:poss
18	's	's	POS	_	17	case
19	disease	disease	NN	_	13	nmod
20	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	tested	test	VBD	_	0	ROOT
8	whether	whether	IN	_	20	mark
9	the	the	DT	_	14	det
10	highly	highly	RB	_	11	advmod
11	specific	specific	JJ	_	14	amod
12	metabotropic	metabotropic	JJ	_	14	amod
13	glutamate	glutamate	NN	_	14	compound
14	receptor	receptor	NN	_	20	nsubj
15	5	5	CD	_	14	nummod
16	antagonist	antagonist	NN	_	14	dep
17	,	,	,	_	14	punct
18	drug1	drug1	NN	_	14	appos
19	,	,	,	_	14	punct
20	reduces	reduce	VBZ	_	7	ccomp
21	dopaminergic	dopaminergic	JJ	_	25	amod
22	and	and	CC	_	21	cc
23	noradrenergic	noradrenergic	JJ	_	21	conj
24	neuronal	neuronal	JJ	_	25	amod
25	loss	loss	NN	_	20	dobj
26	in	in	IN	_	27	case
27	monkeys	monkey	NNS	_	25	nmod
28	rendered	render	VBN	_	27	acl
29	parkinsonian	parkinsonian	JJ	_	28	xcomp
30	by	by	IN	_	32	case
31	chronic	chronic	JJ	_	32	amod
32	treatment	treatment	NN	_	28	nmod
33	with	with	IN	_	35	case
34	low	low	JJ	_	35	amod
35	doses	dose	NNS	_	32	nmod
36	of	of	IN	_	37	case
37	drug2	drug2	NN	_	35	nmod
38	.	.	.	_	7	punct

1	Weekly	Weekly	NNP	_	4	compound
2	intramuscular	intramuscular	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	injections	injection	NNS	_	24	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	10	punct
6	0.2-0	0.2-0	CD	_	10	nummod
7	.5	.5	CD	_	10	nummod
8	mg/kg	mg/kg	NN	_	10	compound
9	body	body	NN	_	10	compound
10	weight	weight	NN	_	4	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	4	punct
13	in	in	IN	_	14	case
14	combination	combination	NN	_	4	nmod
15	with	with	IN	_	17	case
16	daily	daily	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	vehicle	vehicle	NN	_	19	conj
22	,	,	,	_	4	punct
23	were	be	VBD	_	24	auxpass
24	performed	perform	VBN	_	0	ROOT
25	until	until	IN	_	27	case
26	the	the	DT	_	27	det
27	development	development	NN	_	24	nmod
28	of	of	IN	_	31	case
29	parkinsonian	parkinsonian	JJ	_	31	amod
30	motor	motor	NN	_	31	compound
31	symptoms	symptom	NNS	_	27	nmod
32	in	in	IN	_	33	case
33	either	either	DT	_	31	nmod
34	of	of	IN	_	38	case
35	the	the	DT	_	38	det
36	two	two	CD	_	38	nummod
37	experimental	experimental	JJ	_	38	amod
38	groups	group	NNS	_	33	nmod
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	drug3	drug3	NN	_	38	dep
41	/	/	:	_	40	punct
42	drug4	drug4	NN	_	40	dep
43	versus	versus	CC	_	42	cc
44	drug5	drug5	NN	_	42	conj
45	/	/	:	_	40	punct
46	vehicle	vehicle	NN	_	40	dep
47	-RRB-	-rrb-	-RRB-	_	40	punct
48	.	.	.	_	24	punct

1	After	after	IN	_	3	case
2	21	21	CD	_	3	nummod
3	weeks	week	NNS	_	13	nmod
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	treatment	treatment	NN	_	3	nmod
7	,	,	,	_	13	punct
8	all	all	DT	_	9	det
9	drug2	drug2	NN	_	12	dep
10	/	/	:	_	12	punct
11	vehicle-treated	vehicle-treated	JJ	_	12	amod
12	animals	animal	NNS	_	13	nsubj
13	displayed	display	VBD	_	0	ROOT
14	parkinsonian	parkinsonian	JJ	_	15	amod
15	symptoms	symptom	NNS	_	13	dobj
16	,	,	,	_	13	punct
17	whereas	whereas	IN	_	13	dep
18	none	none	NN	_	29	nsubjpass
19	of	of	IN	_	23	case
20	the	the	DT	_	23	det
21	drug3	drug3	NN	_	23	compound
22	/	/	:	_	23	punct
23	drug4	drug4	NN	_	18	nmod
24	-	-	:	_	23	punct
25	treated	treat	VBN	_	26	amod
26	monkeys	monkey	NNS	_	23	dep
27	were	be	VBD	_	29	auxpass
28	significantly	significantly	RB	_	29	advmod
29	affected	affect	VBN	_	13	parataxis
30	.	.	.	_	13	punct

1	These	these	DT	_	3	det
2	behavioural	behavioural	JJ	_	3	amod
3	observations	observation	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	consistent	consistent	JJ	_	0	ROOT
6	with	with	IN	_	15	case
7	in	in	FW	_	15	amod
8	vivo	vivo	FW	_	7	dep
9	positron	positron	FW	_	15	compound
10	emission	emission	NN	_	15	compound
11	tomography	tomography	NN	_	15	compound
12	dopamine	dopamine	NN	_	15	compound
13	transporter	transporter	NN	_	15	compound
14	imaging	imaging	NN	_	15	compound
15	data	datum	NNS	_	5	nmod
16	,	,	,	_	5	punct
17	and	and	CC	_	5	cc
18	with	with	IN	_	21	case
19	post-mortem	post-mortem	NN	_	21	compound
20	stereological	stereological	JJ	_	21	amod
21	counts	count	NNS	_	5	conj
22	of	of	IN	_	25	case
23	midbrain	midbrain	JJ	_	25	amod
24	dopaminergic	dopaminergic	JJ	_	25	amod
25	neurons	neuron	NNS	_	21	nmod
26	,	,	,	_	21	punct
27	as	as	RB	_	21	cc
28	well	well	RB	_	27	mwe
29	as	as	IN	_	27	mwe
30	striatal	striatal	JJ	_	32	amod
31	intensity	intensity	NN	_	32	compound
32	measurements	measurement	NNS	_	21	conj
33	of	of	IN	_	35	case
34	dopamine	dopamine	NN	_	35	compound
35	transporter	transporter	NN	_	32	nmod
36	and	and	CC	_	35	cc
37	tyrosine	tyrosine	NN	_	39	compound
38	hydroxylase	hydroxylase	NN	_	39	compound
39	immunoreactivity	immunoreactivity	NN	_	35	conj
40	,	,	,	_	32	punct
41	which	which	WDT	_	45	nsubj
42	were	be	VBD	_	45	cop
43	all	all	DT	_	45	advmod
44	significantly	significantly	RB	_	45	advmod
45	higher	higher	JJR	_	32	acl:relcl
46	in	in	IN	_	47	case
47	drug1	drug1	NN	_	45	nmod
48	/	/	:	_	47	punct
49	drug2	drug2	NN	_	47	dep
50	-	-	:	_	47	punct
51	treated	treat	VBN	_	52	amod
52	animals	animal	NNS	_	47	dep
53	than	than	IN	_	55	case
54	in	in	IN	_	55	case
55	drug3	drug3	NN	_	52	nmod
56	/	/	:	_	47	punct
57	vehicle-treated	vehicle-treated	JJ	_	58	amod
58	monkeys	monkey	NNS	_	47	dep
59	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	treatment	treatment	NN	_	5	nsubj
4	also	also	RB	_	5	advmod
5	had	have	VBD	_	0	ROOT
6	a	a	DT	_	8	det
7	significant	significant	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	drug2	drug2	NN	_	8	nmod
12	-	-	:	_	8	punct
13	induced	induced	JJ	_	14	amod
14	loss	loss	NN	_	8	dep
15	of	of	IN	_	17	case
16	norepinephrine	norepinephrine	NN	_	17	compound
17	neurons	neuron	NNS	_	14	nmod
18	in	in	IN	_	21	case
19	the	the	DT	_	21	det
20	locus	locus	NN	_	21	compound
21	coeruleus	coeruleus	NN	_	14	nmod
22	and	and	CC	_	21	cc
23	adjoining	adjoining	JJ	_	24	amod
24	A5	a5	NN	_	21	conj
25	and	and	CC	_	24	cc
26	A7	a7	NN	_	29	compound
27	noradrenaline	noradrenaline	NN	_	29	compound
28	cell	cell	NN	_	29	compound
29	groups	group	NNS	_	24	conj
30	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	drug1	drug1	NN	_	17	nmod
3	/	/	:	_	5	punct
4	vehicle-treated	vehicle-treated	JJ	_	5	amod
5	animals	animal	NNS	_	17	nsubjpass
6	,	,	,	_	5	punct
7	almost	almost	RB	_	8	advmod
8	40	40	CD	_	9	dep
9	%	%	NN	_	10	dep
10	loss	loss	NN	_	5	appos
11	of	of	IN	_	15	case
12	tyrosine	tyrosine	NN	_	15	compound
13	hydroxylase-positive	hydroxylase-positive	JJ	_	15	amod
14	norepinephrine	norepinephrine	NN	_	15	compound
15	neurons	neuron	NNS	_	10	nmod
16	was	be	VBD	_	17	auxpass
17	found	find	VBN	_	0	ROOT
18	in	in	IN	_	23	case
19	locus	locus	NN	_	23	compound
20	coeruleus/A5/A7	coeruleus/a5/a7	NN	_	23	compound
21	noradrenaline	noradrenaline	NN	_	23	compound
22	cell	cell	NN	_	23	compound
23	groups	group	NNS	_	17	nmod
24	,	,	,	_	17	punct
25	whereas	whereas	IN	_	17	dep
26	the	the	DT	_	27	det
27	extent	extent	NN	_	32	nsubj
28	of	of	IN	_	30	case
29	neuronal	neuronal	JJ	_	30	amod
30	loss	loss	NN	_	27	nmod
31	was	be	VBD	_	32	cop
32	lower	lower	JJR	_	17	parataxis
33	than	than	IN	_	35	case
34	15	15	CD	_	35	nummod
35	%	%	NN	_	32	nmod
36	of	of	IN	_	38	case
37	control	control	NN	_	38	compound
38	values	value	NNS	_	35	nmod
39	in	in	IN	_	40	case
40	drug2	drug2	NN	_	38	nmod
41	/	/	:	_	32	punct
42	drug3	drug3	NN	_	45	compound
43	-	-	:	_	45	punct
44	treated	treat	VBN	_	45	amod
45	monkeys	monkey	NNS	_	32	dep
46	.	.	.	_	17	punct

1	Our	we	PRP$	_	2	nmod:poss
2	data	datum	NNS	_	3	nsubj
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	that	that	IN	_	18	mark
5	chronic	chronic	JJ	_	6	amod
6	treatment	treatment	NN	_	18	nsubj
7	with	with	IN	_	11	case
8	the	the	DT	_	11	det
9	metabotropic	metabotropic	JJ	_	11	amod
10	glutamate	glutamate	NN	_	11	compound
11	receptor	receptor	NN	_	6	nmod
12	5	5	CD	_	13	nummod
13	antagonist	antagonist	NN	_	11	dep
14	,	,	,	_	11	punct
15	drug1	drug1	NN	_	11	appos
16	,	,	,	_	11	punct
17	significantly	significantly	RB	_	18	advmod
18	reduces	reduce	VBZ	_	3	ccomp
19	drug2	drug2	NN	_	20	compound
20	toxicity	toxicity	NN	_	18	dobj
21	towards	towards	IN	_	26	case
22	dopaminergic	dopaminergic	JJ	_	26	amod
23	and	and	CC	_	22	cc
24	noradrenergic	noradrenergic	JJ	_	22	conj
25	cell	cell	NN	_	26	compound
26	groups	group	NNS	_	18	nmod
27	in	in	IN	_	29	case
28	non-human	non-human	JJ	_	29	amod
29	primates	primate	NNS	_	26	nmod
30	.	.	.	_	3	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	that	that	IN	_	16	mark
4	the	the	DT	_	5	det
5	use	use	NN	_	16	nsubj
6	of	of	IN	_	11	case
7	metabotropic	metabotropic	JJ	_	11	amod
8	glutamate	glutamate	NN	_	11	compound
9	receptor	receptor	NN	_	11	compound
10	5	5	CD	_	11	nummod
11	antagonists	antagonist	NNS	_	5	nmod
12	may	may	MD	_	16	aux
13	be	be	VB	_	16	cop
14	a	a	DT	_	16	det
15	useful	useful	JJ	_	16	amod
16	strategy	strategy	NN	_	2	ccomp
17	to	to	TO	_	18	mark
18	reduce	reduce	VB	_	16	acl
19	degeneration	degeneration	NN	_	18	dobj
20	of	of	IN	_	22	case
21	catecholaminergic	catecholaminergic	JJ	_	22	amod
22	neurons	neuron	NNS	_	19	nmod
23	in	in	IN	_	26	case
24	Parkinson	Parkinson	NNP	_	26	nmod:poss
25	's	's	POS	_	24	case
26	disease	disease	NN	_	18	nmod
27	.	.	.	_	2	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	activity	activity	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	combined	combine	VBN	_	3	acl
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	against	against	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	isolates	isolate	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-	-	:	_	3	punct
15	resistant	resistant	JJ	_	17	amod
16	Staphylococcus	staphylococcus	FW	_	17	compound
17	aureus	aureus	FW	_	3	dep
18	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	0	ROOT
3	aimed	aim	VBN	_	2	acl
4	to	to	TO	_	5	mark
5	evaluate	evaluate	VB	_	3	xcomp
6	the	the	DT	_	9	det
7	in	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	activity	activity	NN	_	5	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	combined	combine	VBN	_	11	acl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	against	against	IN	_	16	case
16	isolates	isolate	NNS	_	14	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	-	-	:	_	2	punct
20	resistant	resistant	JJ	_	22	amod
21	Staphylococcus	staphylococcus	FW	_	22	compound
22	aureus	aureus	FW	_	2	dep
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	MRSA	mrsa	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	.	.	.	_	2	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	15	nsubjpass
3	of	of	IN	_	6	case
4	87	87	CD	_	6	nummod
5	clinical	clinical	JJ	_	6	amod
6	isolates	isolate	NNS	_	2	nmod
7	of	of	IN	_	8	case
8	MRSA	MRSA	NNP	_	6	nmod
9	collected	collect	VBN	_	2	acl
10	from	from	IN	_	13	case
11	three	three	CD	_	13	nummod
12	Chinese	chinese	JJ	_	13	amod
13	hospitals	hospital	NNS	_	9	nmod
14	were	be	VBD	_	15	auxpass
15	included	include	VBN	_	0	ROOT
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	study	study	NN	_	15	nmod
19	.	.	.	_	15	punct

1	The	the	DT	_	3	det
2	checkerboard	checkerboard	NN	_	3	compound
3	method	method	NN	_	15	nsubjpass
4	with	with	IN	_	5	case
5	determination	determination	NN	_	3	nmod
6	of	of	IN	_	10	case
7	the	the	DT	_	10	det
8	fractional	fractional	JJ	_	10	amod
9	IC	ic	NN	_	10	compound
10	index	index	NN	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	FICI	fici	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	was	be	VBD	_	15	auxpass
15	used	use	VBN	_	0	ROOT
16	to	to	TO	_	17	mark
17	determine	determine	VB	_	15	xcomp
18	whether	whether	IN	_	21	mark
19	drug1	drug1	NN	_	20	compound
20	combinations	combination	NNS	_	21	nsubj
21	act	act	VBP	_	17	ccomp
22	synergistically	synergistically	RB	_	21	advmod
23	against	against	IN	_	25	case
24	these	these	DT	_	25	det
25	isolates	isolate	NNS	_	21	nmod
26	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	susceptibility	susceptibility	NN	_	3	nsubj
3	results	result	VBZ	_	9	csubjpass
4	for	for	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	were	be	VBD	_	9	auxpass
9	interpreted	interpret	VBN	_	0	ROOT
10	according	accord	VBG	_	15	case
11	to	to	TO	_	10	mwe
12	the	the	DT	_	15	det
13	most	most	RBS	_	14	advmod
14	relevant	relevant	JJ	_	15	amod
15	criteria	criterion	NNS	_	9	nmod
16	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	following	following	JJ	_	6	amod
6	interactions	interaction	NNS	_	3	dobj
7	:	:	:	_	6	punct
8	76	76	CD	_	9	nummod
9	isolates	isolate	NNS	_	14	nsubj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	87.4	87.4	CD	_	12	nummod
12	%	%	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	showed	show	VBD	_	6	dep
15	synergistic	synergistic	JJ	_	16	amod
16	interactions	interaction	NNS	_	14	dobj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	FICI	fici	NN	_	16	appos
19	0.5	0.5	CD	_	18	nummod
20	-RRB-	-rrb-	-RRB-	_	18	punct
21	and	and	CC	_	16	cc
22	11	11	CD	_	23	nummod
23	isolates	isolate	NNS	_	16	conj
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	12.6	12.6	CD	_	26	nummod
26	%	%	NN	_	23	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	showed	show	VBD	_	14	dep
29	indifferent	indifferent	JJ	_	30	amod
30	interactions	interaction	NNS	_	28	dobj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	0.5	0.5	CD	_	30	dep
33	&	&	CC	_	32	cc
34	lt	lt	NN	_	32	conj
35	;	;	:	_	32	punct
36	FICI	FICI	NNP	_	32	conj
37	&	&	CC	_	36	cc
38	lt	lt	NN	_	36	conj
39	;	;	:	_	32	punct
40	4	4	LS	_	32	dep
41	-RRB-	-rrb-	-RRB-	_	32	punct
42	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	antagonistic	antagonistic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	FICI	fici	NN	_	3	appos
6	4	4	CD	_	5	nummod
7	-RRB-	-rrb-	-RRB-	_	5	punct
8	were	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	combination	combination	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	can	can	MD	_	9	aux
8	be	be	VB	_	9	cop
9	synergistic	synergistic	JJ	_	0	ROOT
10	against	against	IN	_	11	case
11	MRSA	MRSA	NNP	_	9	nmod
12	.	.	.	_	9	punct

1	Further	further	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	required	require	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	determine	determine	VB	_	4	xcomp
7	the	the	DT	_	10	det
8	potential	potential	JJ	_	10	amod
9	clinical	clinical	JJ	_	10	amod
10	role	role	NN	_	6	dobj
11	of	of	IN	_	14	case
12	this	this	DT	_	14	det
13	combination	combination	NN	_	14	compound
14	regimen	regimen	NN	_	10	nmod
15	as	as	IN	_	18	case
16	a	a	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	alternative	alternative	NN	_	10	nmod
19	for	for	IN	_	21	case
20	certain	certain	JJ	_	21	amod
21	types	type	NNS	_	18	nmod
22	of	of	IN	_	24	case
23	MRSA	mrsa	NN	_	24	compound
24	infections	infection	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	enhances	enhance	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	2	dobj
4	-	-	:	_	3	punct
5	mediated	mediate	VBN	_	8	amod
6	antibody-dependent	antibody-dependent	JJ	_	8	amod
7	cellular	cellular	JJ	_	8	amod
8	cytotoxicity	cytotoxicity	NN	_	3	dep
9	by	by	IN	_	10	case
10	up-regulation	up-regulation	NN	_	8	nmod
11	of	of	IN	_	15	case
12	cell	cell	NN	_	15	compound
13	surface	surface	NN	_	15	compound
14	HER2	her2	NN	_	15	compound
15	expression	expression	NN	_	10	nmod
16	.	.	.	_	2	punct

1	Although	although	IN	_	5	mark
2	it	it	PRP	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	previously	previously	RB	_	5	advmod
5	reported	report	VBN	_	0	ROOT
6	that	that	IN	_	11	mark
7	drug1	drug1	NN	_	11	nsubj
8	combined	combine	VBN	_	7	acl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	improved	improve	VBD	_	5	ccomp
12	the	the	DT	_	15	det
13	progression-free	progression-free	JJ	_	15	amod
14	survival	survival	NN	_	15	compound
15	rate	rate	NN	_	11	dobj
16	compared	compare	VBN	_	18	case
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	11	advcl
19	alone	alone	RB	_	18	advmod
20	for	for	IN	_	21	case
21	patients	patient	NNS	_	18	nmod
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	-	-	:	_	29	punct
25	refractory	refractory	JJ	_	29	amod
26	HER2-positive	her2-positive	JJ	_	29	amod
27	metastatic	metastatic	JJ	_	29	amod
28	breast	breast	NN	_	29	compound
29	cancer	cancer	NN	_	5	dobj
30	,	,	,	_	29	punct
31	the	the	DT	_	32	det
32	mechanism	mechanism	NN	_	34	nsubj
33	is	be	VBZ	_	34	cop
34	purported	purported	JJ	_	29	acl:relcl
35	to	to	TO	_	39	mark
36	be	be	VB	_	39	cop
37	an	a	DT	_	39	det
38	antiproliferative	antiproliferative	JJ	_	39	amod
39	effect	effect	NN	_	34	xcomp
40	relating	relate	VBG	_	39	acl
41	to	to	TO	_	43	case
42	the	the	DT	_	43	det
43	synergism	synergism	NN	_	40	nmod
44	of	of	IN	_	47	case
45	these	these	DT	_	47	det
46	two	two	CD	_	47	nummod
47	agents	agent	NNS	_	43	nmod
48	.	.	.	_	5	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	how	how	WRB	_	5	advmod
4	drug1	drug1	NN	_	5	nsubj
5	interacts	interact	VBZ	_	2	ccomp
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	in	in	IN	_	11	case
9	HER2-positive	her2-positive	JJ	_	11	amod
10	breast	breast	NN	_	11	compound
11	cancer	cancer	NN	_	5	nmod
12	,	,	,	_	5	punct
13	with	with	IN	_	16	case
14	a	a	DT	_	16	det
15	particular	particular	JJ	_	16	amod
16	focus	focus	NN	_	5	nmod
17	on	on	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	-	-	:	_	16	punct
20	mediated	mediate	VBN	_	23	amod
21	antibody-dependent	antibody-dependent	JJ	_	23	amod
22	cellular	cellular	JJ	_	23	amod
23	cytotoxicity	cytotoxicity	NN	_	16	dep
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	ADCC	adcc	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	.	.	.	_	2	punct

1	In	in	IN	_	5	case
2	an	a	DT	_	5	det
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	assay	assay	NN	_	8	nmod
6	,	,	,	_	8	punct
7	drug1	drug1	NN	_	8	nsubj
8	induced	induce	VBD	_	0	ROOT
9	HER2	her2	NN	_	10	compound
10	expression	expression	NN	_	8	dobj
11	at	at	IN	_	14	case
12	the	the	DT	_	14	det
13	cell	cell	NN	_	14	compound
14	surface	surface	NN	_	8	nmod
15	of	of	IN	_	20	case
16	HER2-positive	her2-positive	JJ	_	20	amod
17	breast	breast	NN	_	20	compound
18	cancer	cancer	NN	_	20	compound
19	cell	cell	NN	_	20	compound
20	lines	line	NNS	_	14	nmod
21	,	,	,	_	8	punct
22	leading	lead	VBG	_	8	advcl
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	enhancement	enhancement	NN	_	22	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-	-	:	_	25	punct
29	mediated	mediate	VBN	_	30	amod
30	ADCC	adcc	NN	_	25	dep
31	.	.	.	_	8	punct

1	Furthermore	furthermore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	present	present	VBP	_	0	ROOT
5	a	a	DT	_	7	det
6	case	case	NN	_	7	compound
7	report	report	NN	_	4	dobj
8	in	in	IN	_	9	case
9	which	which	WDT	_	16	nmod
10	a	a	DT	_	13	det
11	second	second	JJ	_	13	amod
12	drug1	drug1	NN	_	13	compound
13	treatment	treatment	NN	_	16	nsubj
14	following	follow	VBG	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	resulted	result	VBD	_	7	acl:relcl
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	marked	marked	JJ	_	20	amod
20	shrinkage	shrinkage	NN	_	16	nmod
21	of	of	IN	_	24	case
22	multiple	multiple	JJ	_	24	amod
23	metastatic	metastatic	JJ	_	24	amod
24	tumors	tumor	NNS	_	20	nmod
25	in	in	IN	_	28	case
26	HER2-positive	her2-positive	JJ	_	28	amod
27	breast	breast	NN	_	28	compound
28	cancer	cancer	NN	_	24	nmod
29	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	have	have	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	potential	potential	JJ	_	3	dobj
6	to	to	TO	_	7	mark
7	convert	convert	VB	_	5	acl
8	drug2	drug2	NN	_	7	dobj
9	-	-	:	_	8	punct
10	refractory	refractory	JJ	_	8	amod
11	to	to	TO	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	-	-	:	_	8	punct
14	sensitive	sensitive	JJ	_	15	amod
15	tumors	tumor	NNS	_	8	dep
16	in	in	IN	_	19	case
17	HER2-positive	her2-positive	JJ	_	19	amod
18	breast	breast	NN	_	19	compound
19	cancer	cancer	NN	_	15	nmod
20	by	by	IN	_	21	case
21	up-regulation	up-regulation	NN	_	15	nmod
22	of	of	IN	_	26	case
23	the	the	DT	_	26	det
24	cell	cell	NN	_	26	compound
25	surface	surface	NN	_	26	compound
26	expression	expression	NN	_	21	nmod
27	of	of	IN	_	28	case
28	HER2	her2	NN	_	26	nmod
29	.	.	.	_	3	punct

1	Improved	improve	VBN	_	4	amod
2	parathyroid	parathyroid	JJ	_	4	amod
3	hormone	hormone	NN	_	4	compound
4	control	control	NN	_	8	nsubjpass
5	by	by	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	reduction	reduction	NN	_	8	nmod
11	in	in	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	requirement	requirement	NN	_	10	nmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	with	with	IN	_	19	case
17	end-stage	end-stage	JJ	_	19	amod
18	renal	renal	JJ	_	19	amod
19	disease	disease	NN	_	15	nmod
20	.	.	.	_	8	punct

1	Uncontrolled	uncontrolled	JJ	_	2	amod
2	hy-per-parathyroidism	hy-per-parathyroidism	NN	_	3	nsubj
3	causes	cause	VBZ	_	0	ROOT
4	bone	bone	NN	_	6	compound
5	marrow	marrow	NN	_	6	compound
6	fibrosis	fibrosis	NN	_	3	dobj
7	,	,	,	_	3	punct
8	leading	lead	VBG	_	3	advcl
9	to	to	TO	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	resistance	resistance	NN	_	10	dep
15	.	.	.	_	3	punct

1	Medical	medical	JJ	_	2	amod
2	treatment	treatment	NN	_	6	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	cop
6	effective	effective	JJ	_	0	ROOT
7	in	in	IN	_	8	mark
8	reducing	reduce	VBG	_	6	advcl
9	plasma	plasma	NN	_	11	compound
10	parathyroid	parathyroid	JJ	_	11	amod
11	hormone	hormone	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	PTH	pth	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	levels	level	NNS	_	8	dobj
16	,	,	,	_	6	punct
17	but	but	CC	_	6	cc
18	its	its	PRP$	_	19	nmod:poss
19	effect	effect	NN	_	24	nsubj
20	on	on	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	dosing	dosing	NN	_	19	nmod
23	is	be	VBZ	_	24	cop
24	unknown	unknown	JJ	_	6	conj
25	.	.	.	_	6	punct

1	METHODS	method	NNS	_	0	ROOT
2	AND	and	CC	_	1	cc
3	AIMS	aim	NNS	_	1	conj
4	:	:	:	_	1	punct
5	We	we	PRP	_	6	nsubj
6	conducted	conduct	VBD	_	1	dep
7	a	a	DT	_	10	det
8	retrospective	retrospective	JJ	_	10	amod
9	cohort	cohort	NN	_	10	compound
10	study	study	NN	_	6	dobj
11	of	of	IN	_	15	case
12	40	40	CD	_	15	nummod
13	end-stage	end-stage	JJ	_	15	amod
14	renal	renal	JJ	_	15	amod
15	disease	disease	NN	_	10	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	ESRD	esrd	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	patients	patient	NNS	_	15	dep
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	age	age	NN	_	19	dep
22	:	:	:	_	21	punct
23	55	55	CD	_	24	compound
24	14	14	CD	_	21	dep
25	;	;	:	_	21	punct
26	mean	mean	VB	_	21	dep
27	SD	sd	NN	_	26	dobj
28	;	;	:	_	21	punct
29	21	21	CD	_	31	nummod
30	:	:	:	_	31	punct
31	male	male	NN	_	21	dep
32	-RRB-	-rrb-	-RRB-	_	21	punct
33	who	who	WP	_	34	nsubj
34	had	have	VBD	_	10	acl:relcl
35	at	at	IN	_	36	case
36	least	least	JJS	_	37	nmod:npmod
37	12	12	CD	_	38	nummod
38	months	month	NNS	_	34	dobj
39	of	of	IN	_	41	case
40	drug1	drug1	NN	_	41	compound
41	therapy	therapy	NN	_	38	nmod
42	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	distribution	distribution	NN	_	11	nsubj
3	of	of	IN	_	6	case
4	renal	renal	JJ	_	6	amod
5	replacement	replacement	NN	_	6	compound
6	therapies	therapy	NNS	_	2	nmod
7	were	be	VBD	_	11	cop
8	:	:	:	_	11	punct
9	14	14	CD	_	11	nummod
10	peritoneal	peritoneal	JJ	_	11	amod
11	dialysis	dialysis	NN	_	0	ROOT
12	,	,	,	_	11	punct
13	18	18	CD	_	15	nummod
14	conventional	conventional	JJ	_	15	amod
15	hemodialysis	hemodialysis	NN	_	11	conj
16	and	and	CC	_	11	cc
17	8	8	CD	_	19	nummod
18	nocturnal	nocturnal	JJ	_	19	amod
19	hemodialysis	hemodialysis	NN	_	11	conj
20	.	.	.	_	11	punct

1	Standard	Standard	NNP	_	5	compound
2	dialysis	dialysis	NN	_	5	compound
3	related	related	JJ	_	5	amod
4	biochemical	biochemical	JJ	_	5	amod
5	indices	index	NNS	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	medications	medication	NNS	_	5	conj
8	used	use	VBN	_	5	acl
9	were	be	VBD	_	10	auxpass
10	recorded	record	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	primary	primary	JJ	_	3	amod
3	objective	objective	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	study	study	NN	_	3	nmod
7	was	be	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	ascertain	ascertain	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	difference	difference	NN	_	9	dobj
12	in	in	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	responsiveness	responsiveness	NN	_	11	nmod
15	before	before	IN	_	19	case
16	and	and	CC	_	15	cc
17	after	after	IN	_	15	conj
18	12	12	CD	_	19	nummod
19	months	month	NNS	_	9	nmod
20	of	of	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	19	nmod
23	.	.	.	_	7	punct

1	Our	we	PRP$	_	3	nmod:poss
2	secondary	secondary	JJ	_	3	amod
3	objective	objective	NN	_	4	nsubj
4	was	be	VBD	_	0	ROOT
5	to	to	TO	_	6	mark
6	determine	determine	VB	_	4	xcomp
7	if	if	IN	_	9	mark
8	there	there	EX	_	9	expl
9	was	be	VBD	_	6	advcl
10	a	a	DT	_	11	det
11	relationship	relationship	NN	_	9	nsubj
12	between	between	IN	_	14	case
13	the	the	DT	_	14	det
14	changes	change	NNS	_	11	nmod
15	in	in	IN	_	16	case
16	PTH	pth	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug1	drug1	NN	_	19	compound
19	requirement	requirement	NN	_	16	conj
20	.	.	.	_	4	punct

1	Overall	overall	RB	_	5	advmod
2	,	,	,	_	5	punct
3	PTH	pth	NN	_	4	compound
4	levels	level	NNS	_	5	nsubj
5	decreased	decrease	VBD	_	0	ROOT
6	from	from	IN	_	7	case
7	197.5	197.5	CD	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	151.8	151.8	CD	_	7	dep
10	;	;	:	_	9	punct
11	249.2	249.2	CD	_	9	dep
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	to	to	TO	_	14	case
14	66.1	66.1	CD	_	5	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	41.2	41.2	CD	_	14	dep
17	;	;	:	_	16	punct
18	136.5	136.5	CD	_	16	dep
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	median	median	NN	_	14	dep
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	25th	25th	JJ	_	21	dep
24	;	;	:	_	23	punct
25	75th	75th	JJ	_	26	amod
26	percentile	percentile	NN	_	23	dep
27	-RRB-	-rrb-	-RRB-	_	23	punct
28	-RRB-	-rrb-	-RRB-	_	21	punct
29	pmol/l	pmol/l	NN	_	14	dep
30	;	;	:	_	5	punct

1	p	p	NN	_	0	ROOT
2	&	&	CC	_	1	cc
3	lt	lt	NN	_	1	conj
4	;	;	:	_	1	punct

1	0.001	0.001	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	3	nsubj
3	increased	increase	VBN	_	0	ROOT
4	from	from	IN	_	6	case
5	30.0	30.0	CD	_	6	compound
6	6	6	CD	_	3	nmod
7	to	to	TO	_	10	case
8	63	63	CD	_	9	compound
9	25	25	CD	_	10	nummod
10	mg/day	mg/day	NN	_	3	nmod
11	,	,	,	_	3	punct
12	p	p	NN	_	3	parataxis
13	<	<	JJR	_	12	dep

1	0.05	0.05	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Hemoglobin	hemoglobin	NN	_	2	nsubj
2	remained	remain	VBD	_	0	ROOT
3	unchanged	unchanged	JJ	_	2	xcomp
4	-LRB-	-lrb-	-LRB-	_	10	punct
5	116	116	CD	_	6	compound
6	13	13	CD	_	10	nummod
7	to	to	TO	_	6	dep
8	116	116	CD	_	9	compound
9	13	13	CD	_	6	dep
10	g/l	g/l	NN	_	2	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	2	punct
13	while	while	IN	_	16	mark
14	drug1	drug1	NN	_	15	compound
15	requirement	requirement	NN	_	16	nsubj
16	decreased	decrease	VBD	_	2	advcl
17	from	from	IN	_	18	case
18	40	40	CD	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	20	20	CD	_	18	dep
21	;	;	:	_	20	punct
22	60	60	CD	_	20	dep
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	to	to	TO	_	25	dep
25	24	24	CD	_	18	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	19	19	CD	_	25	dep
28	;	;	:	_	27	punct
29	59	59	CD	_	27	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	g/week	g/week	NN	_	25	dep
32	,	,	,	_	16	punct
33	p	p	NN	_	34	nsubj
34	=	=	JJ	_	16	dep
35	0.02	0.02	CD	_	34	dobj
36	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	remainder	remainder	NN	_	21	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	dialysis-related	dialysis-related	JJ	_	6	amod
6	biochemistry	biochemistry	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	electrolytes	electrolyte	NNS	_	6	dep
9	,	,	,	_	8	punct
10	calcium	calcium	NN	_	8	conj
11	,	,	,	_	8	punct
12	phosphate	phosphate	NN	_	8	conj
13	,	,	,	_	8	punct
14	iron	iron	NN	_	15	compound
15	status	status	NN	_	8	conj
16	-RRB-	-rrb-	-RRB-	_	8	punct
17	and	and	CC	_	6	cc
18	vitamin	vitamin	NN	_	20	compound
19	D	d	NN	_	20	compound
20	use	use	NN	_	6	conj
21	remained	remain	VBD	_	0	ROOT
22	unchanged	unchanged	JJ	_	21	xcomp
23	.	.	.	_	21	punct

1	A	a	DT	_	2	det
2	reduction	reduction	NN	_	12	nsubjpass
3	in	in	IN	_	5	case
4	PTH	pth	NN	_	5	compound
5	level	level	NN	_	2	nmod
6	of	of	IN	_	10	case
7	greater	greater	JJR	_	9	advmod
8	than	than	IN	_	9	advmod
9	30	30	CD	_	10	nummod
10	%	%	NN	_	5	nmod
11	was	be	VBD	_	12	auxpass
12	experienced	experience	VBN	_	0	ROOT
13	by	by	IN	_	15	case
14	82.5	82.5	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	33/40	33/40	CD	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	of	of	IN	_	21	case
20	our	we	PRP$	_	21	nmod:poss
21	cohort	cohort	NN	_	15	nmod
22	.	.	.	_	12	punct

1	Among	among	IN	_	3	case
2	the	the	DT	_	3	det
3	responders	responder	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	the	the	DT	_	6	det
6	fall	fall	NN	_	14	nsubj
7	in	in	IN	_	8	case
8	PTH	pth	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	reduction	reduction	NN	_	12	compound
11	drug1	drug1	NN	_	12	compound
12	requirement	requirement	NN	_	8	conj
13	were	be	VBD	_	14	cop
14	related	related	JJ	_	0	ROOT
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	R	r	NN	_	17	nsubj
17	=	=	JJ	_	14	dep
18	-0.48	-0.48	CD	_	17	dobj
19	,	,	,	_	17	punct
20	p	p	NN	_	21	nsubj
21	=	=	JJ	_	17	parataxis
22	0.004	0.004	CD	_	21	dobj
23	-RRB-	-rrb-	-RRB-	_	17	punct
24	.	.	.	_	14	punct

1	Reduction	reduction	NN	_	7	nsubjpass
2	of	of	IN	_	3	case
3	PTH	pth	NN	_	1	nmod
4	by	by	IN	_	5	case
5	drug1	drug1	NN	_	1	nmod
6	is	be	VBZ	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	a	a	DT	_	10	det
10	decrease	decrease	NN	_	7	nmod
11	in	in	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	requirement	requirement	NN	_	10	nmod
14	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	interface	interface	NN	_	10	nsubj
3	between	between	IN	_	4	case
4	bone	bone	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	bone	bone	NN	_	7	compound
7	marrow	marrow	NN	_	4	conj
8	in	in	IN	_	9	case
9	uremia	uremia	NN	_	2	nmod
10	represents	represent	VBZ	_	0	ROOT
11	a	a	DT	_	13	det
12	critical	critical	JJ	_	13	amod
13	step	step	NN	_	10	dobj
14	in	in	IN	_	18	case
15	red	red	JJ	_	18	amod
16	blood	blood	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	production	production	NN	_	13	nmod
19	which	which	WDT	_	20	det
20	merits	merit	NNS	_	22	nsubj
21	further	further	RB	_	22	advmod
22	investigation	investigation	NN	_	13	acl:relcl
23	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	9	case
8	5	5	CD	_	9	nummod
9	milligrams	milligram	NNS	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	at	at	IN	_	15	case
15	doses	dose	NNS	_	6	nmod
16	less	less	JJR	_	18	advmod
17	than	than	IN	_	16	mwe
18	800	800	CD	_	19	nummod
19	milligrams	milligram	NNS	_	15	dep
20	in	in	IN	_	22	case
21	nonpregnant	nonpregnant	JJ	_	22	amod
22	women	woman	NNS	_	19	nmod
23	.	.	.	_	4	punct

1	drug1	drug1	NN	_	6	nsubj
2	is	be	VBZ	_	6	cop
3	the	the	DT	_	6	det
4	only	only	RB	_	5	advmod
5	known	known	JJ	_	6	amod
6	component	component	NN	_	0	ROOT
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	diet	diet	NN	_	6	nmod
10	that	that	WDT	_	12	nsubj
11	may	may	MD	_	12	aux
12	affect	affect	VB	_	6	acl:relcl
13	absorption	absorption	NN	_	12	dobj
14	of	of	IN	_	16	case
15	both	both	CC	_	16	cc:preconj
16	drug2	drug2	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	6	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	evidence	evidence	NN	_	2	root
5	for	for	IN	_	8	case
6	a	a	DT	_	8	det
7	drug1	drug1	NN	_	8	compound
8	effect	effect	NN	_	4	nmod
9	on	on	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	absorption	absorption	NN	_	8	nmod
12	mainly	mainly	RB	_	13	advmod
13	comes	come	VBZ	_	8	acl
14	from	from	IN	_	15	case
15	studies	study	NNS	_	13	nmod
16	that	that	WDT	_	19	nsubj
17	did	do	VBD	_	19	aux
18	not	not	RB	_	19	neg
19	isolate	isolate	VB	_	15	acl:relcl
20	the	the	DT	_	21	det
21	effect	effect	NN	_	19	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	from	from	IN	_	25	case
25	that	that	DT	_	19	nmod
26	of	of	IN	_	29	case
27	other	other	JJ	_	29	amod
28	dietary	dietary	JJ	_	29	amod
29	components	component	NNS	_	25	nmod
30	,	,	,	_	4	punct
31	because	because	IN	_	34	mark
32	it	it	PRP	_	34	nsubjpass
33	was	be	VBD	_	34	auxpass
34	detected	detect	VBN	_	30	root
35	in	in	IN	_	37	case
36	single-meal	single-meal	JJ	_	37	amod
37	studies	study	NNS	_	34	nmod
38	.	.	.	_	34	punct

1	Our	we	PRP$	_	2	nmod:poss
2	objective	objective	NN	_	3	nsubj
3	was	be	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	establish	establish	VB	_	3	xcomp
6	potential	potential	JJ	_	7	amod
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	on	on	IN	_	11	case
11	absorption	absorption	NN	_	7	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	and	and	CC	_	11	cc
17	the	the	DT	_	19	det
18	dose	dose	NN	_	19	compound
19	response	response	NN	_	11	conj
20	for	for	IN	_	22	case
21	this	this	DT	_	22	det
22	effect	effect	NN	_	19	nmod
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	absence	absence	NN	_	22	nmod
26	of	of	IN	_	28	case
27	a	a	DT	_	28	det
28	meal	meal	NN	_	25	nmod
29	.	.	.	_	3	punct

1	Fifty-four	fifty-four	CD	_	7	dep
2	healthy	healthy	JJ	_	7	dep
3	,	,	,	_	7	punct
4	nonpregnant	nonpregnant	JJ	_	5	amod
5	women	woman	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	selected	select	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	participate	participate	VB	_	7	xcomp
10	in	in	IN	_	14	case
11	4	4	CD	_	14	nummod
12	drug1	drug1	NN	_	14	compound
13	absorption	absorption	NN	_	14	compound
14	studies	study	NNS	_	9	nmod
15	using	use	VBG	_	14	acl
16	iron	iron	NN	_	18	compound
17	radioactive	radioactive	JJ	_	18	amod
18	tracers	tracer	NNS	_	15	dobj
19	.	.	.	_	7	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	doses	dose	NNS	_	4	nmod
8	between	between	IN	_	12	case
9	200	200	CD	_	12	nummod
10	and	and	CC	_	9	cc
11	1500	1500	CD	_	9	conj
12	mg	mg	NN	_	4	nmod
13	on	on	IN	_	14	case
14	absorption	absorption	NN	_	4	nmod
15	of	of	IN	_	18	case
16	5	5	CD	_	18	nummod
17	mg	mg	NN	_	18	compound
18	drug2	drug2	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	as	as	IN	_	21	case
21	drug3	drug3	NN	_	14	nmod
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	.	.	.	_	2	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	evaluated	evaluate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	doses	dose	NNS	_	5	nmod
9	between	between	IN	_	13	case
10	200	200	CD	_	13	nummod
11	and	and	CC	_	10	cc
12	800	800	CD	_	10	conj
13	mg	mg	NN	_	5	nmod
14	on	on	IN	_	15	case
15	absorption	absorption	NN	_	5	nmod
16	of	of	IN	_	19	case
17	5	5	CD	_	19	nummod
18	mg	mg	NN	_	19	compound
19	drug2	drug2	NN	_	15	nmod
20	-LSB-	-lsb-	-LRB-	_	23	punct
21	as	as	IN	_	23	case
22	concentrated	concentrated	JJ	_	23	amod
23	RBC	rbc	NNS	_	5	nmod
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	CRBC	crbc	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	-RSB-	-rsb-	-RRB-	_	23	punct
28	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	12	csubjpass
4	as	as	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	in	in	IN	_	8	case
7	all	all	DT	_	8	det
8	studies	study	NNS	_	3	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	were	be	VBD	_	12	auxpass
12	ingested	ingest	VBN	_	0	ROOT
13	on	on	IN	_	16	case
14	an	a	DT	_	16	det
15	empty	empty	JJ	_	16	amod
16	stomach	stomach	NN	_	12	nmod
17	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	compound
2	doses	dose	NNS	_	5	nsubj
3	1000	1000	CD	_	4	nummod
4	mg	mg	NN	_	2	dep
5	diminished	diminish	VBD	_	0	ROOT
6	drug2	drug2	NN	_	7	compound
7	absorption	absorption	NN	_	5	dobj
8	by	by	IN	_	10	case
9	an	a	DT	_	10	det
10	average	average	NN	_	5	nmod
11	of	of	IN	_	13	case
12	49.6	49.6	CD	_	13	nummod
13	%	%	NN	_	10	nmod
14	.	.	.	_	5	punct

1	A	a	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	dose	dose	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	800	800	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	diminished	diminish	VBD	_	0	ROOT
8	absorption	absorption	NN	_	7	dobj
9	of	of	IN	_	12	case
10	5	5	CD	_	11	compound
11	mg	mg	NN	_	12	amod
12	drug2	drug2	NN	_	8	nmod
13	by	by	IN	_	15	case
14	37.7	37.7	CD	_	15	nummod
15	%	%	NN	_	7	nmod
16	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	5	nmod
3	,	,	,	_	5	punct
4	we	we	PRP	_	5	nsubj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	an	a	DT	_	8	det
7	isolated	isolate	VBN	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	as	as	IN	_	13	case
13	chloride	chloride	NN	_	8	nmod
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	on	on	IN	_	16	case
16	absorption	absorption	NN	_	8	nmod
17	of	of	IN	_	19	case
18	5	5	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	of	of	IN	_	21	case
21	iron	iron	NN	_	19	nmod
22	provided	provide	VBN	_	8	acl
23	as	as	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	as	as	IN	_	27	case
27	sulfate	sulfate	NN	_	24	nmod
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	and	and	CC	_	24	cc
30	drug3	drug3	NN	_	35	compound
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	as	as	IN	_	33	case
33	CRBC	crbc	NN	_	35	dep
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	drug3	drug3	NN	_	24	conj
36	.	.	.	_	5	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	4	nmod
7	higher	higher	JJR	_	6	amod
8	than	than	IN	_	10	mark
9	previously	previously	RB	_	10	advmod
10	reported	report	VBN	_	7	advcl
11	from	from	IN	_	13	case
12	single-meal	single-meal	JJ	_	13	amod
13	studies	study	NNS	_	10	nmod
14	,	,	,	_	4	punct
15	starting	start	VBG	_	4	xcomp
16	at	at	IN	_	19	case
17	~	~	CD	_	18	compound
18	800	800	CD	_	19	nummod
19	mg	mg	NN	_	15	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	4	punct

1	Synergistic	synergistic	JJ	_	2	amod
2	interaction	interaction	NN	_	9	nsubj
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	9	cop
8	sequence	sequence	NN	_	9	nmod:npmod
9	dependent	dependent	JJ	_	0	ROOT
10	in	in	IN	_	14	case
11	human	human	JJ	_	14	amod
12	non-small	non-small	JJ	_	14	amod
13	lung	lung	NN	_	14	compound
14	cancer	cancer	NN	_	9	nmod
15	with	with	IN	_	18	case
16	EGFR	egfr	NN	_	18	compound
17	TKIs-resistant	tkis-resistant	JJ	_	18	amod
18	mutation	mutation	NN	_	14	nmod
19	.	.	.	_	9	punct

1	Previous	previous	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	that	that	IN	_	7	mark
6	drug1	drug1	NN	_	7	nsubj
7	has	have	VBZ	_	4	ccomp
8	the	the	DT	_	10	det
9	anti-tumor	anti-tumor	JJ	_	10	amod
10	activity	activity	NN	_	7	dobj
11	in	in	IN	_	16	case
12	human	human	JJ	_	16	amod
13	non-small	non-small	JJ	_	16	amod
14	cell	cell	NN	_	16	compound
15	lung	lung	NN	_	16	compound
16	cancer	cancer	NN	_	10	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	NSCLC	nsclc	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	aimed	aim	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	investigate	investigate	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	efficacy	efficacy	NN	_	6	dobj
9	of	of	IN	_	11	case
10	single	single	JJ	_	11	amod
11	use	use	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	4	cc
15	that	that	IN	_	4	conj
16	of	of	IN	_	20	case
17	concurrent	concurrent	JJ	_	20	amod
18	or	or	CC	_	17	cc
19	sequential	sequential	JJ	_	17	conj
20	administration	administration	NN	_	15	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	in	in	IN	_	28	case
26	NSCLC	nsclc	NN	_	28	compound
27	cell	cell	NN	_	28	compound
28	lines	line	NNS	_	20	nmod
29	that	that	WDT	_	31	nsubj
30	are	be	VBP	_	31	cop
31	resistant	resistant	JJ	_	28	acl:relcl
32	to	to	TO	_	34	case
33	EGFR	egfr	NN	_	34	compound
34	TKIs	tki	NNS	_	31	nmod
35	.	.	.	_	4	punct

1	NSCLC	nsclc	NN	_	3	compound
2	cell	cell	NN	_	3	compound
3	lines	line	NNS	_	12	nsubjpass
4	with	with	IN	_	7	case
5	EGFR	egfr	NN	_	7	compound
6	T790M	t790m	NN	_	7	compound
7	mutation	mutation	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	K-ras	k-ras	NN	_	10	compound
10	mutation	mutation	NN	_	7	conj
11	were	be	VBD	_	12	auxpass
12	exposed	expose	VBN	_	0	ROOT
13	to	to	TO	_	15	case
14	either	either	CC	_	15	cc:preconj
15	drug1	drug1	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	or	or	CC	_	15	cc
19	both	both	DT	_	15	conj
20	based	base	VBN	_	24	case
21	on	on	IN	_	24	case
22	various	various	JJ	_	24	amod
23	sequential	sequential	JJ	_	24	amod
24	administrations	administration	NNS	_	19	nmod
25	.	.	.	_	12	punct

1	After	after	IN	_	2	case
2	exposure	exposure	NN	_	8	nmod
3	,	,	,	_	8	punct
4	the	the	DT	_	6	det
5	cell	cell	NN	_	6	compound
6	viability	viability	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	measured	measure	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	MTT	MTT	NNP	_	11	compound
11	assay	assay	NN	_	8	nmod
12	,	,	,	_	11	punct
13	cell	cell	NN	_	15	compound
14	cycle	cycle	NN	_	15	compound
15	distribution	distribution	NN	_	11	appos
16	was	be	VBD	_	17	auxpass
17	analyzed	analyze	VBN	_	28	csubjpass
18	by	by	IN	_	20	case
19	flow	flow	NN	_	20	compound
20	cytometry	cytometry	NN	_	17	nmod
21	,	,	,	_	20	punct
22	and	and	CC	_	20	cc
23	alterations	alteration	NNS	_	20	conj
24	in	in	IN	_	26	case
25	signaling	signaling	NN	_	26	compound
26	pathway	pathway	NN	_	20	nmod
27	were	be	VBD	_	28	auxpass
28	determined	determine	VBN	_	8	ccomp
29	by	by	IN	_	30	case
30	immunoblotting	immunoblotting	NN	_	28	nmod
31	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	exhibited	exhibit	VBD	_	0	ROOT
3	dose-dependent	dose-dependent	JJ	_	5	amod
4	growth	growth	NN	_	5	compound
5	inhibition	inhibition	NN	_	2	dobj
6	in	in	IN	_	9	case
7	NSCLC	nsclc	NN	_	9	compound
8	cell	cell	NN	_	9	compound
9	lines	line	NNS	_	5	nmod
10	and	and	CC	_	2	cc
11	arrested	arrest	VBN	_	13	amod
12	cell	cell	NN	_	13	compound
13	cycle	cycle	NN	_	2	conj
14	at	at	IN	_	16	case
15	G1	g1	NN	_	16	compound
16	phase	phase	NN	_	13	nmod
17	,	,	,	_	2	punct
18	whereas	whereas	IN	_	2	dep
19	drug2	drug2	NN	_	2	dep
20	arrested	arrest	VBN	_	19	acl
21	at	at	IN	_	23	case
22	S	s	NN	_	23	compound
23	phase	phase	NN	_	20	nmod
24	.	.	.	_	2	punct

1	Although	although	IN	_	10	mark
2	single	single	JJ	_	5	amod
3	or	or	CC	_	2	cc
4	concurrent	concurrent	JJ	_	2	conj
5	use	use	NN	_	10	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	has	have	VBZ	_	22	advcl
11	some	some	DT	_	13	det
12	anti-proliferative	anti-proliferative	JJ	_	13	amod
13	effects	effect	NNS	_	10	dobj
14	,	,	,	_	22	punct
15	the	the	DT	_	17	det
16	sequential	sequential	JJ	_	17	amod
17	administrations	administration	NNS	_	22	nsubj
18	of	of	IN	_	20	case
19	both	both	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	remarkably	remarkably	RB	_	22	advmod
22	enhanced	enhance	VBD	_	0	ROOT
23	anti-tumor	anti-tumor	JJ	_	24	amod
24	activity	activity	NN	_	22	dobj
25	.	.	.	_	22	punct

1	When	when	WRB	_	4	advmod
2	cells	cell	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	exposed	expose	VBN	_	13	advcl
5	to	to	TO	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	followed	follow	VBN	_	4	dep
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	13	punct
11	synergism	synergism	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	molecular	molecular	JJ	_	3	amod
3	basis	basis	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	synergism	synergism	NN	_	3	nmod
7	is	be	VBZ	_	0	ROOT
8	that	that	IN	_	21	mark
9	the	the	DT	_	11	det
10	signaling	signaling	NN	_	11	compound
11	pathways	pathway	NNS	_	21	nsubjpass
12	that	that	WDT	_	15	nsubjpass
13	were	be	VBD	_	15	auxpass
14	initially	initially	RB	_	15	advmod
15	activated	activate	VBN	_	11	acl:relcl
16	by	by	IN	_	18	case
17	drug1	drug1	NN	_	18	compound
18	exposure	exposure	NN	_	15	nmod
19	were	be	VBD	_	21	auxpass
20	efficiently	efficiently	RB	_	21	advmod
21	suppressed	suppress	VBN	_	7	ccomp
22	by	by	IN	_	25	case
23	the	the	DT	_	25	det
24	subsequent	subsequent	JJ	_	25	amod
25	exposure	exposure	NN	_	21	nmod
26	to	to	TO	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	10	nmod
3	,	,	,	_	10	punct
4	the	the	DT	_	5	det
5	reverse	reverse	NN	_	10	nsubj
6	of	of	IN	_	9	case
7	this	this	DT	_	9	det
8	sequential	sequential	JJ	_	9	amod
9	administration	administration	NN	_	5	nmod
10	resulted	result	VBD	_	0	ROOT
11	in	in	IN	_	12	case
12	antagonism	antagonism	NN	_	10	nmod
13	,	,	,	_	12	punct
14	which	which	WDT	_	20	nsubj
15	may	may	MD	_	20	aux
16	be	be	VB	_	20	cop
17	due	due	JJ	_	20	case
18	to	to	TO	_	17	mwe
19	differential	differential	JJ	_	20	amod
20	effects	effect	NNS	_	12	acl:relcl
21	on	on	IN	_	24	case
22	cell	cell	NN	_	24	compound
23	cycle	cycle	NN	_	24	compound
24	arrest	arrest	NN	_	20	nmod
25	.	.	.	_	10	punct

1	drug1	drug1	NN	_	6	nsubj
2	as	as	IN	_	5	case
3	a	a	DT	_	5	det
4	single	single	JJ	_	5	amod
5	agent	agent	NN	_	1	nmod
6	exhibits	exhibit	VBZ	_	0	ROOT
7	anti-proliferative	anti-proliferative	JJ	_	8	amod
8	effects	effect	NNS	_	6	dobj
9	in	in	FW	_	10	compound
10	vitro	vitro	FW	_	6	advmod
11	in	in	IN	_	14	case
12	NSCLC	nsclc	NN	_	14	compound
13	cell	cell	NN	_	14	compound
14	lines	line	NNS	_	6	nmod
15	with	with	IN	_	17	case
16	EGFR	egfr	NN	_	17	compound
17	T790M	t790m	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	K-ras	k-ras	NN	_	20	compound
20	mutations	mutation	NNS	_	17	conj
21	but	but	CC	_	6	cc
22	the	the	DT	_	24	det
23	sequential	sequential	JJ	_	24	amod
24	administration	administration	NN	_	31	nsubj
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	followed	follow	VBN	_	24	acl
28	by	by	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	is	be	VBZ	_	31	cop
31	superior	superior	JJ	_	6	conj
32	to	to	TO	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	followed	follow	VBN	_	33	acl
35	by	by	IN	_	36	case
36	drug5	drug5	NN	_	34	nmod
37	and	and	CC	_	36	cc
38	concurrent	concurrent	JJ	_	39	amod
39	administration	administration	NN	_	36	conj
40	.	.	.	_	6	punct

1	Determinants	determinant	NNS	_	6	nsubj
2	of	of	IN	_	3	case
3	sensitivity	sensitivity	NN	_	1	nmod
4	to	to	TO	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	induced	induce	VBD	_	0	ROOT
7	apoptosis	apoptosis	NN	_	6	dobj
8	in	in	IN	_	11	case
9	multiple	multiple	JJ	_	11	amod
10	myeloma	myeloma	NN	_	11	compound
11	cells	cell	NNS	_	6	nmod
12	.	.	.	_	6	punct

1	The	the	DT	_	0	ROOT
2	drug1	drug1	NN	_	17	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	,	,	,	_	2	punct
7	one	one	CD	_	2	appos
8	of	of	IN	_	9	case
9	S-adenosylhomocysteine	s-adenosylhomocysteine	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	AdoHcy	adohcy	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	hydrolase	hydrolase	NN	_	14	compound
14	inhibitors	inhibitor	NNS	_	9	dep
15	,	,	,	_	2	punct
16	has	have	VBZ	_	17	aux
17	shown	show	VBN	_	1	acl:relcl
18	antitumor	antitumor	NN	_	19	compound
19	activities	activity	NNS	_	17	dobj
20	in	in	IN	_	23	case
21	a	a	DT	_	23	det
22	broad	broad	JJ	_	23	amod
23	range	range	NN	_	17	nmod
24	of	of	IN	_	26	case
25	solid	solid	JJ	_	26	amod
26	tumors	tumor	NNS	_	23	nmod
27	and	and	CC	_	26	cc
28	acute	acute	JJ	_	30	amod
29	myeloid	myeloid	JJ	_	30	amod
30	leukemia	leukemia	NN	_	26	conj
31	.	.	.	_	1	punct

1	Here	here	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	examined	examine	VBD	_	0	ROOT
5	its	its	PRP$	_	6	nmod:poss
6	effects	effect	NNS	_	4	dobj
7	on	on	IN	_	13	case
8	multiple	multiple	JJ	_	9	amod
9	myeloma	myeloma	NN	_	13	compound
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	MM	mm	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	cells	cell	NNS	_	6	nmod
14	and	and	CC	_	4	cc
15	found	find	VBD	_	4	conj
16	that	that	IN	_	24	mark
17	,	,	,	_	24	punct
18	at	at	IN	_	20	case
19	500	500	CD	_	20	nummod
20	nM	nm	NN	_	24	nmod
21	,	,	,	_	24	punct
22	it	it	PRP	_	24	nsubj
23	potently	potently	RB	_	24	advmod
24	inhibited	inhibit	VBD	_	15	ccomp
25	growth	growth	NN	_	24	dobj
26	and	and	CC	_	24	cc
27	induced	induce	VBD	_	24	conj
28	apoptosis	apoptosis	NN	_	27	dobj
29	in	in	IN	_	27	nmod
30	2	2	CD	_	29	dep
31	of	of	IN	_	35	case
32	8	8	CD	_	35	nummod
33	MM	mm	NN	_	35	compound
34	cell	cell	NN	_	35	compound
35	lines	line	NNS	_	30	nmod
36	.	.	.	_	4	punct

1	RNA	rna	NN	_	9	nsubjpass
2	from	from	IN	_	7	case
3	un-treated	un-treated	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	drug1	drug1	NN	_	3	conj
6	treated	treated	JJ	_	7	amod
7	cells	cell	NNS	_	1	nmod
8	was	be	VBD	_	9	auxpass
9	profiled	profile	VBN	_	26	csubjpass
10	by	by	IN	_	13	case
11	Affymetrix	Affymetrix	NNP	_	13	compound
12	HG-U133	HG-U133	NNP	_	13	compound
13	Plus	Plus	NNP	_	9	nmod
14	2.0	2.0	CD	_	15	nummod
15	microarray	microarray	NN	_	13	dep
16	and	and	CC	_	15	cc
17	genes	gene	NNS	_	15	conj
18	with	with	IN	_	21	case
19	a	a	DT	_	21	det
20	significant	significant	JJ	_	21	amod
21	change	change	NN	_	9	nmod
22	in	in	IN	_	24	case
23	gene	gene	NN	_	24	compound
24	expression	expression	NN	_	21	nmod
25	were	be	VBD	_	26	auxpass
26	determined	determine	VBN	_	0	ROOT
27	by	by	IN	_	29	case
28	significance	significance	NN	_	29	compound
29	analysis	analysis	NN	_	26	nmod
30	of	of	IN	_	31	case
31	microarray	microarray	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	SAM	sam	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	testing	testing	NN	_	31	dep
36	.	.	.	_	26	punct

1	ALOX5	alox5	NN	_	6	nsubj
2	was	be	VBD	_	6	cop
3	the	the	DT	_	6	det
4	most	most	RBS	_	5	advmod
5	down-regulated	down-regulate	VBN	_	6	amod
6	gene	gene	NN	_	0	ROOT
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	5.8-fold	5.8-fold	JJ	_	6	dep
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	in	in	IN	_	12	case
11	sensitive	sensitive	JJ	_	12	amod
12	cells	cell	NNS	_	6	nmod
13	and	and	CC	_	6	cc
14	was	be	VBD	_	15	auxpass
15	expressed	express	VBN	_	6	conj
16	at	at	IN	_	18	case
17	low	low	JJ	_	18	amod
18	level	level	NN	_	15	nmod
19	in	in	IN	_	21	case
20	resistant	resistant	JJ	_	21	amod
21	cells	cell	NNS	_	15	nmod
22	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	corroborated	corroborate	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	quantitative	quantitative	JJ	_	7	amod
7	RT-PCR	rt-pcr	NN	_	4	nmod
8	.	.	.	_	4	punct

1	Western-blot	western-blot	JJ	_	2	amod
2	analysis	analysis	NN	_	3	nsubj
3	indicated	indicate	VBD	_	0	ROOT
4	ALOX5	alox5	NN	_	7	nsubjpass
5	was	be	VBD	_	7	auxpass
6	highly	highly	RB	_	7	advmod
7	expressed	express	VBN	_	3	ccomp
8	only	only	RB	_	13	advmod
9	in	in	IN	_	13	case
10	sensitive	sensitive	JJ	_	13	amod
11	cell	cell	NN	_	13	compound
12	line	line	NN	_	13	compound
13	H929	h929	NN	_	7	nmod
14	and	and	CC	_	13	cc
15	greatly	greatly	RB	_	16	advmod
16	decreased	decrease	VBN	_	13	conj
17	upon	upon	IN	_	19	case
18	drug1	drug1	NN	_	19	compound
19	treatment	treatment	NN	_	16	nmod
20	.	.	.	_	3	punct

1	Ectopic	ectopic	JJ	_	2	amod
2	expression	expression	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	ALOX5	alox5	NN	_	2	nmod
5	reduced	reduce	VBD	_	0	ROOT
6	sensitivity	sensitivity	NN	_	5	dobj
7	to	to	TO	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	in	in	IN	_	11	case
10	H929	h929	NN	_	11	compound
11	cells	cell	NNS	_	6	nmod
12	.	.	.	_	5	punct

1	Furthermore	furthermore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	down-regulation	down-regulation	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	ALOX5	alox5	NN	_	3	nmod
6	by	by	IN	_	8	case
7	RNA	rna	NN	_	8	compound
8	interference	interference	NN	_	3	nmod
9	could	could	MD	_	11	aux
10	also	also	RB	_	11	advmod
11	induce	induce	VB	_	0	ROOT
12	apoptosis	apoptosis	NN	_	11	dobj
13	in	in	IN	_	14	case
14	H929	h929	NN	_	11	nmod
15	.	.	.	_	11	punct

1	Gene	gene	NN	_	3	compound
2	expression	expression	NN	_	3	compound
3	analysis	analysis	NN	_	8	nsubj
4	on	on	IN	_	7	case
5	MM	mm	NN	_	7	compound
6	patient	patient	NN	_	7	compound
7	dataset	dataset	NN	_	3	nmod
8	indicated	indicate	VBD	_	0	ROOT
9	ALOX5	alox5	NN	_	10	compound
10	expression	expression	NN	_	13	nsubj
11	was	be	VBD	_	13	cop
12	significantly	significantly	RB	_	13	advmod
13	higher	higher	JJR	_	8	ccomp
14	in	in	IN	_	16	case
15	MM	mm	NN	_	16	compound
16	patients	patient	NNS	_	13	nmod
17	compared	compare	VBN	_	21	case
18	to	to	TO	_	21	case
19	normal	normal	JJ	_	21	amod
20	plasma	plasma	NN	_	21	compound
21	cells	cell	NNS	_	13	advcl
22	.	.	.	_	8	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	found	find	VBD	_	0	ROOT
4	that	that	IN	_	7	mark
5	Bcl-2	bcl-2	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	overexpressed	overexpress	VBN	_	3	ccomp
8	in	in	IN	_	11	case
9	drug1	drug1	NN	_	11	compound
10	insensitive	insensitive	JJ	_	11	amod
11	cells	cell	NNS	_	7	nmod
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	cotreatment	cotreatment	NN	_	26	nsubj
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	a	a	DT	_	23	det
21	Bcl-2	bcl-2	NN	_	23	compound
22	family	family	NN	_	23	compound
23	inhibitor	inhibitor	NN	_	16	appos
24	,	,	,	_	16	punct
25	synergistically	synergistically	RB	_	26	advmod
26	inhibited	inhibit	VBD	_	7	conj
27	growth	growth	NN	_	26	dobj
28	and	and	CC	_	26	cc
29	induced	induce	VBD	_	26	conj
30	apoptosis	apoptosis	NN	_	29	dobj
31	of	of	IN	_	35	case
32	drug4	drug4	NN	_	35	compound
33	insensitive	insensitive	JJ	_	35	amod
34	MM	mm	NN	_	35	compound
35	cells	cell	NNS	_	30	nmod
36	.	.	.	_	3	punct

1	Taken	take	VBN	_	6	advcl
2	together	together	RB	_	1	advmod
3	,	,	,	_	6	punct
4	this	this	DT	_	5	det
5	study	study	NN	_	6	nsubj
6	shows	show	VBZ	_	0	ROOT
7	one	one	CD	_	16	nsubj
8	of	of	IN	_	9	case
9	mechanisms	mechanism	NNS	_	7	nmod
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	drug1	drug1	NN	_	13	compound
13	efficacy	efficacy	NN	_	9	nmod
14	on	on	IN	_	15	case
15	MM	mm	NN	_	13	nmod
16	correlates	correlate	VBZ	_	6	ccomp
17	with	with	IN	_	19	case
18	its	its	PRP$	_	19	nmod:poss
19	ability	ability	NN	_	16	nmod
20	to	to	TO	_	21	mark
21	down-regulate	down-regulate	VB	_	19	acl
22	the	the	DT	_	24	det
23	ALOX5	alox5	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	drug1	drug1	NN	_	5	compound
5	insensitivity	insensitivity	NN	_	8	nsubjpass
6	might	might	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	overexpression	overexpression	NN	_	8	nmod
11	of	of	IN	_	12	case
12	Bcl-2	bcl-2	NN	_	10	nmod
13	,	,	,	_	8	punct
14	and	and	CC	_	8	cc
15	the	the	DT	_	16	det
16	combination	combination	NN	_	23	nsubj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	could	could	MD	_	23	aux
22	synergistically	synergistically	RB	_	23	advmod
23	induced	induce	VBN	_	8	conj
24	apoptosis	apoptosis	NN	_	23	dobj
25	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	exploited	exploit	VBN	_	3	ccomp
9	therapeutically	therapeutically	RB	_	8	advmod
10	for	for	IN	_	12	case
11	a	a	DT	_	12	det
12	subset	subset	NN	_	8	nmod
13	of	of	IN	_	14	case
14	MM	mm	NN	_	12	nmod
15	.	.	.	_	3	punct

1	Drug	drug	NN	_	2	compound
2	interaction	interaction	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	infant	infant	NN	_	8	compound
7	colic	colic	JJ	_	8	amod
8	drops	drop	NNS	_	2	nmod
9	.	.	.	_	2	punct

1	drug1	drug1	NN	_	16	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	Forest	forest	NN	_	5	compound
4	Laboratories	Laboratories	NNPS	_	5	compound
5	UK	UK	NNP	_	1	dep
6	,	,	,	_	5	punct
7	Kent	Kent	NNP	_	5	appos
8	,	,	,	_	5	punct
9	UK	UK	NNP	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	5	punct
11	is	be	VBZ	_	16	cop
12	a	a	DT	_	16	det
13	widely	widely	RB	_	14	advmod
14	available	available	JJ	_	16	amod
15	over-the-counter	over-the-counter	JJ	_	16	amod
16	preparation	preparation	NN	_	0	ROOT
17	used	use	VBN	_	16	acl
18	to	to	TO	_	19	mark
19	relieve	relieve	VB	_	17	xcomp
20	colic	colic	JJ	_	21	amod
21	symptoms	symptom	NNS	_	19	dobj
22	in	in	IN	_	23	case
23	neonates	neonate	NNS	_	21	nmod
24	and	and	CC	_	23	cc
25	infants	infant	NNS	_	23	conj
26	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	active	active	JJ	_	3	amod
3	ingredient	ingredient	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	drug1	drug1	NN	_	0	ROOT
6	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	7	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	are	be	VBP	_	7	auxpass
7	documented	document	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	current	current	JJ	_	11	amod
11	summary	summary	NN	_	7	nmod
12	of	of	IN	_	14	case
13	product	product	NN	_	14	compound
14	characteristics	characteristic	NNS	_	11	nmod
15	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	authors	author	NNS	_	3	nsubj
3	report	report	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	case	case	NN	_	3	dobj
6	of	of	IN	_	8	case
7	an	a	DT	_	8	det
8	infant	infant	NN	_	5	nmod
9	with	with	IN	_	12	case
10	confirmed	confirm	VBN	_	12	amod
11	congenital	congenital	JJ	_	12	amod
12	hypothyroidism	hypothyroidism	NN	_	8	nmod
13	on	on	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	who	who	WP	_	16	nsubj
16	experienced	experience	VBD	_	8	acl:relcl
17	a	a	DT	_	20	det
18	possible	possible	JJ	_	20	amod
19	drug	drug	NN	_	20	compound
20	interaction	interaction	NN	_	16	dobj
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	3	punct

1	Despite	despite	IN	_	4	case
2	adequate	adequate	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	dosage	dosage	NN	_	13	nmod
5	,	,	,	_	13	punct
6	thyroid	thyroid	NN	_	8	compound
7	stimulating	stimulating	NN	_	8	compound
8	hormone	hormone	NN	_	13	nsubj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	TSH	tsh	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	was	be	VBD	_	13	cop
13	high	high	JJ	_	0	ROOT
14	,	,	,	_	13	punct
15	suggesting	suggest	VBG	_	13	xcomp
16	undertreatment	undertreatment	NN	_	15	dobj
17	.	.	.	_	13	punct

1	Questioning	question	VBG	_	2	nsubj
2	revealed	reveal	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	child	child	NN	_	6	nsubj
5	was	be	VBD	_	6	aux
6	taking	take	VBG	_	2	ccomp
7	drug1	drug1	NN	_	8	compound
8	drops	drop	NNS	_	6	dobj
9	before	before	IN	_	10	mark
10	feeds	feed	VBZ	_	6	advcl
11	while	while	IN	_	13	mark
12	on	on	IN	_	13	case
13	drug2	drug2	NN	_	10	advcl
14	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	colic	colic	JJ	_	3	amod
3	drops	drop	NNS	_	6	nsubjpass
4	were	be	VBD	_	6	auxpass
5	immediately	immediately	RB	_	6	advmod
6	discontinued	discontinue	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	TSH	tsh	NN	_	10	nsubj
9	promptly	promptly	RB	_	10	advmod
10	normalised	normalise	VBD	_	6	conj
11	with	with	IN	_	13	case
12	a	a	DT	_	13	det
13	reduction	reduction	NN	_	10	nmod
14	in	in	IN	_	16	case
15	thyroxine	thyroxine	NN	_	16	compound
16	requirement	requirement	NN	_	13	nmod
17	to	to	TO	_	21	case
18	an	a	DT	_	21	det
19	age	age	NN	_	21	compound
20	appropriate	appropriate	JJ	_	21	amod
21	dosage	dosage	NN	_	13	nmod
22	.	.	.	_	6	punct

1	Drug	drug	NN	_	2	compound
2	interaction	interaction	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	previously	previously	RB	_	10	advmod
12	and	and	CC	_	10	cc
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	listed	list	VBN	_	10	conj
16	in	in	IN	_	20	case
17	the	the	DT	_	20	det
18	British	British	NNP	_	20	compound
19	National	National	NNP	_	20	compound
20	Formulary	Formulary	NNP	_	15	nmod
21	for	for	IN	_	22	case
22	Children	Children	NNP	_	15	nmod
23	.	.	.	_	10	punct

1	Clinicians	clinician	NNS	_	4	nsubj
2	and	and	CC	_	1	cc
3	parents	parent	NNS	_	1	conj
4	need	need	VBP	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	cop
7	aware	aware	JJ	_	4	xcomp
8	of	of	IN	_	10	case
9	this	this	DT	_	10	det
10	interaction	interaction	NN	_	7	nmod
11	to	to	TO	_	12	mark
12	avoid	avoid	VB	_	10	acl
13	unnecessary	unnecessary	JJ	_	14	amod
14	undertreatment	undertreatment	NN	_	12	dobj
15	and	and	CC	_	12	cc
16	prevent	prevent	VB	_	12	conj
17	potential	potential	JJ	_	20	amod
18	long-term	long-term	JJ	_	20	amod
19	neurological	neurological	JJ	_	20	amod
20	sequelae	sequelae	NN	_	16	dobj
21	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	compound
2	locomotor	locomotor	NN	_	3	compound
3	sensitization	sensitization	NN	_	0	ROOT
4	and	and	CC	_	3	cc
5	conditioned	condition	VBN	_	7	amod
6	place	place	NN	_	7	compound
7	preference	preference	NN	_	3	conj
8	in	in	IN	_	10	case
9	adolescent	adolescent	JJ	_	10	amod
10	male	male	NN	_	3	nmod
11	and	and	CC	_	10	cc
12	female	female	JJ	_	13	amod
13	rats	rat	NNS	_	10	conj
14	neonatally	neonatally	RB	_	15	advmod
15	treated	treat	VBN	_	10	acl
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	3	punct

1	Neonatal	neonatal	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	treatment	treatment	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	shown	show	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	produce	produce	VB	_	6	xcomp
9	an	a	DT	_	10	det
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	15	case
12	dopamine	dopamine	NN	_	15	compound
13	D2-like	d2-like	JJ	_	15	amod
14	receptor	receptor	NN	_	15	compound
15	sensitivity	sensitivity	NN	_	10	nmod
16	that	that	WDT	_	17	nsubj
17	persists	persist	VBZ	_	10	acl:relcl
18	throughout	throughout	IN	_	22	case
19	the	the	DT	_	20	det
20	subject	subject	NN	_	22	nmod:poss
21	's	's	POS	_	20	case
22	lifetime	lifetime	NN	_	17	nmod
23	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	objective	objective	NN	_	3	nsubj
3	was	be	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	analyze	analyze	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	11	case
9	neonatal	neonatal	JJ	_	11	amod
10	drug1	drug1	NN	_	11	compound
11	treatment	treatment	NN	_	7	nmod
12	on	on	IN	_	13	case
13	effects	effect	NNS	_	7	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	in	in	IN	_	18	case
17	adolescent	adolescent	JJ	_	18	amod
18	rats	rat	NNS	_	13	nmod
19	using	use	VBG	_	5	xcomp
20	locomotor	locomotor	JJ	_	21	amod
21	sensitization	sensitization	NN	_	19	dobj
22	and	and	CC	_	21	cc
23	conditioned	condition	VBN	_	26	amod
24	place	place	NN	_	26	compound
25	preference	preference	NN	_	26	compound
26	procedures	procedure	NNS	_	21	conj
27	.	.	.	_	3	punct

1	Sprague-Dawley	sprague-dawley	JJ	_	2	amod
2	rats	rat	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	treated	treat	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	1	1	CD	_	9	nummod
9	mg/kg	mg/kg	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	or	or	CC	_	6	cc
12	saline	saline	NN	_	6	conj
13	from	from	IN	_	15	case
14	postnatal	postnatal	JJ	_	15	amod
15	days	day	NNS	_	4	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	P	p	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	1	1	CD	_	15	nummod
20	to	to	TO	_	21	case
21	P11	p11	CD	_	19	nmod
22	and	and	CC	_	4	cc
23	raised	raise	VBD	_	4	conj
24	to	to	TO	_	25	case
25	adolescence	adolescence	NN	_	23	nmod
26	.	.	.	_	4	punct

1	For	for	IN	_	3	case
2	locomotor	locomotor	JJ	_	3	amod
3	sensitization	sensitization	NN	_	7	nmod
4	,	,	,	_	7	punct
5	subjects	subject	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	drug1	drug1	NN	_	7	dobj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	1	1	CD	_	11	nummod
11	mg/kg	mg/kg	NN	_	8	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	or	or	CC	_	8	cc
14	saline	saline	NN	_	8	conj
15	every	every	DT	_	17	det
16	second	second	JJ	_	17	amod
17	day	day	NN	_	7	nmod:tmod
18	from	from	IN	_	19	case
19	P35	p35	NN	_	7	nmod
20	to	to	TO	_	21	case
21	P47	p47	NN	_	19	nmod
22	and	and	CC	_	7	cc
23	were	be	VBD	_	24	auxpass
24	placed	place	VBN	_	7	conj
25	into	into	IN	_	28	case
26	a	a	DT	_	28	det
27	locomotor	locomotor	JJ	_	28	amod
28	arena	arena	NN	_	24	nmod
29	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	female	female	JJ	_	3	amod
3	rats	rat	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	neonatal	neonatal	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	treatment	treatment	NN	_	8	nsubj
8	enhanced	enhance	VBD	_	0	ROOT
9	drug2	drug2	NN	_	11	compound
10	locomotor	locomotor	NN	_	11	compound
11	sensitization	sensitization	NN	_	8	dobj
12	compared	compare	VBN	_	14	case
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	8	advcl
15	-	-	:	_	14	punct
16	free	free	JJ	_	17	amod
17	controls	control	NNS	_	14	dep
18	sensitized	sensitize	VBN	_	17	acl
19	to	to	TO	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	.	.	.	_	8	punct

1	Male	male	JJ	_	2	amod
2	rats	rat	NNS	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	sensitization	sensitization	NN	_	3	dobj
5	to	to	TO	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	3	punct
8	although	although	IN	_	11	mark
9	this	this	DT	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	muted	mute	VBN	_	3	advcl
12	compared	compare	VBN	_	15	case
13	with	with	IN	_	15	case
14	female	female	JJ	_	15	amod
15	rats	rat	NNS	_	11	advcl
16	,	,	,	_	3	punct
17	and	and	CC	_	3	cc
18	were	be	VBD	_	19	aux
19	unaffected	unaffected	JJ	_	3	conj
20	by	by	IN	_	22	case
21	neonatal	neonatal	JJ	_	22	amod
22	drug2	drug2	NN	_	19	nmod
23	.	.	.	_	3	punct

1	For	for	IN	_	4	case
2	conditioned	condition	VBN	_	4	amod
3	place	place	NN	_	4	compound
4	preference	preference	NN	_	8	nmod
5	,	,	,	_	8	punct
6	subjects	subject	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	conditioned	condition	VBN	_	0	ROOT
9	for	for	IN	_	12	case
10	8	8	CD	_	12	nummod
11	consecutive	consecutive	JJ	_	12	amod
12	days	day	NNS	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	P32-39	p32-39	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	12	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	1	1	CD	_	20	nummod
20	mg/kg	mg/kg	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	or	or	CC	_	17	cc
23	saline	saline	NN	_	17	conj
24	and	and	CC	_	23	cc
25	a	a	DT	_	28	det
26	drug-free	drug-free	JJ	_	28	amod
27	preference	preference	NN	_	28	compound
28	test	test	NN	_	23	conj
29	was	be	VBD	_	30	auxpass
30	conducted	conduct	VBN	_	8	dep
31	at	at	IN	_	32	case
32	P40	p40	NN	_	30	nmod
33	.	.	.	_	8	punct

1	Rats	rat	NNS	_	6	nsubj
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	5	case
4	neonatal	neonatal	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	enhanced	enhance	VBD	_	0	ROOT
7	time	time	NN	_	6	dobj
8	spent	spend	VBN	_	7	acl
9	in	in	IN	_	14	case
10	the	the	DT	_	14	det
11	drug2	drug2	NN	_	14	compound
12	-	-	:	_	14	punct
13	paired	paired	JJ	_	14	amod
14	context	context	NN	_	8	nmod
15	compared	compare	VBN	_	17	case
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	6	advcl
18	-	-	:	_	17	punct
19	free	free	JJ	_	20	amod
20	controls	control	NNS	_	17	dep
21	conditioned	condition	VBN	_	20	acl
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	,	,	,	_	6	punct
25	but	but	CC	_	6	cc
26	only	only	RB	_	28	advmod
27	female	female	JJ	_	28	amod
28	controls	control	NNS	_	32	nsubj
29	conditioned	condition	VBN	_	28	acl
30	with	with	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	spent	spend	VBD	_	6	conj
33	more	more	JJR	_	34	amod
34	time	time	NN	_	32	dobj
35	in	in	IN	_	38	case
36	the	the	DT	_	38	det
37	drug-paired	drug-paired	JJ	_	38	amod
38	context	context	NN	_	32	nmod
39	compared	compare	VBN	_	42	case
40	with	with	IN	_	42	case
41	saline-treated	saline-treated	JJ	_	42	amod
42	controls	control	NNS	_	32	advcl
43	.	.	.	_	6	punct

1	Increased	increase	VBN	_	2	amod
2	D	d	NN	_	7	nsubj
3	-	-	:	_	2	punct
4	like	like	IN	_	6	case
5	receptor	receptor	NN	_	6	compound
6	sensitivity	sensitivity	NN	_	2	nmod
7	appears	appear	VBZ	_	0	ROOT
8	to	to	TO	_	10	mark
9	have	have	VB	_	10	aux
10	enhanced	enhance	VBN	_	7	xcomp
11	the	the	DT	_	13	det
12	behavioral	behavioral	JJ	_	13	amod
13	effects	effect	NNS	_	10	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	,	,	,	_	7	punct
17	but	but	CC	_	7	cc
18	these	these	DT	_	19	det
19	effects	effect	NNS	_	22	nsubj
20	were	be	VBD	_	22	cop
21	more	more	RBR	_	22	advmod
22	prevalent	prevalent	JJ	_	7	conj
23	in	in	IN	_	26	case
24	adolescent	adolescent	JJ	_	26	amod
25	female	female	JJ	_	26	amod
26	rats	rat	NNS	_	22	nmod
27	compared	compare	VBN	_	30	case
28	with	with	IN	_	30	case
29	male	male	JJ	_	30	amod
30	rats	rat	NNS	_	22	advcl
31	.	.	.	_	7	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-	-	:	_	1	punct
5	mediated	mediate	VBN	_	7	amod
6	CYP3A4	cyp3a4	NN	_	7	compound
7	inhibition	inhibition	NN	_	1	dep
8	on	on	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	12	punct
17	an	a	DT	_	20	det
18	orally	orally	RB	_	19	advmod
19	active	active	JJ	_	20	amod
20	drug4	drug4	NN	_	12	appos
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	partly	partly	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	CYP3A4	cyp3a4	NN	_	4	nmod
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	4	advmod
9	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	evaluated	evaluate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	10	case
7	a	a	DT	_	10	det
8	potent	potent	JJ	_	10	amod
9	CYP3A	cyp3a	NN	_	10	compound
10	inhibitor	inhibitor	NN	_	5	nmod
11	,	,	,	_	10	punct
12	drug1	drug1	NN	_	10	appos
13	,	,	,	_	10	punct
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
17	and	and	CC	_	16	cc
18	safety	safety	NN	_	16	conj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	16	nmod
21	.	.	.	_	3	punct

1	Patients	patient	NNS	_	2	nsubj
2	received	receive	VBD	_	0	ROOT
3	a	a	DT	_	7	det
4	single	single	JJ	_	7	amod
5	drug1	drug1	NN	_	7	compound
6	oral	oral	JJ	_	7	amod
7	dose	dose	NN	_	2	dobj
8	on	on	IN	_	9	case
9	day	day	NN	_	2	nmod
10	1	1	CD	_	9	nummod
11	,	,	,	_	2	punct
12	followed	follow	VBN	_	2	advcl
13	by	by	IN	_	15	case
14	4	4	CD	_	15	nummod
15	days	day	NNS	_	12	nmod
16	wash-out	wash-out	JJ	_	17	amod
17	period	period	NN	_	15	dep
18	.	.	.	_	2	punct

1	On	on	IN	_	2	case
2	days	day	NNS	_	7	nmod
3	5-9	5-9	CD	_	2	nummod
4	,	,	,	_	7	punct
5	drug1	drug1	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	10	nmod
3	8	8	CD	_	2	nummod
4	,	,	,	_	10	punct
5	a	a	DT	_	8	det
6	single	single	JJ	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	dose	dose	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	co-administered	co-administer	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	10	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	0	ROOT
4	as	as	IN	_	6	case
5	single	single	JJ	_	6	amod
6	agent	agent	NN	_	3	nmod
7	three	three	CD	_	8	nummod
8	times	time	NNS	_	3	nmod:tmod
9	a	a	DT	_	10	det
10	week	week	NN	_	8	nmod:npmod
11	on	on	IN	_	12	case
12	day	day	NN	_	3	nmod
13	15	15	CD	_	12	nummod
14	and	and	CC	_	12	cc
15	onward	onward	RB	_	12	conj
16	.	.	.	_	3	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	dep
3	presence	presence	NN	_	5	dep
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	8	nmod
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	was	be	VBD	_	0	ROOT
9	1.6	1.6	CD	_	13	dep
10	-	-	:	_	13	punct
11	and	and	CC	_	13	cc
12	1.8-fold	1.8-fold	JJ	_	13	amod
13	increase	increase	NN	_	8	dep
14	in	in	IN	_	17	case
15	C	c	NN	_	17	compound
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	max	max	NN	_	13	nmod
18	-RRB-	-rrb-	-RRB-	_	13	punct
19	and	and	CC	_	13	cc
20	AUC	auc	NN	_	13	conj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	,	,	,	_	13	punct
24	respectively	respectively	RB	_	13	advmod
25	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	substantial	substantial	JJ	_	3	amod
3	change	change	NN	_	12	nsubjpass
4	in	in	IN	_	7	case
5	T	t	NN	_	7	compound
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	max	max	NN	_	3	nmod
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	or	or	CC	_	7	cc
10	half-life	half-life	NN	_	7	conj
11	was	be	VBD	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	No	no	DT	_	2	neg
2	difference	difference	NN	_	0	ROOT
3	in	in	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-	-	:	_	2	punct
6	pharmacokinetics	pharmacokinetic	NNS	_	2	dep
7	between	between	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	carrying	carry	VBG	_	8	acl
10	CYP3A5	cyp3a5	NN	_	9	dobj
11	*	*	SYM	_	12	dep
12	1	1	CD	_	25	nsubjpass
13	/	/	:	_	12	punct
14	*	*	SYM	_	15	dep
15	3	3	CD	_	12	dep
16	and	and	CC	_	15	cc
17	CYP3A5	cyp3a5	NN	_	19	dep
18	*	*	SYM	_	19	dep
19	3	3	CD	_	15	conj
20	/	/	:	_	12	punct
21	*	*	SYM	_	22	dep
22	3	3	CD	_	23	nummod
23	alleles	allele	NNS	_	12	dep
24	was	be	VBD	_	25	auxpass
25	observed	observe	VBN	_	8	acl:relcl
26	.	.	.	_	2	punct

1	Most	most	JJS	_	3	nsubj
2	frequently	frequently	RB	_	3	advmod
3	reported	report	VBN	_	0	ROOT
4	adverse	adverse	JJ	_	5	amod
5	events	event	NNS	_	8	nsubj
6	were	be	VBD	_	8	cop
7	gastrointestinal	gastrointestinal	JJ	_	8	amod
8	related	related	JJ	_	3	ccomp
9	.	.	.	_	3	punct

1	Patients	patient	NNS	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	asymptomatic	asymptomatic	JJ	_	4	amod
4	hypophosphatemia	hypophosphatemia	NN	_	13	nsubj
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	64	64	CD	_	7	nummod
7	%	%	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	urine	urine	NN	_	12	compound
12	analysis	analysis	NN	_	4	conj
13	suggested	suggest	VBD	_	2	ccomp
14	renal	renal	JJ	_	15	amod
15	phosphate	phosphate	NN	_	16	nsubj
16	wasting	waste	VBG	_	13	ccomp
17	.	.	.	_	2	punct

1	Co-administration	co-administration	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	CYP3A	cyp3a	NN	_	6	compound
6	inhibitors	inhibitor	NNS	_	1	nmod
7	is	be	VBZ	_	8	cop
8	feasible	feasible	JJ	_	19	csubjpass
9	as	as	IN	_	12	case
10	the	the	DT	_	12	det
11	observed	observe	VBN	_	12	amod
12	increase	increase	NN	_	8	nmod
13	in	in	IN	_	16	case
14	drug2	drug2	NN	_	16	compound
15	PK	pk	NN	_	16	compound
16	parameters	parameter	NNS	_	12	nmod
17	was	be	VBD	_	19	auxpass
18	not	not	RB	_	19	neg
19	considered	consider	VBN	_	0	ROOT
20	clinically	clinically	RB	_	21	advmod
21	relevant	relevant	JJ	_	19	xcomp
22	.	.	.	_	19	punct

1	Considering	consider	VBG	_	0	ROOT
2	the	the	DT	_	3	det
3	variability	variability	NN	_	1	dobj
4	in	in	IN	_	5	case
5	exposure	exposure	NN	_	1	nmod
6	following	follow	VBG	_	8	case
7	enzyme	enzyme	NN	_	8	compound
8	inhibition	inhibition	NN	_	5	nmod
9	and	and	CC	_	1	cc
10	the	the	DT	_	11	det
11	fact	fact	NN	_	1	conj
12	that	that	IN	_	19	mark
13	chronic	chronic	JJ	_	14	amod
14	dosing	dosing	NN	_	19	nsubjpass
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	was	be	VBD	_	19	auxpass
18	not	not	RB	_	19	neg
19	studied	study	VBN	_	11	ccomp
20	with	with	IN	_	22	case
21	CYP3A	cyp3a	NN	_	22	compound
22	inhibitors	inhibitor	NNS	_	33	nmod
23	,	,	,	_	22	punct
24	close	close	JJ	_	25	amod
25	monitoring	monitoring	NN	_	22	appos
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-	-	:	_	22	punct
29	related	related	JJ	_	31	amod
30	adverse	adverse	JJ	_	31	amod
31	events	event	NNS	_	33	nsubj
32	is	be	VBZ	_	33	cop
33	necessary	necessary	JJ	_	19	ccomp
34	.	.	.	_	1	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	CYP	cyp	NN	_	4	compound
4	inhibitors	inhibitor	NNS	_	1	nmod
5	on	on	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	metabolism	metabolism	NN	_	1	nmod
8	and	and	CC	_	7	cc
9	toxicity	toxicity	NN	_	7	conj
10	in	in	IN	_	13	case
11	rat	rat	NN	_	13	compound
12	liver	liver	NN	_	13	compound
13	slices	slice	NNS	_	7	nmod
14	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	present	present	VBP	_	0	ROOT
3	a	a	DT	_	7	det
4	comprehensive	comprehensive	JJ	_	7	amod
5	in	in	FW	_	7	amod
6	vitro	vitro	FW	_	5	dep
7	approach	approach	NN	_	2	dobj
8	to	to	TO	_	9	mark
9	assessing	assess	VBG	_	7	acl
10	metabolism-mediated	metabolism-mediated	JJ	_	11	amod
11	hepatotoxicity	hepatotoxicity	NN	_	9	dobj
12	using	use	VBG	_	9	xcomp
13	male	male	JJ	_	17	amod
14	Sprague-Dawley	sprague-dawley	JJ	_	17	amod
15	rat	rat	NN	_	17	compound
16	liver	liver	NN	_	17	compound
17	slices	slice	NNS	_	12	dobj
18	incubated	incubate	VBN	_	17	acl
19	with	with	IN	_	23	case
20	the	the	DT	_	23	det
21	well	well	RB	_	22	advmod
22	characterized	characterize	VBN	_	23	amod
23	hepatotoxicant	hepatotoxicant	NN	_	18	nmod
24	,	,	,	_	23	punct
25	drug1	drug1	NN	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	inhibitors	inhibitor	NNS	_	23	conj
29	of	of	IN	_	31	case
30	cytochrome	cytochrome	NN	_	31	compound
31	P450	p450	NN	_	28	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	CYP	cyp	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	enzymes	enzyme	NNS	_	31	dep
36	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	approach	approach	NN	_	3	nsubj
3	combines	combine	VBZ	_	0	ROOT
4	liquid	liquid	JJ	_	7	amod
5	chromatography	chromatography	NN	_	7	compound
6	mass	mass	NN	_	7	compound
7	spectrometry	spectrometry	NN	_	13	compound
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	LC	lc	NN	_	10	compound
10	MS	ms	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	detection	detection	NN	_	13	compound
13	methods	method	NNS	_	3	dobj
14	with	with	IN	_	17	case
15	multiple	multiple	JJ	_	17	amod
16	toxicity	toxicity	NN	_	17	compound
17	endpoints	endpoint	NNS	_	13	nmod
18	to	to	TO	_	19	mark
19	enable	enable	VB	_	3	advcl
20	identification	identification	NN	_	19	dobj
21	of	of	IN	_	24	case
22	critical	critical	JJ	_	24	amod
23	metabolic	metabolic	JJ	_	24	amod
24	pathways	pathway	NNS	_	20	nmod
25	for	for	IN	_	26	case
26	hepatotoxicity	hepatotoxicity	NN	_	24	nmod
27	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	incubations	incubation	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	performed	perform	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	dep
7	absence	absence	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	presence	presence	NN	_	7	conj
10	of	of	IN	_	14	case
11	the	the	DT	_	14	det
12	non-specific	non-specific	JJ	_	14	amod
13	CYP	cyp	NN	_	14	compound
14	inhibitor	inhibitor	NN	_	7	nmod
15	,	,	,	_	14	punct
16	drug1	drug1	NN	_	14	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug2	drug2	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	and	and	CC	_	14	cc
21	isoform-specific	isoform-specific	JJ	_	22	amod
22	inhibitors	inhibitor	NNS	_	14	conj
23	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	metabolite	metabolite	NN	_	3	compound
3	profile	profile	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	in	in	IN	_	9	case
7	rat	rat	NN	_	9	compound
8	liver	liver	NN	_	9	compound
9	slices	slice	NNS	_	3	nmod
10	shares	share	VBZ	_	0	ROOT
11	some	some	DT	_	12	det
12	features	feature	NNS	_	10	dobj
13	of	of	IN	_	17	case
14	the	the	DT	_	17	det
15	in	in	FW	_	17	amod
16	vivo	vivo	FW	_	15	dep
17	profile	profile	NN	_	12	nmod
18	,	,	,	_	10	punct
19	but	but	CC	_	10	cc
20	also	also	RB	_	21	advmod
21	had	have	VBD	_	10	conj
22	a	a	DT	_	24	det
23	major	major	JJ	_	24	amod
24	difference	difference	NN	_	21	dobj
25	in	in	IN	_	33	mark
26	that	that	DT	_	33	mark
27	epoxide	epoxide	NN	_	30	compound
28	dihydrodiol	dihydrodiol	NN	_	30	compound
29	hydrolysis	hydrolysis	NN	_	30	compound
30	products	product	NNS	_	33	nsubjpass
31	were	be	VBD	_	33	auxpass
32	not	not	RB	_	33	neg
33	observed	observe	VBN	_	24	acl
34	to	to	TO	_	37	case
35	a	a	DT	_	37	det
36	measurable	measurable	JJ	_	37	amod
37	extent	extent	NN	_	33	nmod
38	.	.	.	_	10	punct

1	As	as	IN	_	2	case
2	examples	example	NNS	_	25	nmod
3	of	of	IN	_	9	case
4	our	we	PRP$	_	9	nmod:poss
5	liver	liver	NN	_	9	compound
6	slice	slice	NN	_	9	compound
7	metabolite	metabolite	NN	_	9	compound
8	identification	identification	NN	_	9	compound
9	procedure	procedure	NN	_	2	nmod
10	,	,	,	_	25	punct
11	a	a	DT	_	14	det
12	minor	minor	JJ	_	14	amod
13	glutathione	glutathione	NN	_	14	compound
14	adduct	adduct	NN	_	25	nsubjpass
15	and	and	CC	_	14	cc
16	previously	previously	RB	_	17	advmod
17	unreported	unreported	JJ	_	18	amod
18	7-O-desmethyl	7-o-desmethyl	NN	_	14	conj
19	and	and	CC	_	14	cc
20	glucuronidated	glucuronidate	VBN	_	21	amod
21	metabolites	metabolite	NNS	_	14	conj
22	of	of	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	are	be	VBP	_	25	auxpass
25	reported	report	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	drug1	drug1	NN	_	2	nsubj
2	induced	induce	VBD	_	0	ROOT
3	hepatocellular	hepatocellular	JJ	_	4	amod
4	necrosis	necrosis	NN	_	2	dobj
5	in	in	IN	_	7	case
6	a	a	DT	_	7	det
7	dose	dose	NN	_	2	nmod
8	-	-	:	_	2	punct
9	and	and	CC	_	2	cc
10	time-dependent	time-dependent	JJ	_	11	amod
11	manner	manner	NN	_	2	conj
12	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	toxicity	toxicity	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	2	punct
8	increased	increase	VBD	_	9	amod
9	exposure	exposure	NN	_	2	conj
10	to	to	TO	_	12	case
11	parent	parent	NN	_	12	compound
12	compound	compound	NN	_	9	nmod
13	,	,	,	_	2	punct
14	and	and	CC	_	2	cc
15	decreased	decrease	VBD	_	2	conj
16	metabolite	metabolite	NN	_	17	compound
17	levels	level	NNS	_	15	dobj
18	in	in	IN	_	21	case
19	a	a	DT	_	21	det
20	dose-dependent	dose-dependent	JJ	_	21	amod
21	manner	manner	NN	_	15	nmod
22	.	.	.	_	2	punct

1	Of	of	IN	_	5	case
2	the	the	DT	_	5	det
3	isoform-specific	isoform-specific	JJ	_	5	amod
4	CYP	cyp	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	20	nmod
6	tested	test	VBN	_	5	acl
7	for	for	IN	_	9	case
8	an	a	DT	_	9	det
9	effect	effect	NN	_	6	nmod
10	on	on	IN	_	14	case
11	the	the	DT	_	14	det
12	drug1	drug1	NN	_	14	compound
13	metabolite	metabolite	NN	_	14	compound
14	profile	profile	NN	_	9	nmod
15	,	,	,	_	20	punct
16	only	only	RB	_	17	advmod
17	drug2	drug2	NN	_	20	nsubj
18	was	be	VBD	_	20	cop
19	noticeably	noticeably	RB	_	20	advmod
20	effective	effective	JJ	_	0	ROOT
21	,	,	,	_	20	punct
22	indicating	indicate	VBG	_	20	xcomp
23	a	a	DT	_	24	det
24	role	role	NN	_	22	dobj
25	of	of	IN	_	27	case
26	CYPs	cyp	NNS	_	27	compound
27	2A6	2a6	NN	_	24	nmod
28	,	,	,	_	27	punct
29	2C9	2c9	NN	_	27	conj
30	,	,	,	_	27	punct
31	2Cl9	2cl9	NN	_	27	conj
32	,	,	,	_	27	punct
33	and	and	CC	_	27	cc
34	2E1	2e1	NN	_	27	conj
35	.	.	.	_	20	punct

1	With	with	IN	_	2	case
2	respect	respect	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	toxicity	toxicity	NN	_	2	nmod
5	,	,	,	_	2	punct
6	the	the	DT	_	7	det
7	order	order	NN	_	5	root
8	of	of	IN	_	11	case
9	CYP	cyp	NN	_	11	compound
10	inhibitor	inhibitor	NN	_	11	compound
11	effectiveness	effectiveness	NN	_	7	nmod
12	was	be	VBD	_	7	acl
13	drug1	drug1	CD	_	17	nummod
14	>	>	JJR	_	17	dep
15	drug2	drug2	NN	_	17	compound
16	~	~	CD	_	17	nummod
17	drug3	drug3	NN	_	12	nsubj
18	>	>	JJR	_	19	amod
19	drug4	drug4	NN	_	17	dep
20	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	had	have	VBD	_	0	ROOT
5	no	no	DT	_	6	neg
6	effect	effect	NN	_	4	dobj
7	,	,	,	_	4	punct
8	while	while	IN	_	10	mark
9	drug3	drug3	NN	_	10	nsubj
10	appeared	appear	VBD	_	4	advcl
11	to	to	TO	_	12	mark
12	augment	augment	VB	_	10	xcomp
13	drug4	drug4	NN	_	14	compound
14	toxicity	toxicity	NN	_	12	dobj
15	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	rat	rat	NN	_	7	compound
6	liver	liver	NN	_	7	compound
7	slices	slice	NNS	_	10	nsubj
8	do	do	VBP	_	10	aux
9	not	not	RB	_	10	neg
10	reproduce	reproduce	VB	_	3	ccomp
11	the	the	DT	_	15	det
12	reported	report	VBN	_	15	amod
13	in	in	FW	_	15	amod
14	vivo	vivo	FW	_	13	dep
15	biotransformation	biotransformation	NN	_	10	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	10	cc
19	therefore	therefore	RB	_	25	advmod
20	may	may	MD	_	25	aux
21	not	not	RB	_	25	neg
22	be	be	VB	_	25	cop
23	an	a	DT	_	25	det
24	appropriate	appropriate	JJ	_	25	amod
25	model	model	NN	_	10	conj
26	for	for	IN	_	28	case
27	drug2	drug2	NN	_	28	compound
28	metabolism	metabolism	NN	_	25	nmod
29	.	.	.	_	3	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	these	these	DT	_	4	det
4	results	result	NNS	_	5	nsubj
5	provide	provide	VBP	_	0	ROOT
6	an	a	DT	_	7	det
7	example	example	NN	_	5	dobj
8	of	of	IN	_	12	case
9	how	how	WRB	_	10	advmod
10	small	small	JJ	_	12	amod
11	molecule	molecule	NN	_	12	compound
12	manipulation	manipulation	NN	_	7	nmod
13	of	of	IN	_	15	case
14	CYP	cyp	NN	_	15	compound
15	activity	activity	NN	_	12	nmod
16	in	in	IN	_	20	case
17	an	a	DT	_	20	det
18	in	in	FW	_	20	amod
19	vitro	vitro	FW	_	18	dep
20	model	model	NN	_	5	nmod
21	can	can	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	5	dep
24	to	to	TO	_	25	mark
25	confirm	confirm	VB	_	23	xcomp
26	metabolism-mediated	metabolism-mediated	JJ	_	27	amod
27	toxicity	toxicity	NN	_	25	dobj
28	.	.	.	_	5	punct

1	Glycosidic	glycosidic	JJ	_	2	amod
2	enzymes	enzyme	NNS	_	3	nsubj
3	enhance	enhance	VBP	_	0	ROOT
4	retinal	retinal	JJ	_	5	amod
5	transduction	transduction	NN	_	3	dobj
6	following	follow	VBG	_	8	case
7	intravitreal	intravitreal	JJ	_	8	amod
8	delivery	delivery	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	3	punct

1	To	to	TO	_	2	mark
2	determine	determine	VB	_	0	ROOT
3	whether	whether	IN	_	11	mark
4	the	the	DT	_	5	det
5	co-injection	co-injection	NN	_	11	nsubj
6	of	of	IN	_	10	case
7	extracellular	extracellular	JJ	_	10	amod
8	matrix	matrix	NN	_	10	compound
9	degrading	degrading	JJ	_	10	amod
10	enzymes	enzyme	NNS	_	5	nmod
11	improves	improve	VBZ	_	2	ccomp
12	retinal	retinal	JJ	_	13	amod
13	transduction	transduction	NN	_	11	dobj
14	following	follow	VBG	_	16	case
15	intravitreal	intravitreal	JJ	_	16	amod
16	delivery	delivery	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug2	drug2	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubj
2	containing	contain	VBG	_	1	acl
3	cDNA	cdna	NN	_	4	compound
4	encoding	encoding	NN	_	2	dobj
5	enhanced	enhance	VBD	_	0	ROOT
6	green	green	JJ	_	8	amod
7	fluorescent	fluorescent	JJ	_	8	amod
8	protein	protein	NN	_	5	dobj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	GFP	gfp	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	5	punct
13	under	under	IN	_	15	case
14	the	the	DT	_	15	det
15	control	control	NN	_	5	nmod
16	of	of	IN	_	21	case
17	a	a	DT	_	21	det
18	chicken	chicken	NN	_	21	compound
19	-	-	:	_	21	punct
20	actin	actin	NN	_	21	compound
21	promoter	promoter	NN	_	15	nmod
22	,	,	,	_	5	punct
23	was	be	VBD	_	24	auxpass
24	delivered	deliver	VBN	_	5	dep
25	by	by	IN	_	27	case
26	intravitreal	intravitreal	JJ	_	27	amod
27	injection	injection	NN	_	24	nmod
28	to	to	TO	_	30	case
29	adult	adult	JJ	_	30	amod
30	mice	mouse	NNS	_	27	nmod
31	in	in	IN	_	32	case
32	conjunction	conjunction	NN	_	24	nmod
33	with	with	IN	_	34	case
34	enzymes	enzyme	NNS	_	32	nmod
35	including	include	VBG	_	36	case
36	drug2	drug2	NN	_	34	nmod
37	,	,	,	_	36	punct
38	drug3	drug3	NN	_	36	conj
39	,	,	,	_	36	punct
40	drug4	drug4	NN	_	36	conj
41	,	,	,	_	36	punct
42	or	or	CC	_	36	cc
43	drug5	drug5	NN	_	36	conj
44	.	.	.	_	5	punct

1	Two	two	CD	_	2	nummod
2	weeks	week	NNS	_	3	nmod:npmod
3	later	later	RB	_	8	advmod
4	,	,	,	_	8	punct
5	retinal	retinal	JJ	_	6	amod
6	flatmounts	flatmount	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	examined	examine	VBN	_	0	ROOT
9	for	for	IN	_	11	case
10	GFP	gfp	NN	_	11	compound
11	expression	expression	NN	_	8	nmod
12	using	use	VBG	_	11	acl
13	confocal	confocal	JJ	_	14	amod
14	microscopy	microscopy	NN	_	12	dobj
15	.	.	.	_	8	punct

1	Without	without	IN	_	3	case
2	the	the	DT	_	3	det
3	addition	addition	NN	_	9	nmod
4	of	of	IN	_	5	case
5	enzymes	enzyme	NNS	_	3	nmod
6	,	,	,	_	9	punct
7	transduction	transduction	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	limited	limit	VBN	_	0	ROOT
10	to	to	TO	_	12	case
11	occasional	occasional	JJ	_	12	amod
12	cells	cell	NNS	_	9	nmod
13	in	in	IN	_	18	case
14	the	the	DT	_	18	det
15	retinal	retinal	JJ	_	18	amod
16	ganglion	ganglion	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	layer	layer	NN	_	12	nmod
19	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	greatly	greatly	RB	_	8	advmod
8	enhanced	enhance	VBD	_	0	ROOT
9	transduction	transduction	NN	_	8	dobj
10	of	of	IN	_	15	case
11	the	the	DT	_	15	det
12	retinal	retinal	JJ	_	15	amod
13	ganglion	ganglion	NN	_	15	compound
14	cell	cell	NN	_	15	compound
15	layer	layer	NN	_	9	nmod
16	and	and	CC	_	8	cc
17	increased	increase	VBD	_	8	conj
18	the	the	DT	_	19	det
19	depth	depth	NN	_	17	dobj
20	of	of	IN	_	21	case
21	transduction	transduction	NN	_	19	nmod
22	into	into	IN	_	25	case
23	the	the	DT	_	25	det
24	outer	outer	JJ	_	25	amod
25	retina	retina	NN	_	17	nmod
26	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	a	a	DT	_	5	det
4	limited	limited	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	and	and	CC	_	2	cc
7	drug2	drug2	NN	_	9	nsubj
8	was	be	VBD	_	9	cop
9	ineffective	ineffective	JJ	_	2	conj
10	.	.	.	_	2	punct

1	Electroretinograms	electroretinograms	NN	_	2	nsubj
2	survived	survive	VBD	_	0	ROOT
3	with	with	IN	_	5	case
4	higher	higher	JJR	_	5	amod
5	concentrations	concentration	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	than	than	IN	_	12	mark
11	were	be	VBD	_	12	auxpass
12	required	require	VBN	_	5	dep
13	for	for	IN	_	16	case
14	optimal	optimal	JJ	_	16	amod
15	retinal	retinal	JJ	_	16	amod
16	transduction	transduction	NN	_	12	nmod
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-	-	:	_	1	punct
3	mediated	mediate	VBN	_	5	amod
4	retinal	retinal	JJ	_	5	amod
5	transduction	transduction	NN	_	1	dep
6	is	be	VBZ	_	7	auxpass
7	improved	improve	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	co-injection	co-injection	NN	_	7	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	.	.	.	_	7	punct

1	Improved	improve	VBN	_	3	amod
2	transduction	transduction	NN	_	3	compound
3	efficiency	efficiency	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	allow	allow	VB	_	0	ROOT
6	intravitreal	intravitreal	JJ	_	7	amod
7	injection	injection	NN	_	5	dobj
8	to	to	TO	_	9	mark
9	become	become	VB	_	5	xcomp
10	the	the	DT	_	12	det
11	preferred	preferred	JJ	_	12	amod
12	route	route	NN	_	9	xcomp
13	for	for	IN	_	14	mark
14	delivering	deliver	VBG	_	12	acl
15	gene	gene	NN	_	16	compound
16	therapy	therapy	NN	_	14	dobj
17	to	to	TO	_	23	case
18	both	both	CC	_	23	cc:preconj
19	the	the	DT	_	23	det
20	inner	inner	JJ	_	23	amod
21	and	and	CC	_	20	cc
22	outer	outer	JJ	_	20	conj
23	retina	retina	NN	_	14	nmod
24	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	--	--	:	_	1	punct
6	better	better	JJR	_	1	dep
7	than	than	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug4	drug4	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct

1	The	the	DT	_	2	det
2	FDA	FDA	NNP	_	4	nsubj
3	has	have	VBZ	_	4	aux
4	approved	approve	VBN	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-	-	:	_	7	punct
9	AstraZeneca	AstraZeneca	NNP	_	7	dep
10	-RRB-	-rrb-	-RRB-	_	7	punct
11	,	,	,	_	5	punct
12	an	a	DT	_	14	det
13	oral	oral	JJ	_	14	amod
14	drug3	drug3	NN	_	5	appos
15	,	,	,	_	5	punct
16	for	for	IN	_	17	case
17	use	use	NN	_	4	nmod
18	with	with	IN	_	20	case
19	low-dose	low-dose	JJ	_	20	amod
20	drug4	drug4	NN	_	17	nmod
21	to	to	TO	_	22	mark
22	reduce	reduce	VB	_	17	acl
23	the	the	DT	_	24	det
24	rate	rate	NN	_	22	dobj
25	of	of	IN	_	28	case
26	thrombotic	thrombotic	JJ	_	28	amod
27	cardiovascular	cardiovascular	JJ	_	28	amod
28	events	event	NNS	_	24	nmod
29	in	in	IN	_	30	case
30	patients	patient	NNS	_	28	nmod
31	with	with	IN	_	34	case
32	acute	acute	JJ	_	34	amod
33	coronary	coronary	JJ	_	34	amod
34	syndrome	syndrome	NN	_	30	nmod
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	ACS	acs	NN	_	34	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	.	.	.	_	4	punct

1	It	it	PRP	_	3	nsubj
2	will	will	MD	_	3	aux
3	compete	compete	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	and	and	CC	_	5	cc
10	drug3	drug3	NN	_	5	conj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug4	drug4	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	for	for	IN	_	16	case
15	such	such	JJ	_	16	amod
16	use	use	NN	_	3	nmod
17	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	expected	expect	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	become	become	VB	_	3	xcomp
6	available	available	JJ	_	5	xcomp
7	generically	generically	RB	_	5	advmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	US	US	NNP	_	7	nmod
11	within	within	IN	_	15	case
12	the	the	DT	_	15	det
13	next	next	JJ	_	15	amod
14	few	few	JJ	_	15	amod
15	months	month	NNS	_	5	nmod
16	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	role	role	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	p27	p27	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	Kip1	kip1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	in	in	IN	_	9	case
9	drug1	drug1	NN	_	2	nmod
10	-	-	:	_	2	punct
11	enhanced	enhance	VBN	_	13	amod
12	drug2	drug2	NN	_	13	compound
13	cytotoxicity	cytotoxicity	NN	_	2	dep
14	in	in	IN	_	18	case
15	human	human	JJ	_	18	amod
16	ovarian	ovarian	JJ	_	18	amod
17	cancer	cancer	NN	_	18	compound
18	cells	cell	NNS	_	13	nmod
19	.	.	.	_	2	punct

1	Less	less	RBR	_	3	advmod
2	than	than	IN	_	1	mwe
3	50	50	CD	_	4	nummod
4	%	%	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	ovarian	ovarian	JJ	_	7	amod
7	cancers	cancer	NNS	_	4	nmod
8	respond	respond	VBP	_	0	ROOT
9	to	to	TO	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Effective	effective	JJ	_	2	amod
2	strategies	strategy	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	needed	need	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	enhance	enhance	VB	_	4	xcomp
7	drug1	drug1	NN	_	8	compound
8	sensitivity	sensitivity	NN	_	6	dobj
9	.	.	.	_	4	punct

1	A	a	DT	_	2	det
2	library	library	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	silencing	silencing	NN	_	5	compound
5	RNAs	rna	NNS	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	siRNAs	sirna	NNS	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	was	be	VBD	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	identify	identify	VB	_	10	xcomp
13	kinases	kinase	NNS	_	12	dobj
14	that	that	WDT	_	15	nsubj
15	regulate	regulate	VBP	_	13	acl:relcl
16	drug1	drug1	NN	_	17	compound
17	sensitivity	sensitivity	NN	_	15	dobj
18	in	in	IN	_	23	case
19	human	human	JJ	_	23	amod
20	ovarian	ovarian	JJ	_	23	amod
21	cancer	cancer	NN	_	23	compound
22	SKOv3	skov3	NN	_	23	compound
23	cells	cell	NNS	_	17	nmod
24	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	an	a	DT	_	7	det
7	inhibitor	inhibitor	NN	_	4	appos
8	of	of	IN	_	12	case
9	Src	src	NN	_	12	compound
10	and	and	CC	_	9	cc
11	Abl	abl	NN	_	9	conj
12	kinases	kinase	NNS	_	7	nmod
13	,	,	,	_	4	punct
14	on	on	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	sensitivity	sensitivity	NN	_	2	nmod
17	was	be	VBD	_	18	auxpass
18	measured	measure	VBN	_	0	ROOT
19	in	in	IN	_	22	case
20	ovarian	ovarian	JJ	_	22	amod
21	cancer	cancer	NN	_	22	compound
22	cells	cell	NNS	_	18	nmod
23	and	and	CC	_	22	cc
24	HEY	hey	NN	_	25	compound
25	xenografts	xenograft	NNS	_	22	conj
26	.	.	.	_	18	punct

1	The	the	DT	_	2	det
2	roles	role	NNS	_	21	nsubjpass
3	of	of	IN	_	4	case
4	p27	p27	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	Kip1	kip1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	,	,	,	_	4	punct
9	Bcl-2	bcl-2	NN	_	4	conj
10	,	,	,	_	4	punct
11	and	and	CC	_	4	cc
12	Cdk1	cdk1	NN	_	4	conj
13	in	in	IN	_	14	case
14	apoptosis	apoptosis	NN	_	2	nmod
15	induced	induce	VBN	_	14	acl
16	by	by	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	were	be	VBD	_	21	auxpass
21	assessed	assess	VBN	_	0	ROOT
22	using	use	VBG	_	21	xcomp
23	a	a	DT	_	29	det
24	terminal	terminal	JJ	_	29	amod
25	deoxynucleotidyl	deoxynucleotidyl	NN	_	29	compound
26	transferase-mediated	transferase-mediated	JJ	_	29	amod
27	dUTP	dutp	NN	_	29	compound
28	nick-end	nick-end	JJ	_	29	amod
29	labeling	labeling	NN	_	33	compound
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	TUNEL	tunel	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	assay	assay	NN	_	22	dobj
34	,	,	,	_	21	punct
35	siRNA	sirna	NN	_	36	compound
36	knockdown	knockdown	NN	_	21	dobj
37	of	of	IN	_	39	case
38	gene	gene	NN	_	39	compound
39	expression	expression	NN	_	36	nmod
40	,	,	,	_	36	punct
41	transfection	transfection	NN	_	36	conj
42	with	with	IN	_	43	case
43	Bcl-2	bcl-2	NN	_	41	nmod
44	and	and	CC	_	43	cc
45	Cdk1	cdk1	NN	_	47	compound
46	expression	expression	NN	_	47	compound
47	vectors	vector	NNS	_	43	conj
48	,	,	,	_	36	punct
49	and	and	CC	_	36	cc
50	flow	flow	NN	_	51	compound
51	cytometry	cytometry	NN	_	36	conj
52	.	.	.	_	21	punct

1	All	all	DT	_	3	det
2	statistical	statistical	JJ	_	3	amod
3	tests	test	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	two-sided	two-sided	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Src	src	NN	_	2	compound
2	family	family	NN	_	7	nsubjpass
3	and	and	CC	_	2	cc
4	Abl	abl	NN	_	5	compound
5	kinases	kinase	NNS	_	2	conj
6	were	be	VBD	_	7	auxpass
7	identified	identify	VBN	_	0	ROOT
8	as	as	IN	_	9	case
9	modulators	modulator	NNS	_	7	nmod
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	sensitivity	sensitivity	NN	_	9	nmod
13	in	in	IN	_	15	case
14	SKOv3	skov3	NN	_	15	compound
15	cells	cell	NNS	_	12	nmod
16	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	siRNA	sirna	NN	_	3	compound
3	knockdown	knockdown	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	Src	src	NN	_	3	nmod
6	,	,	,	_	5	punct
7	Fyn	fyn	NN	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	Abl1	abl1	NN	_	5	conj
11	enhanced	enhance	VBD	_	0	ROOT
12	drug1	drug1	NN	_	11	dobj
13	-	-	:	_	12	punct
14	mediated	mediate	VBN	_	16	amod
15	growth	growth	NN	_	16	compound
16	inhibition	inhibition	NN	_	12	dep
17	in	in	IN	_	20	case
18	ovarian	ovarian	JJ	_	20	amod
19	cancer	cancer	NN	_	20	compound
20	cells	cell	NNS	_	16	nmod
21	compared	compare	VBN	_	25	case
22	with	with	IN	_	25	case
23	a	a	DT	_	25	det
24	control	control	NN	_	25	compound
25	siRNA	siRNA	NNP	_	16	nmod
26	.	.	.	_	11	punct

1	HEY	hey	NN	_	2	compound
2	cells	cell	NNS	_	8	nsubj
3	treated	treat	VBN	_	2	acl
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	plus	plus	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	formed	form	VBD	_	0	ROOT
9	fewer	fewer	JJR	_	10	amod
10	colonies	colony	NNS	_	8	dobj
11	than	than	IN	_	12	dep
12	did	do	VBD	_	10	dep
13	cells	cell	NNS	_	12	nsubj
14	treated	treat	VBN	_	13	acl
15	with	with	IN	_	17	case
16	either	either	CC	_	17	det
17	agent	agent	NN	_	14	nmod
18	alone	alone	RB	_	17	advmod
19	.	.	.	_	8	punct

1	Treatment	treatment	NN	_	10	nsubj
2	of	of	IN	_	5	case
3	HEY	hey	NN	_	5	compound
4	xenograft-bearing	xenograft-bearing	JJ	_	5	amod
5	mice	mouse	NNS	_	1	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	1	nmod
8	plus	plus	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	inhibited	inhibit	VBD	_	0	ROOT
11	tumor	tumor	NN	_	12	compound
12	growth	growth	NN	_	10	dobj
13	more	more	JJR	_	10	advmod
14	than	than	IN	_	15	case
15	treatment	treatment	NN	_	13	nmod
16	with	with	IN	_	18	case
17	either	either	CC	_	18	det
18	agent	agent	NN	_	15	nmod
19	alone	alone	RB	_	18	advmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	average	average	JJ	_	23	amod
22	tumor	tumor	NN	_	23	compound
23	volume	volume	NN	_	10	dep
24	per	per	IN	_	25	case
25	mouse	mouse	NN	_	23	nmod
26	,	,	,	_	23	punct
27	drug3	drug3	NN	_	23	appos
28	+	+	CC	_	27	cc
29	drug4	drug4	NN	_	27	conj
30	vs	vs	CC	_	27	cc
31	drug5	drug5	NN	_	27	conj
32	:	:	:	_	23	punct
33	0.28	0.28	CD	_	36	nummod
34	vs.	vs.	CC	_	33	cc
35	0.81	0.81	CD	_	33	conj
36	cm3	cm3	NN	_	23	dep
37	,	,	,	_	36	punct
38	difference	difference	NN	_	36	appos
39	=	=	JJ	_	38	amod
40	0.53	0.53	CD	_	41	nummod
41	cm3	cm3	NN	_	39	dep
42	,	,	,	_	36	punct
43	95	95	CD	_	44	compound
44	%	%	NN	_	46	amod
45	confidence	confidence	NN	_	46	compound
46	interval	interval	NN	_	36	appos
47	-LSB-	-lsb-	-LRB-	_	48	punct
48	CI	ci	NN	_	46	appos
49	-RSB-	-rsb-	-RRB-	_	48	punct
50	=	=	JJ	_	46	amod
51	0.44	0.44	CD	_	53	compound
52	to	to	TO	_	53	dep
53	0.62	0.62	CD	_	54	nummod
54	cm3	cm3	NN	_	50	dep
55	,	,	,	_	36	punct
56	P	p	NN	_	57	nsubj
57	=	=	JJ	_	36	dep
58	.014	.014	CD	_	57	dobj
59	-RRB-	-rrb-	-RRB-	_	23	punct
60	;	;	:	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	+	+	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	vs.	vs.	NN	_	1	dep

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	0.28	0.28	CD	_	1	dep
4	vs.	vs.	CC	_	1	dep

1	0.55	0.55	CD	_	2	nummod
2	cm3	cm3	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	difference	difference	NN	_	2	appos
5	=	=	JJ	_	4	amod
6	0.27	0.27	CD	_	7	nummod
7	cm3	cm3	NN	_	5	dep
8	,	,	,	_	2	punct
9	95	95	CD	_	10	compound
10	%	%	NN	_	11	amod
11	CI	ci	NN	_	2	appos
12	=	=	JJ	_	11	amod
13	0.21	0.21	CD	_	15	compound
14	to	to	TO	_	15	dep
15	0.33	0.33	CD	_	16	nummod
16	cm3	cm3	NN	_	12	dep
17	,	,	,	_	2	punct
18	P	p	NN	_	19	nsubj
19	=	=	JJ	_	2	dep
20	.035	.035	CD	_	19	dobj
21	-RRB-	-rrb-	-RRB-	_	19	punct
22	.	.	.	_	2	punct

1	Combined	combined	JJ	_	2	amod
2	treatment	treatment	NN	_	3	nsubj
3	induced	induce	VBD	_	0	ROOT
4	more	more	RBR	_	5	advmod
5	TUNEL-positive	tunel-positive	JJ	_	7	amod
6	apoptotic	apoptotic	JJ	_	7	amod
7	cells	cell	NNS	_	3	dobj
8	than	than	IN	_	9	dep
9	did	do	VBD	_	7	dep
10	either	either	DT	_	11	det
11	agent	agent	NN	_	9	nsubj
12	alone	alone	RB	_	11	advmod
13	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	siRNA	sirna	NN	_	3	compound
3	knockdown	knockdown	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	p27	p27	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	Kip1	kip1	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	decreased	decrease	VBD	_	0	ROOT
10	drug1	drug1	NN	_	9	dobj
11	-	-	:	_	10	punct
12	and	and	CC	_	10	cc
13	drug2	drug2	NN	_	10	conj
14	-	-	:	_	10	punct
15	induced	induced	JJ	_	16	amod
16	apoptosis	apoptosis	NN	_	10	dep
17	compared	compare	VBN	_	22	case
18	with	with	IN	_	22	case
19	a	a	DT	_	22	det
20	negative	negative	JJ	_	22	amod
21	control	control	NN	_	22	compound
22	siRNA	sirna	NN	_	16	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	sub-G1	sub-g1	NN	_	25	compound
25	fraction	fraction	NN	_	22	dep
26	,	,	,	_	25	punct
27	control	control	NN	_	28	compound
28	siRNA	siRNA	NNP	_	25	appos
29	vs.	vs.	CC	_	28	cc
30	p27	p27	NN	_	34	compound
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	Kip1	kip1	NN	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	siRNA	sirna	NN	_	28	conj
35	:	:	:	_	25	punct
36	42.5	42.5	CD	_	37	nummod
37	%	%	NN	_	25	dep
38	vs.	vs.	CC	_	37	cc
39	20.1	20.1	CD	_	40	nummod
40	%	%	NN	_	37	conj
41	,	,	,	_	37	punct
42	difference	difference	NN	_	37	appos
43	=	=	JJ	_	42	amod
44	22.4	22.4	CD	_	45	nummod
45	%	%	NN	_	43	dep
46	,	,	,	_	37	punct
47	95	95	CD	_	48	nummod
48	%	%	NN	_	37	appos
49	CI	ci	NN	_	58	nsubj
50	=	=	JJ	_	58	dep
51	20.1	20.1	CD	_	58	punct
52	%	%	NN	_	58	dep
53	to	to	TO	_	55	case
54	24.7	24.7	CD	_	55	nummod
55	%	%	NN	_	52	nmod
56	,	,	,	_	58	punct
57	P	p	NN	_	58	nsubj
58	=	=	JJ	_	48	acl:relcl
59	.017	.017	CD	_	58	dobj
60	-RRB-	-rrb-	-RRB-	_	25	punct
61	.	.	.	_	9	punct

1	Studies	study	NNS	_	12	nsubj
2	with	with	IN	_	4	case
3	forced	force	VBN	_	4	amod
4	expression	expression	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	siRNA	sirna	NN	_	7	compound
7	knockdown	knockdown	NN	_	4	conj
8	of	of	IN	_	9	case
9	Bcl-2	bcl-2	NN	_	4	nmod
10	and	and	CC	_	9	cc
11	Cdk1	cdk1	NN	_	9	conj
12	suggest	suggest	VBP	_	0	ROOT
13	that	that	IN	_	12	dobj
14	drug1	drug1	NN	_	13	dep
15	-	-	:	_	14	punct
16	mediated	mediated	JJ	_	17	amod
17	induction	induction	NN	_	23	nsubj
18	of	of	IN	_	19	case
19	p27	p27	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	Kip1	kip1	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	enhanced	enhance	VBD	_	14	dep
24	drug2	drug2	NN	_	23	dobj
25	-	-	:	_	24	punct
26	induced	induced	JJ	_	27	amod
27	apoptosis	apoptosis	NN	_	24	dep
28	by	by	IN	_	30	mark
29	negatively	negatively	RB	_	30	advmod
30	regulating	regulate	VBG	_	27	acl
31	Bcl-2	bcl-2	NN	_	34	compound
32	and	and	CC	_	31	cc
33	Cdk1	cdk1	NN	_	31	conj
34	expression	expression	NN	_	30	dobj
35	.	.	.	_	12	punct

1	Inhibition	inhibition	NN	_	13	nsubj
2	of	of	IN	_	4	case
3	Src	src	NN	_	4	compound
4	family	family	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	Abl	abl	NN	_	7	compound
7	kinases	kinase	NNS	_	4	conj
8	with	with	IN	_	10	case
9	either	either	CC	_	10	cc:preconj
10	siRNAs	sirnas	NN	_	1	nmod
11	or	or	CC	_	10	cc
12	drug1	drug1	NN	_	10	conj
13	enhances	enhance	VBZ	_	0	ROOT
14	drug2	drug2	NN	_	15	compound
15	sensitivity	sensitivity	NN	_	13	dobj
16	of	of	IN	_	19	case
17	ovarian	ovarian	JJ	_	19	amod
18	cancer	cancer	NN	_	19	compound
19	cells	cell	NNS	_	15	nmod
20	through	through	IN	_	21	case
21	p27	p27	NN	_	13	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	Kip1	kip1	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	-	-	:	_	21	punct
26	mediated	mediate	VBN	_	27	amod
27	suppression	suppression	NN	_	21	dep
28	of	of	IN	_	29	case
29	Bcl-2	bcl-2	NN	_	27	nmod
30	and	and	CC	_	29	cc
31	Cdk1	cdk1	NN	_	29	conj
32	expression	expression	NN	_	29	dep
33	.	.	.	_	13	punct

1	Influence	influence	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	induced	induce	VBD	_	0	ROOT
7	antinociception	antinociception	NN	_	6	dobj
8	and	and	CC	_	7	cc
9	its	its	PRP$	_	10	nmod:poss
10	pharmacokinetics	pharmacokinetic	NNS	_	7	conj
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	CAS	cas	NN	_	1	appos
4	94-62-2	94-62-2	CD	_	3	nummod
5	-RRB-	-rrb-	-RRB-	_	3	punct
6	,	,	,	_	1	punct
7	an	a	DT	_	8	det
8	alkaloid	alkaloid	NN	_	1	appos
9	obtained	obtain	VBN	_	8	acl
10	from	from	IN	_	12	case
11	Piper	Piper	NNP	_	12	compound
12	nigrum	nigrum	NNP	_	9	nmod
13	and	and	CC	_	12	cc
14	P.	P.	NNP	_	12	conj

1	longum	longum	NN	_	6	nsubj
2	,	,	,	_	6	punct
3	is	be	VBZ	_	6	cop
4	a	a	DT	_	6	det
5	known	known	JJ	_	6	amod
6	inhibitor	inhibitor	NN	_	0	ROOT
7	of	of	IN	_	9	case
8	various	various	JJ	_	9	amod
9	enzymes	enzyme	NNS	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	CYP	cyp	NN	_	12	compound
12	isozymes	isozyme	NNS	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	responsible	responsible	JJ	_	9	amod
15	for	for	IN	_	16	case
16	biotransformation	biotransformation	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	.	.	.	_	6	punct

1	By	by	IN	_	2	mark
2	inhibiting	inhibit	VBG	_	9	advcl
3	the	the	DT	_	4	det
4	metabolism	metabolism	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	,	,	,	_	9	punct
8	drug1	drug1	NN	_	9	nsubj
9	improves	improve	VBZ	_	0	ROOT
10	the	the	DT	_	11	det
11	bioavailability	bioavailability	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drugs	drug	NNS	_	11	nmod
14	.	.	.	_	9	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	det
3	present	present	JJ	_	5	amod
4	study	study	NN	_	5	compound
5	drug1	drug1	NN	_	11	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	10	10	CD	_	8	nummod
8	mg/kg	mg/kg	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	significantly	significantly	RB	_	11	advmod
11	increased	increase	VBD	_	0	ROOT
12	the	the	DT	_	15	det
13	dose-dependent	dose-dependent	JJ	_	15	amod
14	antinociceptive	antinociceptive	JJ	_	15	amod
15	activity	activity	NN	_	11	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	evaluated	evaluate	VBN	_	17	acl
19	by	by	IN	_	22	case
20	both	both	CC	_	22	cc:preconj
21	drug3	drug3	NN	_	22	compound
22	writhing	writhe	VBG	_	18	nmod
23	and	and	CC	_	22	cc
24	formalin	formalin	NN	_	25	compound
25	test	test	NN	_	22	conj
26	,	,	,	_	11	punct
27	when	when	WRB	_	30	advmod
28	it	it	PRP	_	30	nsubjpass
29	was	be	VBD	_	30	auxpass
30	administered	administer	VBN	_	11	advcl
31	with	with	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	compound
2	plasma	plasma	NN	_	3	compound
3	concentration	concentration	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	also	also	RB	_	6	advmod
6	increased	increase	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	it	it	PRP	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	6	punct

1	The	the	DT	_	4	det
2	synergistic	synergistic	JJ	_	4	amod
3	antinociception	antinociception	NN	_	4	compound
4	activity	activity	NN	_	13	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	when	when	WRB	_	8	advmod
8	administered	administer	VBN	_	4	acl:relcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	can	can	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	attributed	attribute	VBN	_	0	ROOT
14	to	to	TO	_	17	case
15	increased	increase	VBN	_	17	amod
16	plasma	plasma	NN	_	17	compound
17	concentration	concentration	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	13	punct

1	From	from	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	7	nmod
4	it	it	PRP	_	7	nsubjpass
5	can	can	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	concluded	conclude	VBN	_	0	ROOT
8	that	that	IN	_	12	mark
9	drug1	drug1	NN	_	12	nsubjpass
10	can	can	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	7	ccomp
13	as	as	IN	_	15	case
14	a	a	DT	_	15	det
15	bioenhancer	bioenhancer	NN	_	12	nmod
16	along	along	IN	_	18	case
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	15	nmod
19	.	.	.	_	7	punct

1	Prevention	Prevention	NNP	_	0	ROOT
2	of	of	IN	_	4	case
3	emergence	emergence	NN	_	4	compound
4	agitation	agitation	NN	_	1	nmod
5	in	in	IN	_	7	case
6	seven	seven	CD	_	7	nummod
7	children	child	NNS	_	1	nmod
8	receiving	receive	VBG	_	7	acl
9	low-dose	low-dose	JJ	_	10	amod
10	drug1	drug1	NN	_	8	dobj
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	15	compound
13	total	total	JJ	_	15	amod
14	intravenous	intravenous	JJ	_	15	amod
15	anesthesia	anesthesia	NN	_	10	conj
16	.	.	.	_	1	punct

1	Emergence	emergence	NN	_	2	compound
2	agitation	agitation	NN	_	11	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	EA	ea	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	can	can	MD	_	11	aux
7	be	be	VB	_	11	cop
8	a	a	DT	_	11	det
9	distressing	distressing	JJ	_	11	amod
10	side	side	NN	_	11	compound
11	effect	effect	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	pediatric	pediatric	JJ	_	14	amod
14	anesthesia	anesthesia	NN	_	11	nmod
15	.	.	.	_	11	punct

1	We	we	PRP	_	3	nsubj
2	retrospectively	retrospectively	RB	_	3	advmod
3	reviewed	review	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	records	record	NNS	_	3	dobj
6	of	of	IN	_	10	case
7	7	7	CD	_	10	nummod
8	pediatric	pediatric	JJ	_	10	amod
9	oncology	oncology	NN	_	10	compound
10	patients	patient	NNS	_	5	nmod
11	who	who	WP	_	12	nsubj
12	received	receive	VBD	_	10	acl:relcl
13	low-dose	low-dose	JJ	_	14	amod
14	drug1	drug1	NN	_	12	dobj
15	in	in	IN	_	16	case
16	conjunction	conjunction	NN	_	12	nmod
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	for	for	IN	_	22	case
20	total	total	JJ	_	22	amod
21	intravenous	intravenous	JJ	_	22	amod
22	anesthesia	anesthesia	NN	_	12	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	TIVA	tiva	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	repeatedly	repeatedly	RB	_	22	advmod
27	for	for	IN	_	29	case
28	radiation	radiation	NN	_	29	compound
29	therapy	therapy	NN	_	22	nmod
30	.	.	.	_	3	punct

1	EA	ea	NN	_	2	compound
2	signs	sign	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	8	case
6	all	all	DT	_	8	det
7	7	7	CD	_	8	nummod
8	patients	patient	NNS	_	4	nmod
9	in	in	IN	_	10	case
10	association	association	NN	_	8	nmod
11	with	with	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	TIVA	tiva	NN	_	10	nmod
14	but	but	CC	_	4	cc
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	recur	recur	VB	_	4	conj
18	in	in	IN	_	17	nmod
19	any	any	DT	_	18	dep
20	of	of	IN	_	24	case
21	123	123	CD	_	24	nummod
22	subsequent	subsequent	JJ	_	24	amod
23	anesthetics	anesthetic	NNS	_	24	compound
24	sessions	session	NNS	_	19	nmod
25	during	during	IN	_	26	case
26	which	which	WDT	_	30	nmod
27	low-dose	low-dose	JJ	_	28	amod
28	drug2	drug2	NN	_	30	nsubjpass
29	was	be	VBD	_	30	auxpass
30	added	add	VBN	_	24	acl:relcl
31	to	to	TO	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	.	.	.	_	4	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	this	this	DT	_	4	det
4	experience	experience	NN	_	7	advcl
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	suggest	suggest	VBP	_	0	ROOT
8	that	that	IN	_	11	mark
9	low-dose	low-dose	JJ	_	10	amod
10	drug1	drug1	NN	_	11	nsubj
11	added	add	VBD	_	7	ccomp
12	to	to	TO	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	associated	associate	VBN	_	11	ccomp
17	with	with	IN	_	18	case
18	prevention	prevention	NN	_	16	nmod
19	of	of	IN	_	20	case
20	EA	ea	NN	_	18	nmod
21	in	in	IN	_	22	case
22	children	child	NNS	_	18	nmod
23	with	with	IN	_	25	case
24	a	a	DT	_	25	det
25	history	history	NN	_	22	nmod
26	of	of	IN	_	27	case
27	EA	ea	NN	_	25	nmod
28	with	with	IN	_	30	case
29	drug3	drug3	NN	_	30	compound
30	TIVA	tiva	NN	_	27	nmod
31	.	.	.	_	7	punct

1	-LSB-	-lsb-	-LRB-	_	2	punct
2	Efficacy	efficacy	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	fixed	fix	VBN	_	6	amod
5	combination	combination	NN	_	6	compound
6	drug1	drug1	NN	_	2	nmod
7	/	/	:	_	2	punct
8	drug2	drug2	NN	_	2	dep
9	in	in	IN	_	11	case
10	hospitalized	hospitalize	VBN	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	with	with	IN	_	14	case
13	hypertensive	hypertensive	JJ	_	14	amod
14	disease	disease	NN	_	11	nmod
15	-RSB-	-rsb-	-RRB-	_	2	punct

1	Efficacy	efficacy	NN	_	11	nsubjpass
2	and	and	CC	_	1	cc
3	tolerability	tolerability	NN	_	1	conj
4	of	of	IN	_	6	case
5	fixed	fix	VBN	_	6	amod
6	drug1	drug1	NN	_	1	nmod
7	/	/	:	_	6	punct
8	drug2	drug2	NN	_	9	compound
9	combination	combination	NN	_	6	dep
10	was	be	VBD	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	86	86	CD	_	14	nummod
14	patients	patient	NNS	_	11	nmod
15	with	with	IN	_	17	case
16	hypertensive	hypertensive	JJ	_	17	amod
17	disease	disease	NN	_	14	nmod
18	hospitalized	hospitalize	VBN	_	14	acl
19	in	in	IN	_	20	case
20	departments	department	NNS	_	18	nmod
21	of	of	IN	_	24	case
22	general	general	JJ	_	24	amod
23	internal	internal	JJ	_	24	amod
24	medicine	medicine	NN	_	20	nmod
25	or	or	CC	_	24	cc
26	cardiology	cardiology	NN	_	24	conj
27	.	.	.	_	11	punct

1	All	all	DT	_	2	det
2	patients	patient	NNS	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	indications	indication	NNS	_	3	dobj
5	for	for	IN	_	7	case
6	antihypertensive	antihypertensive	JJ	_	7	amod
7	therapy	therapy	NN	_	4	nmod
8	and	and	CC	_	3	cc
9	were	be	VBD	_	10	auxpass
10	randomized	randomize	VBN	_	3	conj
11	either	either	CC	_	17	cc:preconj
12	to	to	TO	_	17	case
13	fixed	fix	VBN	_	17	amod
14	combination	combination	NN	_	17	compound
15	drug1	drug1	NN	_	17	compound
16	/	/	:	_	17	punct
17	drug2	drug2	NN	_	10	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	n	n	NN	_	17	dep
20	=	=	JJ	_	19	amod
21	43	43	CD	_	20	dep
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	or	or	CC	_	17	cc
24	to	to	TO	_	25	case
25	therapy	therapy	NN	_	17	conj
26	which	which	WDT	_	27	nsubj
27	corresponded	correspond	VBD	_	17	acl:relcl
28	to	to	TO	_	31	case
29	the	the	DT	_	31	det
30	hospital	hospital	NN	_	31	compound
31	formulary	formulary	NN	_	27	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	n	n	NN	_	31	dep
34	=	=	JJ	_	33	amod
35	43	43	CD	_	34	dep
36	-RRB-	-rrb-	-RRB-	_	33	punct
37	.	.	.	_	3	punct

1	Correction	correction	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	therapy	therapy	NN	_	1	nmod
5	was	be	VBD	_	6	auxpass
6	performed	perform	VBN	_	0	ROOT
7	by	by	IN	_	8	mark
8	treating	treat	VBG	_	6	advcl
9	physician	physician	NN	_	8	dobj
10	at	at	IN	_	12	case
11	daily	daily	JJ	_	12	amod
12	rounds	round	NNS	_	8	nmod
13	.	.	.	_	6	punct

1	Self-control	self-control	NN	_	9	nsubjpass
2	of	of	IN	_	4	case
3	blood	blood	NN	_	4	compound
4	pressure	pressure	NN	_	1	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	BP	bp	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	was	be	VBD	_	9	auxpass
9	performed	perform	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	with	with	IN	_	14	case
13	the	the	DT	_	14	det
14	use	use	NN	_	11	nmod
15	of	of	IN	_	17	case
16	UA767PC	ua767pc	NN	_	17	compound
17	apparatus	apparatus	NN	_	14	nmod
18	.	.	.	_	9	punct

1	Results	result	NNS	_	6	nsubjpass
2	of	of	IN	_	4	case
3	BP	BP	NNP	_	4	compound
4	self-control	self-control	NN	_	1	nmod
5	were	be	VBD	_	6	auxpass
6	compared	compare	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	measurements	measurement	NNS	_	6	nmod
10	in	in	IN	_	13	mark
11	order	order	NN	_	10	mwe
12	to	to	TO	_	13	mark
13	detect	detect	VB	_	9	acl
14	concealed	conceal	VBN	_	15	amod
15	inefficacy	inefficacy	NN	_	13	dobj
16	of	of	IN	_	17	case
17	treatment	treatment	NN	_	15	nmod
18	.	.	.	_	6	punct

1	Results	result	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	Rate	rate	NN	_	18	nsubj
2	of	of	IN	_	3	case
3	achievement	achievement	NN	_	1	nmod
4	of	of	IN	_	6	case
5	target	target	NN	_	6	compound
6	BP	bp	NN	_	3	nmod
7	with	with	IN	_	12	case
8	fixed	fix	VBN	_	12	amod
9	combination	combination	NN	_	12	compound
10	drug1	drug1	NN	_	12	compound
11	/	/	:	_	12	punct
12	drug2	drug2	NN	_	1	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	93	93	CD	_	15	nummod
15	%	%	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	was	be	VBD	_	18	cop
18	comparable	comparable	JJ	_	0	ROOT
19	with	with	IN	_	20	case
20	that	that	DT	_	18	nmod
21	on	on	IN	_	23	case
22	traditional	traditional	JJ	_	23	amod
23	therapy	therapy	NN	_	20	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	90	90	CD	_	26	nummod
26	%	%	NN	_	23	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	.	.	.	_	18	punct

1	But	but	CC	_	15	cc
2	the	the	DT	_	3	det
3	use	use	NN	_	15	nsubjpass
4	of	of	IN	_	7	case
5	fixed	fix	VBN	_	7	amod
6	combination	combination	NN	_	7	compound
7	drug1	drug1	NN	_	3	nmod
8	/	/	:	_	7	punct
9	drug2	drug2	NN	_	7	dep
10	compared	compare	VBN	_	13	case
11	with	with	IN	_	13	case
12	traditional	traditional	JJ	_	13	amod
13	therapy	therapy	NN	_	3	nmod
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	0	ROOT
16	with	with	IN	_	18	case
17	lower	lower	JJR	_	18	dep
18	clinical	clinical	JJ	_	15	nmod
19	and	and	CC	_	18	cc
20	self	self	NN	_	18	conj
21	measured	measure	VBD	_	18	dep
22	BP	BP	NNP	_	21	dobj
23	,	,	,	_	22	punct
24	quicker	quicker	JJR	_	25	amod
25	achievement	achievement	NN	_	22	appos
26	of	of	IN	_	28	case
27	target	target	NN	_	28	compound
28	BP	bp	NN	_	25	nmod
29	-LRB-	-lrb-	-LRB-	_	25	punct
30	5.8	5.8	CD	_	29	root
31	+	+	CC	_	30	cc
32	/	/	:	_	33	punct
33	-2.3	-2.3	CD	_	30	conj
34	and	and	CC	_	33	cc
35	9.2	9.2	CD	_	33	conj
36	+	+	CC	_	30	cc
37	/	/	:	_	39	punct
38	-1.8	-1.8	CD	_	39	nummod
39	days	day	NNS	_	30	conj
40	,	,	,	_	39	punct
41	respectively	respectively	RB	_	39	advmod
42	,	,	,	_	39	punct
43	0.05	0.05	CD	_	39	dep
44	-RRB-	-rrb-	-RRB-	_	39	punct
45	,	,	,	_	30	punct
46	lesser	lesser	JJR	_	47	amod
47	number	number	NN	_	45	root
48	of	of	IN	_	49	case
49	drug3	drug3	NN	_	47	nmod
50	-LRB-	-lrb-	-LRB-	_	49	punct
51	2.5	2.5	CD	_	50	root
52	+	+	CC	_	51	cc
53	/	/	:	_	54	punct
54	-0.6	-0.6	CD	_	51	conj
55	and	and	CC	_	54	cc
56	3.0	3.0	CD	_	54	conj
57	+	+	CC	_	51	cc
58	/	/	:	_	60	punct
59	-0.9	-0.9	CD	_	60	nummod
60	days	day	NNS	_	51	conj
61	,	,	,	_	60	punct
62	respectively	respectively	RB	_	60	advmod
63	-RRB-	-rrb-	-RRB-	_	60	punct
64	,	,	,	_	51	punct
65	lower	lower	JJR	_	66	amod
66	rate	rate	NN	_	64	root
67	of	of	IN	_	69	case
68	concealed	conceal	VBN	_	69	amod
69	inefficacy	inefficacy	NN	_	66	nmod
70	of	of	IN	_	71	case
71	treatment	treatment	NN	_	69	nmod
72	-LRB-	-lrb-	-LRB-	_	76	punct
73	12	12	CD	_	76	nummod
74	and	and	CC	_	73	cc
75	31	31	CD	_	73	conj
76	%	%	NN	_	66	dep
77	,	,	,	_	76	punct
78	respectively	respectively	RB	_	76	advmod
79	,	,	,	_	76	punct
80	0.05	0.05	CD	_	76	dep
81	-RRB-	-rrb-	-RRB-	_	76	punct
82	.	.	.	_	66	punct

1	Conclusions	conclusion	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	We	we	PRP	_	3	nsubj
2	have	have	VBP	_	3	aux
3	demonstrated	demonstrate	VBN	_	0	ROOT
4	appropriateness	appropriateness	NN	_	13	dep
5	of	of	IN	_	7	case
6	inhospital	inhospital	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	fixed	fix	VBN	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	/	/	:	_	13	punct
12	drug2	drug2	NN	_	13	compound
13	combination	combination	NN	_	3	ccomp
14	as	as	IN	_	16	case
15	an	a	DT	_	16	det
16	approach	approach	NN	_	13	nmod
17	allowing	allow	VBG	_	16	acl
18	to	to	TO	_	19	mark
19	achieve	achieve	VB	_	17	xcomp
20	target	target	NN	_	21	compound
21	BP	bp	NN	_	19	dobj
22	in	in	IN	_	24	case
23	shorter	shorter	JJR	_	24	amod
24	time	time	NN	_	19	nmod
25	,	,	,	_	13	punct
26	with	with	IN	_	28	case
27	the	the	DT	_	28	det
28	use	use	NN	_	13	nmod
29	of	of	IN	_	31	case
30	fewer	fewer	JJR	_	31	amod
31	drug3	drug3	NN	_	28	nmod
32	,	,	,	_	13	punct
33	and	and	CC	_	13	cc
34	diminishing	diminish	VBG	_	13	conj
35	concealed	conceal	VBN	_	36	amod
36	inefficacy	inefficacy	NN	_	34	dobj
37	of	of	IN	_	38	case
38	treatment	treatment	NN	_	36	nmod
39	.	.	.	_	3	punct

1	Antitumor	antitumor	JJ	_	2	amod
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	a	a	DT	_	8	det
7	specific	specific	JJ	_	8	amod
8	inhibitor	inhibitor	NN	_	4	appos
9	of	of	IN	_	10	case
10	HB-EGF	hb-egf	NN	_	8	nmod
11	,	,	,	_	4	punct
12	in	in	IN	_	16	case
13	T-cell	t-cell	NN	_	16	compound
14	acute	acute	JJ	_	16	amod
15	lymphoblastic	lymphoblastic	JJ	_	16	amod
16	leukemia	leukemia	NN	_	2	nmod
17	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	therapeutic	therapeutic	JJ	_	3	amod
3	outcome	outcome	NN	_	12	nsubj
4	for	for	IN	_	8	case
5	T-cell	t-cell	NN	_	8	compound
6	acute	acute	JJ	_	8	amod
7	lymphoblastic	lymphoblastic	JJ	_	8	amod
8	leukemia	leukemia	NN	_	3	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	T-ALL	t-all	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	remains	remain	VBZ	_	0	ROOT
13	poor	poor	JJ	_	12	xcomp
14	;	;	:	_	12	punct

1	thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	novel	novel	JJ	_	9	dep
4	,	,	,	_	9	punct
5	targeted	target	VBN	_	6	amod
6	therapies	therapy	NNS	_	9	nsubjpass
7	are	be	VBP	_	9	auxpass
8	urgently	urgently	RB	_	9	advmod
9	needed	need	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Recently	recently	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	that	that	IN	_	26	mark
6	heparin-binding	heparin-binding	JJ	_	11	amod
7	epidermal	epidermal	JJ	_	11	amod
8	growth	growth	NN	_	11	compound
9	factor-like	factor-like	JJ	_	11	amod
10	growth	growth	NN	_	11	compound
11	factor	factor	NN	_	26	nsubj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	HB-EGF	hb-egf	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	,	,	,	_	11	punct
16	a	a	DT	_	17	det
17	member	member	NN	_	11	appos
18	of	of	IN	_	21	case
19	the	the	DT	_	21	det
20	EGF	egf	NN	_	21	compound
21	family	family	NN	_	17	nmod
22	,	,	,	_	11	punct
23	is	be	VBZ	_	26	cop
24	a	a	DT	_	26	det
25	promising	promising	JJ	_	26	amod
26	target	target	NN	_	4	ccomp
27	for	for	IN	_	29	case
28	the	the	DT	_	29	det
29	treatment	treatment	NN	_	26	nmod
30	of	of	IN	_	32	case
31	various	various	JJ	_	32	amod
32	types	type	NNS	_	29	nmod
33	of	of	IN	_	34	case
34	cancer	cancer	NN	_	32	nmod
35	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	7	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	present	present	JJ	_	6	amod
6	study	study	NN	_	2	nmod
7	was	be	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	investigate	investigate	VB	_	7	xcomp
10	whether	whether	IN	_	15	mark
11	HB-EGF	hb-egf	NN	_	15	nsubj
12	is	be	VBZ	_	15	cop
13	a	a	DT	_	15	det
14	therapeutic	therapeutic	JJ	_	15	amod
15	target	target	NN	_	9	ccomp
16	for	for	IN	_	17	case
17	T-ALL	t-all	NN	_	15	nmod
18	,	,	,	_	9	punct
19	and	and	CC	_	9	cc
20	to	to	TO	_	22	mark
21	further	further	RB	_	22	advmod
22	elucidate	elucidate	VB	_	9	conj
23	the	the	DT	_	25	det
24	antitumor	antitumor	JJ	_	25	amod
25	effects	effect	NNS	_	22	dobj
26	of	of	IN	_	29	case
27	a	a	DT	_	29	det
28	specific	specific	JJ	_	29	amod
29	inhibitor	inhibitor	NN	_	25	nmod
30	of	of	IN	_	31	case
31	HB-EGF	hb-egf	NN	_	29	nmod
32	,	,	,	_	31	punct
33	drug1	drug1	NN	_	31	appos
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	drug2	drug2	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	.	.	.	_	7	punct

1	We	we	PRP	_	2	nsubj
2	elucidated	elucidate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	expression	expression	NN	_	2	dobj
5	of	of	IN	_	6	case
6	HB-EGF	hb-egf	NN	_	4	nmod
7	in	in	IN	_	10	case
8	T-ALL	t-all	NN	_	10	compound
9	cell	cell	NN	_	10	compound
10	lines	line	NNS	_	4	nmod
11	,	,	,	_	2	punct
12	and	and	CC	_	2	cc
13	evaluated	evaluate	VBD	_	2	conj
14	the	the	DT	_	15	det
15	effect	effect	NN	_	13	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	on	on	IN	_	20	case
19	these	these	DT	_	20	det
20	cells	cell	NNS	_	15	nmod
21	alone	alone	RB	_	22	advmod
22	or	or	CC	_	20	advmod
23	in	in	IN	_	24	case
24	combination	combination	NN	_	22	conj
25	with	with	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	expression	expression	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	EGFR	egfr	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	EGFR	egfr	NN	_	4	conj
7	ligands	ligand	NNS	_	4	dep
8	was	be	VBD	_	9	auxpass
9	determined	determine	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	flow	flow	NN	_	12	compound
12	cytometry	cytometry	NN	_	9	nmod
13	,	,	,	_	12	punct
14	RT-PCR	rt-pcr	NN	_	12	conj
15	and	and	CC	_	12	cc
16	real-time	real-time	JJ	_	18	amod
17	quantitative	quantitative	JJ	_	18	amod
18	PCR	pcr	NN	_	12	conj
19	.	.	.	_	9	punct

1	Induction	induction	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	apoptosis	apoptosis	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	assessed	assess	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	TUNEL	tunel	NN	_	8	compound
8	assay	assay	NN	_	5	nmod
9	.	.	.	_	5	punct

1	HB-EGF	hb-egf	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	strongly	strongly	RB	_	4	advmod
4	expressed	express	VBN	_	0	ROOT
5	by	by	IN	_	8	case
6	T-ALL	t-all	NN	_	8	compound
7	cell	cell	NN	_	8	compound
8	lines	line	NNS	_	4	nmod
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	the	the	DT	_	12	det
12	expression	expression	NN	_	19	nsubjpass
13	of	of	IN	_	15	case
14	both	both	CC	_	15	cc:preconj
15	HB-EGF	hb-egf	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	EGFR	egfr	NN	_	15	conj
18	was	be	VBD	_	19	auxpass
19	enhanced	enhance	VBN	_	4	conj
20	by	by	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	induced	induce	VBD	_	0	ROOT
3	apoptosis	apoptosis	NN	_	2	dobj
4	,	,	,	_	2	punct
5	and	and	CC	_	2	cc
6	furthermore	furthermore	RB	_	14	advmod
7	,	,	,	_	14	punct
8	the	the	DT	_	9	det
9	combination	combination	NN	_	14	nsubj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	plus	plus	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	enhanced	enhance	VBD	_	2	conj
15	cytotoxicity	cytotoxicity	NN	_	14	dobj
16	in	in	IN	_	20	case
17	a	a	DT	_	20	det
18	T-ALL	t-all	NN	_	20	compound
19	cell	cell	NN	_	20	compound
20	line	line	NN	_	14	nmod
21	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	HB-EGF	hb-egf	NN	_	10	nsubj
6	is	be	VBZ	_	10	cop
7	a	a	DT	_	10	det
8	promising	promising	JJ	_	10	amod
9	therapeutic	therapeutic	JJ	_	10	amod
10	target	target	NN	_	3	ccomp
11	for	for	IN	_	12	case
12	T-ALL	t-all	NN	_	10	nmod
13	.	.	.	_	3	punct

1	Distinct	distinct	JJ	_	3	amod
2	synergistic	synergistic	JJ	_	3	amod
3	action	action	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	against	against	IN	_	10	case
9	Pseudomonas	pseudomonas	FW	_	10	compound
10	aeruginosa	aeruginosa	FW	_	3	nmod
11	.	.	.	_	3	punct

1	The	the	DT	_	4	det
2	dicarbonyl	dicarbonyl	NN	_	4	compound
3	compound	compound	NN	_	4	compound
4	drug1	drug1	NN	_	8	nsubj
5	is	be	VBZ	_	8	cop
6	a	a	DT	_	8	det
7	natural	natural	JJ	_	8	amod
8	constituent	constituent	NN	_	0	ROOT
9	of	of	IN	_	11	case
10	Manuka	Manuka	NNP	_	11	compound
11	honey	honey	NN	_	8	nmod
12	produced	produce	VBD	_	8	acl
13	from	from	IN	_	15	case
14	Manuka	Manuka	NNP	_	15	compound
15	flowers	flower	NNS	_	12	nmod
16	in	in	IN	_	18	case
17	New	New	NNP	_	18	compound
18	Zealand	Zealand	NNP	_	15	nmod
19	.	.	.	_	8	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	possess	possess	VB	_	3	xcomp
6	both	both	CC	_	7	cc:preconj
7	anticancer	anticancer	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	antibacterial	antibacterial	JJ	_	7	conj
10	activity	activity	NN	_	5	dobj
11	.	.	.	_	3	punct

1	Such	such	JJ	_	2	amod
2	observations	observation	NNS	_	3	nsubj
3	prompted	prompt	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	investigate	investigate	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	ability	ability	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	as	as	IN	_	13	case
11	a	a	DT	_	13	det
12	potent	potent	JJ	_	13	amod
13	drug	drug	NN	_	7	nmod
14	against	against	IN	_	18	case
15	multidrug	multidrug	JJ	_	18	amod
16	resistant	resistant	JJ	_	18	amod
17	Pseudomonas	pseudomonas	FW	_	18	compound
18	aeruginosa	aeruginosa	FW	_	13	nmod
19	.	.	.	_	3	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	12	12	CD	_	6	nummod
5	test	test	NN	_	6	compound
6	P.	P.	NNP	_	2	nmod

1	aeruginosa	aeruginosa	FW	_	2	compound
2	strains	strain	NNS	_	8	nsubjpass
3	isolated	isolate	VBN	_	2	acl
4	from	from	IN	_	6	case
5	various	various	JJ	_	6	amod
6	hospitals	hospital	NNS	_	3	nmod
7	were	be	VBD	_	8	auxpass
8	tested	test	VBN	_	0	ROOT
9	for	for	IN	_	11	case
10	their	they	PRP$	_	11	nmod:poss
11	resistances	resistance	NNS	_	8	nmod
12	against	against	IN	_	14	case
13	many	many	JJ	_	14	amod
14	drug1	drug1	NN	_	11	nmod
15	,	,	,	_	14	punct
16	most	most	JJS	_	20	nsubjpass
17	of	of	IN	_	18	case
18	which	which	WDT	_	16	nmod
19	are	be	VBP	_	20	auxpass
20	applied	apply	VBN	_	14	acl:relcl
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	treatment	treatment	NN	_	20	nmod
24	of	of	IN	_	25	case
25	P.	P.	NNP	_	23	nmod

1	aeruginosa	aeruginosa	FW	_	2	compound
2	infections	infection	NNS	_	0	ROOT
3	.	.	.	_	2	punct

1	Results	result	NNS	_	2	nsubj
2	revealed	reveal	VBD	_	0	ROOT
3	that	that	IN	_	7	mark
4	the	the	DT	_	5	det
5	strains	strain	NNS	_	7	nsubj
6	were	be	VBD	_	7	cop
7	resistant	resistant	JJ	_	2	ccomp
8	to	to	TO	_	10	case
9	many	many	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	at	at	IN	_	13	case
12	high	high	JJ	_	13	amod
13	levels	level	NNS	_	7	nmod
14	,	,	,	_	7	punct
15	only	only	RB	_	16	advmod
16	drug1	drug1	NN	_	23	nsubj
17	,	,	,	_	16	punct
18	drug2	drug2	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug3	drug3	NN	_	16	conj
21	and	and	CC	_	16	cc
22	drug4	drug4	NN	_	16	conj
23	showed	show	VBD	_	7	ccomp
24	resistances	resistance	NNS	_	23	dobj
25	at	at	IN	_	28	case
26	comparatively	comparatively	RB	_	27	advmod
27	lower	lower	JJR	_	28	amod
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	2	punct

1	Following	follow	VBG	_	3	case
2	multiple	multiple	JJ	_	3	amod
3	experimentations	experimentation	NNS	_	6	nmod
4	it	it	PRP	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	that	that	IN	_	11	mark
8	drug1	drug1	NN	_	11	nsubj
9	was	be	VBD	_	11	cop
10	also	also	RB	_	11	advmod
11	antimicrobic	antimicrobic	JJ	_	6	ccomp
12	against	against	IN	_	15	case
13	all	all	PDT	_	15	det:predet
14	the	the	DT	_	15	det
15	strains	strain	NNS	_	11	nmod
16	at	at	IN	_	18	case
17	comparable	comparable	JJ	_	18	amod
18	levels	level	NNS	_	11	nmod
19	.	.	.	_	6	punct

1	Distinct	distinct	JJ	_	5	amod
2	and	and	CC	_	1	cc
3	statistically	statistically	RB	_	4	advmod
4	significant	significant	JJ	_	1	conj
5	synergism	synergism	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	by	by	IN	_	15	case
13	disc	disc	NN	_	15	compound
14	diffusion	diffusion	NN	_	15	compound
15	tests	test	NNS	_	7	nmod
16	when	when	WRB	_	17	advmod
17	compared	compare	VBN	_	7	advcl
18	with	with	IN	_	21	case
19	their	they	PRP$	_	21	nmod:poss
20	individual	individual	JJ	_	21	amod
21	effects	effect	NNS	_	17	nmod
22	.	.	.	_	7	punct

1	The	the	DT	_	5	det
2	fractional	fractional	JJ	_	5	amod
3	inhibitory	inhibitory	JJ	_	5	amod
4	concentration	concentration	NN	_	5	compound
5	index	index	NN	_	15	nsubj
6	of	of	IN	_	8	case
7	this	this	DT	_	8	det
8	combination	combination	NN	_	5	nmod
9	evaluated	evaluate	VBN	_	8	acl
10	by	by	IN	_	12	case
11	checkerboard	checkerboard	NN	_	12	compound
12	analysis	analysis	NN	_	9	nmod
13	,	,	,	_	5	punct
14	was	be	VBD	_	15	cop
15	0.5	0.5	CD	_	0	ROOT
16	,	,	,	_	15	punct
17	which	which	WDT	_	18	nsubj
18	confirmed	confirm	VBD	_	15	acl:relcl
19	synergism	synergism	NN	_	18	dobj
20	between	between	IN	_	22	case
21	the	the	DT	_	22	det
22	pair	pair	NN	_	19	nmod
23	.	.	.	_	15	punct

1	Synergism	synergism	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	also	also	RB	_	4	advmod
4	noted	note	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	combined	combine	VBN	_	4	advcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	failure	failure	NN	_	0	ROOT
3	in	in	IN	_	6	case
4	an	a	DT	_	6	det
5	HIV-positive	hiv-positive	JJ	_	6	amod
6	woman	woman	NN	_	2	nmod
7	on	on	IN	_	9	case
8	drug2	drug2	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	resulting	result	VBG	_	6	acl
11	in	in	IN	_	14	case
12	two	two	CD	_	14	nummod
13	ectopic	ectopic	JJ	_	14	amod
14	pregnancies	pregnancy	NNS	_	10	nmod
15	.	.	.	_	2	punct

1	Since	since	IN	_	3	case
2	its	its	PRP$	_	3	nmod:poss
3	introduction	introduction	NN	_	8	nmod
4	in	in	IN	_	5	case
5	1999	1999	CD	_	3	nmod
6	,	,	,	_	8	punct
7	drug1	drug1	NN	_	8	nsubj
8	remains	remain	VBZ	_	0	ROOT
9	one	one	CD	_	8	xcomp
10	of	of	IN	_	14	case
11	the	the	DT	_	14	det
12	preferred	preferred	JJ	_	14	amod
13	contraceptive	contraceptive	JJ	_	14	amod
14	choices	choice	NNS	_	9	nmod
15	for	for	IN	_	17	case
16	many	many	JJ	_	17	amod
17	women	woman	NNS	_	14	nmod
18	as	as	IN	_	20	mark
19	it	it	PRP	_	20	nsubj
20	offers	offer	VBZ	_	8	advcl
21	a	a	DT	_	24	det
22	highly	highly	RB	_	23	advmod
23	effective	effective	JJ	_	24	amod
24	means	means	NNS	_	20	dobj
25	of	of	IN	_	27	case
26	long-term	long-term	JJ	_	27	amod
27	contraception	contraception	NN	_	24	nmod
28	for	for	IN	_	30	case
29	three	three	CD	_	30	nummod
30	years	year	NNS	_	27	nmod
31	that	that	WDT	_	34	nsubj
32	does	do	VBZ	_	34	aux
33	not	not	RB	_	34	neg
34	rely	rely	VB	_	24	acl:relcl
35	on	on	IN	_	36	case
36	adherence	adherence	NN	_	34	nmod
37	.	.	.	_	8	punct

1	Like	like	IN	_	3	case
2	all	all	DT	_	3	det
3	drug1	drug1	NN	_	10	nmod
4	,	,	,	_	10	punct
5	certain	certain	JJ	_	8	amod
6	hepatic	hepatic	JJ	_	8	amod
7	enzyme-inducing	enzyme-inducing	JJ	_	8	amod
8	drugs	drug	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	its	its	PRP$	_	12	nmod:poss
12	efficacy	efficacy	NN	_	10	dobj
13	.	.	.	_	10	punct

1	We	we	PRP	_	2	nsubj
2	present	present	VBP	_	0	ROOT
3	an	a	DT	_	5	det
4	interesting	interesting	JJ	_	5	amod
5	case	case	NN	_	2	dobj
6	of	of	IN	_	9	case
7	an	a	DT	_	9	det
8	HIV-positive	hiv-positive	JJ	_	9	amod
9	woman	woman	NN	_	5	nmod
10	on	on	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	9	nmod
13	having	have	VBG	_	9	acl
14	tubal	tubal	JJ	_	15	amod
15	pregnancies	pregnancy	NNS	_	13	dobj
16	on	on	IN	_	19	case
17	two	two	CD	_	19	nummod
18	separate	separate	JJ	_	19	amod
19	occasions	occasion	NNS	_	13	nmod
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	in	in	IN	_	23	case
23	place	place	NN	_	19	nmod
24	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	compound
2	and	and	CC	_	1	cc
3	CYP	cyp	NN	_	1	conj
4	2D6	2d6	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	caution	caution	NN	_	5	dep
8	.	.	.	_	5	punct

1	drug1	drug1	NN	_	10	nsubj
2	,	,	,	_	1	punct
3	an	a	DT	_	4	det
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	is	be	VBZ	_	10	cop
7	the	the	DT	_	10	det
8	standard	standard	JJ	_	10	amod
9	hormone	hormone	NN	_	10	compound
10	treatment	treatment	NN	_	0	ROOT
11	for	for	IN	_	13	case
12	breast	breast	NN	_	13	compound
13	cancer	cancer	NN	_	10	nmod
14	.	.	.	_	10	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	transformed	transform	VBN	_	0	ROOT
5	into	into	IN	_	8	case
6	its	its	PRP$	_	8	nmod:poss
7	active	active	JJ	_	8	amod
8	metabolites	metabolite	NNS	_	4	nmod
9	by	by	IN	_	14	case
10	the	the	DT	_	14	det
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	system	system	NN	_	4	nmod
15	,	,	,	_	4	punct
16	especially	especially	RB	_	18	advmod
17	into	into	IN	_	18	case
18	drug1	drug1	NN	_	4	nmod
19	by	by	IN	_	22	case
20	isoenzyme	isoenzyme	NN	_	22	compound
21	CYP	cyp	NN	_	22	compound
22	2D6	2d6	NN	_	18	nmod
23	.	.	.	_	4	punct

1	Co-administration	co-administration	NN	_	9	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	8	case
5	isoenzyme	isoenzyme	NN	_	8	compound
6	CYP	cyp	NN	_	8	compound
7	2D6	2d6	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	1	nmod
9	reduces	reduce	VBZ	_	0	ROOT
10	this	this	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibit	inhibit	VBP	_	0	ROOT
3	isoenzyme	isoenzyme	NN	_	5	compound
4	CYP	cyp	NN	_	5	compound
5	2D6	2d6	NN	_	2	dobj
6	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	reduce	reduce	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	by	by	IN	_	13	case
11	about	about	IN	_	12	advmod
12	50	50	CD	_	13	nummod
13	%	%	NN	_	4	nmod
14	.	.	.	_	4	punct

1	Two	two	CD	_	3	nummod
2	epidemiological	epidemiological	JJ	_	3	amod
3	studies	study	NNS	_	9	nsubj
4	involving	involve	VBG	_	3	acl
5	about	about	IN	_	6	advmod
6	3700	3700	CD	_	7	nummod
7	women	woman	NNS	_	4	dobj
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	a	a	DT	_	11	det
11	link	link	NN	_	9	dobj
12	between	between	IN	_	14	case
13	the	the	DT	_	14	det
14	use	use	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	and	and	CC	_	14	cc
18	an	a	DT	_	20	det
19	increased	increase	VBN	_	20	amod
20	frequency	frequency	NN	_	14	conj
21	of	of	IN	_	24	case
22	breast	breast	NN	_	24	compound
23	cancer	cancer	NN	_	24	compound
24	recurrence	recurrence	NN	_	20	nmod
25	.	.	.	_	9	punct

1	Other	other	JJ	_	2	amod
2	studies	study	NNS	_	13	nsubj
3	,	,	,	_	2	punct
4	with	with	IN	_	7	case
5	a	a	DT	_	7	det
6	lower	lower	JJR	_	7	amod
7	level	level	NN	_	2	nmod
8	of	of	IN	_	9	case
9	evidence	evidence	NN	_	7	nmod
10	,	,	,	_	2	punct
11	were	be	VBD	_	13	cop
12	less	less	RBR	_	13	advmod
13	convincing	convincing	JJ	_	0	ROOT
14	.	.	.	_	13	punct

1	Studies	study	NNS	_	8	nsubj
2	of	of	IN	_	7	case
3	other	other	JJ	_	7	amod
4	isoenzyme	isoenzyme	NN	_	7	compound
5	CYP	cyp	NN	_	7	compound
6	2D6	2d6	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	1	nmod
8	showed	show	VBD	_	0	ROOT
9	no	no	DT	_	10	neg
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	17	case
15	breast	breast	NN	_	17	compound
16	cancer	cancer	NN	_	17	compound
17	recurrence	recurrence	NN	_	13	nmod
18	,	,	,	_	8	punct
19	but	but	CC	_	8	cc
20	they	they	PRP	_	21	nsubj
21	lacked	lack	VBD	_	8	conj
22	statistical	statistical	JJ	_	23	amod
23	power	power	NN	_	21	dobj
24	.	.	.	_	8	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	better	better	JJR	_	0	ROOT
4	to	to	TO	_	5	mark
5	avoid	avoid	VB	_	3	xcomp
6	prescribing	prescribe	VBG	_	5	xcomp
7	isoenzyme	isoenzyme	NN	_	10	compound
8	CYP	cyp	NN	_	10	compound
9	2D6	2d6	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	6	dobj
11	to	to	TO	_	12	case
12	women	woman	NNS	_	6	nmod
13	treated	treat	VBN	_	12	acl
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	for	for	IN	_	18	case
17	breast	breast	NN	_	18	compound
18	cancer	cancer	NN	_	15	nmod
19	,	,	,	_	3	punct
20	especially	especially	RB	_	21	advmod
21	drug2	drug2	NN	_	3	dep
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug3	drug3	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	drug4	drug4	NN	_	24	conj
27	.	.	.	_	3	punct

1	Depression	depression	NN	_	5	nsubj
2	does	do	VBZ	_	5	aux
3	not	not	RB	_	5	neg
4	always	always	RB	_	5	advmod
5	require	require	VB	_	0	ROOT
6	drug1	drug1	NN	_	7	compound
7	therapy	therapy	NN	_	5	dobj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	drug2	drug2	NN	_	11	nsubj
11	have	have	VBP	_	5	conj
12	no	no	DT	_	15	neg
13	proven	proven	JJ	_	15	amod
14	preventive	preventive	JJ	_	15	amod
15	impact	impact	NN	_	11	dobj
16	on	on	IN	_	18	case
17	hot	hot	JJ	_	18	amod
18	flushes	flush	NNS	_	15	nmod
19	linked	link	VBN	_	18	acl
20	to	to	TO	_	22	case
21	the	the	DT	_	22	det
22	menopause	menopause	NN	_	19	nmod
23	.	.	.	_	5	punct

1	If	if	IN	_	9	mark
2	in	in	IN	_	4	case
3	certain	certain	JJ	_	4	amod
4	cases	case	NNS	_	9	nmod
5	,	,	,	_	9	punct
6	an	a	DT	_	7	det
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	considered	consider	VBN	_	15	advcl
10	necessary	necessary	JJ	_	9	xcomp
11	,	,	,	_	15	punct
12	it	it	PRP	_	15	nsubj
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	cop
15	advisable	advisable	JJ	_	0	ROOT
16	to	to	TO	_	17	mark
17	replace	replace	VB	_	15	xcomp
18	drug2	drug2	NN	_	17	dobj
19	with	with	IN	_	20	case
20	drug3	drug3	NN	_	17	nmod
21	.	.	.	_	15	punct

1	Phase	phase	NN	_	3	compound
2	I	i	CD	_	3	nummod
3	trial	trial	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	3	nmod
10	with	with	IN	_	13	case
11	relapsed	relapse	VBN	_	13	amod
12	multiple	multiple	JJ	_	13	amod
13	myeloma	myeloma	NN	_	9	nmod
14	:	:	:	_	3	punct
15	evidence	evidence	NN	_	3	dep
16	for	for	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	-	-	:	_	17	punct
19	drug4	drug4	NN	_	20	compound
20	interaction	interaction	NN	_	17	dep
21	via	via	IN	_	22	case
22	P-glycoprotein	p-glycoprotein	NN	_	20	nmod
23	.	.	.	_	3	punct

1	Multiple	multiple	JJ	_	2	amod
2	myeloma	myeloma	NN	_	10	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	MM	mm	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	is	be	VBZ	_	10	cop
7	an	a	DT	_	10	det
8	incurable	incurable	JJ	_	10	amod
9	plasma-cell	plasma-cell	NN	_	10	compound
10	neoplasm	neoplasm	NN	_	0	ROOT
11	for	for	IN	_	12	case
12	which	which	WDT	_	15	nmod
13	most	most	RBS	_	14	amod
14	treatments	treatment	NNS	_	15	nsubj
15	involve	involve	VBP	_	10	acl:relcl
16	a	a	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	agent	agent	NN	_	15	dobj
19	combined	combine	VBN	_	18	acl
20	with	with	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	preclinical	preclinical	JJ	_	3	amod
3	combination	combination	NN	_	12	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	10	case
7	the	the	DT	_	10	det
8	mTOR	mtor	NN	_	10	compound
9	inhibitor	inhibitor	NN	_	10	compound
10	drug2	drug2	NN	_	3	nmod
11	has	have	VBZ	_	12	aux
12	displayed	display	VBN	_	0	ROOT
13	synergy	synergy	NN	_	12	dobj
14	in	in	FW	_	15	compound
15	vitro	vitro	FW	_	12	advmod
16	and	and	CC	_	12	cc
17	represents	represent	VBZ	_	12	conj
18	a	a	DT	_	20	det
19	novel	novel	JJ	_	20	amod
20	combination	combination	NN	_	17	dobj
21	in	in	IN	_	22	case
22	MM	mm	NN	_	20	nmod
23	.	.	.	_	12	punct

1	In	in	FW	_	4	amod
2	vivo	vivo	FW	_	1	dep
3	CYP3A	cyp3a	NN	_	4	compound
4	activity	activity	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	significantly	significantly	RB	_	7	advmod
7	lower	lower	JJR	_	0	ROOT
8	in	in	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-	-	:	_	9	punct
11	treated	treat	VBN	_	9	acl
12	as	as	IN	_	13	mark
13	compared	compare	VBN	_	11	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	-	-	:	_	15	punct
17	treated	treat	VBN	_	20	amod
18	renal	renal	JJ	_	20	amod
19	allograft	allograft	NN	_	20	compound
20	recipients	recipient	NNS	_	15	dep
21	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	identified	identify	VBN	_	0	ROOT
6	drug1	drug1	NN	_	5	dobj
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	as	as	IN	_	11	case
10	CYP3A	cyp3a	NN	_	11	compound
11	inhibitors	inhibitor	NNS	_	5	nmod
12	.	.	.	_	5	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	current	current	JJ	_	4	amod
4	study	study	NN	_	11	nmod
5	in	in	IN	_	8	case
6	renal	renal	JJ	_	8	amod
7	allograft	allograft	NN	_	8	compound
8	recipients	recipient	NNS	_	4	nmod
9	,	,	,	_	11	punct
10	we	we	PRP	_	11	nsubj
11	used	use	VBD	_	0	ROOT
12	intravenously	intravenously	RB	_	13	advmod
13	and	and	CC	_	15	advmod
14	orally	orally	RB	_	13	advmod
15	administered	administer	VBN	_	11	dep
16	drug1	drug1	NN	_	15	dobj
17	as	as	IN	_	20	case
18	a	a	DT	_	20	det
19	drug	drug	NN	_	20	compound
20	probe	probe	NN	_	15	nmod
21	to	to	TO	_	22	mark
22	assess	assess	VB	_	15	advcl
23	whether	whether	IN	_	26	mark
24	the	the	DT	_	25	det
25	study	study	NN	_	26	nsubj
26	drugs	drug	NNS	_	22	ccomp
27	at	at	IN	_	28	case
28	doses	dose	NNS	_	26	nmod
29	that	that	WDT	_	32	nsubjpass
30	are	be	VBP	_	32	auxpass
31	generally	generally	RB	_	32	advmod
32	used	use	VBN	_	28	acl:relcl
33	in	in	IN	_	35	case
34	clinical	clinical	JJ	_	35	amod
35	practice	practice	NN	_	32	nmod
36	have	have	VBP	_	15	dep
37	differential	differential	JJ	_	38	amod
38	effects	effect	NNS	_	36	dobj
39	on	on	IN	_	42	case
40	in	in	FW	_	42	amod
41	vivo	vivo	FW	_	40	dep
42	hepatic	hepatic	JJ	_	36	nmod
43	and	and	CC	_	42	cc
44	first-pass	first-pass	JJ	_	42	conj
45	CYP3A	cyp3a	NN	_	46	compound
46	activities	activity	NNS	_	42	dep
47	.	.	.	_	11	punct

1	Systemic	systemic	JJ	_	6	amod
2	and	and	CC	_	1	cc
3	apparent	apparent	JJ	_	1	conj
4	oral	oral	JJ	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	clearance	clearance	NN	_	9	nsubj
7	were	be	VBD	_	9	cop
8	24	24	CD	_	9	nummod
9	%	%	NN	_	0	ROOT
10	-LRB-	-lrb-	-LRB-	_	9	punct
11	269	269	CD	_	12	compound
12	73	73	CD	_	10	root
13	vs.	vs.	IN	_	16	case
14	354	354	CD	_	15	compound
15	102	102	CD	_	16	nummod
16	ml/min	ml/min	NN	_	12	nmod
17	,	,	,	_	16	punct
18	P	p	NN	_	19	nsubj
19	=	=	JJ	_	16	dep
20	0.022	0.022	CD	_	19	dobj
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	and	and	CC	_	12	cc
23	31	31	CD	_	24	nummod
24	%	%	NN	_	40	nmod:npmod
25	-LRB-	-lrb-	-LRB-	_	40	punct
26	479	479	CD	_	27	compound
27	190	190	CD	_	40	dep
28	vs.	vs.	IN	_	31	case
29	688	688	CD	_	30	compound
30	265	265	CD	_	31	nummod
31	ml/min	ml/min	NN	_	27	nmod
32	,	,	,	_	31	punct
33	P	p	NN	_	34	nsubj
34	=	=	JJ	_	31	dep
35	0.013	0.013	CD	_	34	dobj
36	-RRB-	-rrb-	-RRB-	_	31	punct
37	,	,	,	_	40	punct
38	respectively	respectively	RB	_	40	advmod
39	,	,	,	_	40	punct
40	lower	lower	JJR	_	12	conj
41	in	in	IN	_	42	case
42	drug2	drug2	NN	_	40	nmod
43	-	-	:	_	12	punct
44	treated	treated	JJ	_	45	amod
45	patients	patient	NNS	_	12	dep
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	n	n	NN	_	45	dep
48	=	=	JJ	_	47	amod
49	20	20	CD	_	48	dep
50	-RRB-	-rrb-	-RRB-	_	47	punct
51	than	than	IN	_	54	case
52	in	in	IN	_	54	case
53	matched	match	VBN	_	54	amod
54	drug3	drug3	NN	_	45	nmod
55	-	-	:	_	45	punct
56	treated	treated	JJ	_	57	amod
57	patients	patient	NNS	_	45	dep
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	n	n	NN	_	57	dep
60	=	=	JJ	_	59	amod
61	20	20	CD	_	60	dep
62	-RRB-	-rrb-	-RRB-	_	59	punct
63	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	latter	latter	JJ	_	3	nsubj
3	displayed	display	VBD	_	0	ROOT
4	drug1	drug1	NN	_	5	compound
5	clearances	clearance	NNS	_	3	dobj
6	similar	similar	JJ	_	5	amod
7	to	to	TO	_	8	case
8	those	those	DT	_	6	nmod
9	in	in	IN	_	12	case
10	two	two	CD	_	12	nummod
11	larger	larger	JJR	_	12	amod
12	cohorts	cohort	NNS	_	8	nmod
13	of	of	IN	_	15	case
14	nonmatched	nonmatched	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	-	-	:	_	12	punct
17	treated	treated	JJ	_	18	amod
18	patients	patient	NNS	_	12	dep
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	n	n	NN	_	18	dep
21	=	=	JJ	_	20	amod
22	58	58	CD	_	21	dep
23	and	and	CC	_	20	cc
24	n	n	NN	_	25	nsubj
25	=	=	JJ	_	20	conj
26	80	80	CD	_	25	dobj
27	-RRB-	-rrb-	-RRB-	_	20	punct
28	and	and	CC	_	18	cc
29	to	to	TO	_	30	case
30	those	those	DT	_	18	conj
31	receiving	receive	VBG	_	30	acl
32	a	a	DT	_	33	det
33	drug3	drug3	NN	_	31	dobj
34	-	-	:	_	18	punct
35	free	free	JJ	_	36	amod
36	regimen	regimen	NN	_	18	dep
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	n	n	NN	_	36	dep
39	=	=	JJ	_	38	amod
40	6	6	CD	_	39	dep
41	-RRB-	-rrb-	-RRB-	_	38	punct
42	.	.	.	_	3	punct

1	This	this	DT	_	2	nsubj
2	implies	imply	VBZ	_	0	ROOT
3	that	that	IN	_	13	mark
4	in	in	FW	_	6	amod
5	vivo	vivo	FW	_	4	dep
6	hepatic	hepatic	JJ	_	13	nsubj
7	and	and	CC	_	6	cc
8	first-pass	first-pass	JJ	_	6	conj
9	CYP3A	cyp3a	NN	_	10	compound
10	activities	activity	NNS	_	6	dep
11	are	be	VBP	_	13	cop
12	significantly	significantly	RB	_	13	advmod
13	lower	lower	JJR	_	2	ccomp
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	drug1	drug1	NN	_	16	dobj
18	than	than	IN	_	20	case
19	in	in	IN	_	20	case
20	those	those	DT	_	13	nmod
21	receiving	receive	VBG	_	20	acl
22	drug2	drug2	NN	_	21	dobj
23	,	,	,	_	13	punct
24	indicating	indicate	VBG	_	13	xcomp
25	that	that	IN	_	39	mark
26	,	,	,	_	39	punct
27	at	at	IN	_	29	case
28	the	the	DT	_	29	det
29	doses	dose	NNS	_	39	nmod
30	generally	generally	RB	_	31	advmod
31	used	use	VBN	_	29	acl
32	in	in	IN	_	34	case
33	clinical	clinical	JJ	_	34	amod
34	practice	practice	NN	_	31	nmod
35	,	,	,	_	39	punct
36	drug3	drug3	NN	_	39	nsubj
37	is	be	VBZ	_	39	cop
38	the	the	DT	_	39	det
39	stronger	stronger	JJR	_	24	ccomp
40	of	of	IN	_	42	case
41	the	the	DT	_	42	det
42	two	two	CD	_	39	nmod
43	with	with	IN	_	44	case
44	respect	respect	NN	_	39	nmod
45	to	to	TO	_	47	case
46	CYP3A	cyp3a	NN	_	47	compound
47	inhibition	inhibition	NN	_	44	nmod
48	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	observation	observation	NN	_	3	nsubj
3	has	have	VBZ	_	0	ROOT
4	important	important	JJ	_	5	amod
5	implications	implication	NNS	_	3	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	context	context	NN	_	5	nmod
9	of	of	IN	_	11	case
10	drug-drug	drug-drug	JJ	_	11	amod
11	interactions	interaction	NNS	_	8	nmod
12	in	in	IN	_	14	case
13	transplant	transplant	NN	_	14	compound
14	recipients	recipient	NNS	_	11	nmod
15	.	.	.	_	3	punct

1	-LSB-	-lsb-	-LRB-	_	2	punct
2	Influence	influence	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	on	on	IN	_	10	case
8	MPTP-evoked	mptp-evoked	JJ	_	10	amod
9	behavior	behavior	NN	_	10	compound
10	violations	violation	NNS	_	2	nmod
11	in	in	IN	_	13	case
12	C57BL/6	c57bl/6	NN	_	13	compound
13	mice	mouse	NNS	_	10	nmod
14	-RSB-	-rsb-	-RRB-	_	2	punct
15	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	drug2	drug2	NN	_	2	nmod
6	-LSB-	-lsb-	-LRB-	_	7	punct
7	drug3	drug3	NN	_	5	appos
8	-RSB-	-rsb-	-RRB-	_	7	punct
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	10	10	CD	_	11	nummod
11	mg/kg	mg/kg	NN	_	5	dep
12	,	,	,	_	11	punct
13	p.	p.	NN	_	14	compound
14	o.	o.	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	11	punct

1	and/or	and/or	CC	_	0	ROOT
2	drug1	drug1	NN	_	3	compound
3	drug2	drug2	NN	_	1	dep
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	100	100	CD	_	6	nummod
6	mg/kg	mg/kg	NN	_	3	dep
7	,	,	,	_	6	punct
8	p.	p.	NN	_	9	compound
9	o.	o.	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	6	punct
11	,	,	,	_	3	punct
12	as	as	RB	_	3	cc
13	well	well	RB	_	12	mwe
14	as	as	IN	_	12	mwe
15	that	that	DT	_	3	conj
16	of	of	IN	_	18	case
17	neurotoxin	neurotoxin	NN	_	18	compound
18	drug3	drug3	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug4	drug4	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	-LRB-	-lrb-	-LRB-	_	26	punct
23	4	4	CD	_	26	nummod
24	x	x	CC	_	23	cc
25	20	20	CD	_	23	conj
26	mg/kg	mg/kg	NN	_	18	dep
27	,	,	,	_	26	punct
28	i.	i.	NN	_	29	compound
29	p.	p.	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	26	punct

1	were	be	VBD	_	2	auxpass
2	studied	study	VBN	_	0	ROOT
3	in	in	IN	_	7	case
4	elevated	elevated	JJ	_	7	amod
5	plus	plus	CC	_	4	cc
6	maze	maze	NN	_	4	conj
7	test	test	NN	_	2	nmod
8	on	on	IN	_	10	case
9	C57BL/6	c57bl/6	NN	_	10	compound
10	mice	mouse	NNS	_	7	nmod
11	.	.	.	_	2	punct

1	On	on	IN	_	3	case
2	second	second	JJ	_	3	amod
3	day	day	NN	_	8	nmod
4	after	after	IN	_	5	case
5	injection	injection	NN	_	3	nmod
6	,	,	,	_	8	punct
7	drug1	drug1	NN	_	8	nsubj
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	locomot	locomot	NN	_	8	dobj
11	or	or	CC	_	10	cc
12	activity	activity	NN	_	10	conj
13	in	in	IN	_	14	case
14	comparison	comparison	NN	_	8	nmod
15	to	to	TO	_	16	case
16	saline	saline	NN	_	14	nmod
17	.	.	.	_	8	punct

1	Acute	acute	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	failed	fail	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	influence	influence	VB	_	7	xcomp
10	locomotion	locomotion	NN	_	9	dobj
11	in	in	IN	_	12	case
12	mice	mouse	NNS	_	10	nmod
13	,	,	,	_	7	punct
14	while	while	IN	_	17	mark
15	their	they	PRP$	_	16	nmod:poss
16	combination	combination	NN	_	17	nsubj
17	normalized	normalize	VBD	_	7	advcl
18	motor	motor	NN	_	19	compound
19	activity	activity	NN	_	17	dobj
20	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	obtained	obtain	VBN	_	2	acl
4	confirm	confirm	VBP	_	0	ROOT
5	the	the	DT	_	6	det
6	role	role	NN	_	4	dobj
7	of	of	IN	_	9	case
8	inflammatory	inflammatory	JJ	_	9	amod
9	processes	process	NNS	_	6	nmod
10	in	in	IN	_	11	case
11	parkinsonism	parkinsonism	NN	_	6	nmod
12	and	and	CC	_	4	cc
13	suggest	suggest	VBP	_	4	conj
14	expediency	expediency	NN	_	13	dobj
15	of	of	IN	_	17	case
16	combined	combined	JJ	_	17	amod
17	pharmacotherapy	pharmacotherapy	NN	_	14	nmod
18	of	of	IN	_	20	case
19	neurodegenerative	neurodegenerative	JJ	_	20	amod
20	diseases	disease	NNS	_	17	nmod
21	.	.	.	_	4	punct

1	Exposure	exposure	NN	_	6	nsubjpass
2	to	to	TO	_	4	case
3	oral	oral	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	unaffected	unaffected	JJ	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	but	but	CC	_	6	cc
10	greatly	greatly	RB	_	11	advmod
11	increased	increase	VBN	_	6	conj
12	by	by	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	6	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	examined	examine	VBD	_	0	ROOT
4	drug-drug	drug-drug	JJ	_	5	amod
5	interactions	interaction	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	with	with	IN	_	12	case
10	the	the	DT	_	12	det
11	cytochrome	cytochrome	NN	_	12	compound
12	P450	p450	NN	_	5	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	CYP	cyp	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	2B6	2b6	NN	_	18	compound
17	inhibitor	inhibitor	NN	_	18	compound
18	drug2	drug2	NN	_	12	dep
19	and	and	CC	_	12	cc
20	the	the	DT	_	23	det
21	CYP3A	cyp3a	NN	_	23	compound
22	inhibitor	inhibitor	NN	_	23	compound
23	drug3	drug3	NN	_	12	conj
24	.	.	.	_	3	punct

1	In	in	IN	_	0	ROOT
2	this	this	DT	_	1	dep
3	randomized	randomize	VBN	_	2	dep
4	,	,	,	_	3	punct
5	blinded	blind	VBN	_	4	root
6	,	,	,	_	5	punct
7	crossover	crossover	NN	_	8	compound
8	study	study	NN	_	6	root
9	,	,	,	_	8	punct
10	11	11	CD	_	12	nummod
11	healthy	healthy	JJ	_	12	amod
12	volunteers	volunteer	NNS	_	13	nsubj
13	ingested	ingest	VBD	_	8	acl:relcl
14	0.2	0.2	CD	_	16	nummod
15	mg/kg	mg/kg	NN	_	16	compound
16	drug1	drug1	NN	_	13	dobj
17	after	after	IN	_	18	case
18	pretreatments	pretreatment	NNS	_	13	nmod
19	with	with	IN	_	21	case
20	oral	oral	JJ	_	21	amod
21	drug2	drug2	NN	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	250	250	CD	_	24	nummod
24	mg	mg	NN	_	21	appos
25	twice	twice	RB	_	26	advmod
26	daily	daily	RB	_	24	advmod
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	,	,	,	_	21	punct
29	drug3	drug3	NN	_	21	conj
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	200	200	CD	_	32	nummod
32	mg	mg	NN	_	29	dep
33	once	once	RB	_	34	advmod
34	daily	daily	JJ	_	32	amod
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	,	,	,	_	21	punct
37	or	or	CC	_	21	cc
38	placebo	placebo	NN	_	21	conj
39	in	in	IN	_	42	case
40	6-day	6-day	JJ	_	42	amod
41	treatment	treatment	NN	_	42	compound
42	periods	period	NNS	_	18	nmod
43	at	at	IN	_	44	case
44	intervals	interval	NNS	_	42	nmod
45	of	of	IN	_	47	case
46	4	4	CD	_	47	nummod
47	weeks	week	NNS	_	44	nmod
48	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	compound
2	treatment	treatment	NN	_	3	nsubj
3	increased	increase	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	mean	mean	JJ	_	6	amod
6	area	area	NN	_	3	dobj
7	under	under	IN	_	11	case
8	the	the	DT	_	11	det
9	plasma	plasma	NN	_	11	compound
10	concentration-time	concentration-time	NN	_	11	compound
11	curve	curve	NN	_	3	nmod
12	extrapolated	extrapolate	VBD	_	11	acl
13	to	to	TO	_	14	case
14	infinity	infinity	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	AUC	auc	NN	_	14	dep
17	-LRB-	-lrb-	-LRB-	_	24	punct
18	0	0	CD	_	24	nummod
19	-	-	:	_	24	punct
20	-RRB-	-rrb-	-RRB-	_	24	punct
21	-RRB-	-rrb-	-RRB-	_	24	punct
22	of	of	IN	_	24	case
23	oral	oral	JJ	_	24	amod
24	drug2	drug2	NN	_	16	dep
25	by	by	IN	_	26	case
26	2.4-fold	2.4-fold	JJ	_	24	nmod
27	,	,	,	_	24	punct
28	whereas	whereas	IN	_	33	mark
29	drug3	drug3	NN	_	30	compound
30	treatment	treatment	NN	_	33	nsubj
31	did	do	VBD	_	33	aux
32	not	not	RB	_	33	neg
33	increase	increase	VB	_	24	advcl
34	the	the	DT	_	35	det
35	exposure	exposure	NN	_	33	dobj
36	to	to	TO	_	37	case
37	drug4	drug4	NN	_	35	nmod
38	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	ratio	ratio	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	AUC	auc	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	11	punct
7	0	0	CD	_	11	dep
8	-	-	:	_	11	punct
9	-RRB-	-rrb-	-RRB-	_	11	punct
10	to	to	TO	_	11	mark
11	drug2	drug2	VB	_	5	dep
12	AUC	auc	NN	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	19	punct
14	0	0	CD	_	19	dep
15	-	-	:	_	19	punct
16	-RRB-	-rrb-	-RRB-	_	19	punct
17	was	be	VBD	_	19	auxpass
18	significantly	significantly	RB	_	19	advmod
19	decreased	decrease	VBN	_	12	dep
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	drug3	drug3	NN	_	19	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	P	p	NN	_	22	dep
25	&	&	CC	_	24	cc
26	lt	lt	NN	_	24	conj
27	;	;	:	_	24	punct
28	0.001	0.001	CD	_	24	dep
29	-RRB-	-rrb-	-RRB-	_	24	punct
30	drug4	drug4	NN	_	32	compound
31	zole	zole	NN	_	32	compound
32	phases	phase	NNS	_	22	dep
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	P	p	NN	_	32	dep
35	=	=	JJ	_	34	amod
36	0.006	0.006	CD	_	35	dep
37	-RRB-	-rrb-	-RRB-	_	34	punct
38	as	as	IN	_	39	mark
39	compared	compare	VBN	_	19	advcl
40	to	to	TO	_	41	case
41	placebo	placebo	NN	_	39	nmod
42	.	.	.	_	2	punct

1	In	in	IN	_	6	case
2	the	the	DT	_	6	det
3	drug1	drug1	NN	_	6	compound
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	phases	phase	NNS	_	22	nmod
7	,	,	,	_	22	punct
8	the	the	DT	_	9	det
9	areas	area	NNS	_	22	nsubj
10	under	under	IN	_	13	case
11	the	the	DT	_	13	det
12	effect-time	effect-time	JJ	_	13	amod
13	curves	curve	NNS	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	self-reported	self-reported	JJ	_	16	amod
16	drowsiness	drowsiness	NN	_	13	dep
17	and	and	CC	_	16	cc
18	performance	performance	NN	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	were	be	VBD	_	22	cop
21	significantly	significantly	RB	_	22	advmod
22	higher	higher	JJR	_	0	ROOT
23	than	than	IN	_	24	case
24	those	those	DT	_	22	nmod
25	in	in	IN	_	28	case
26	the	the	DT	_	28	det
27	placebo	placebo	NN	_	28	compound
28	phase	phase	NN	_	24	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	P	p	NN	_	31	dep
31	<	<	JJR	_	22	parataxis
32	0.05	0.05	CD	_	31	nummod
33	-RRB-	-rrb-	-RRB-	_	31	punct
34	.	.	.	_	22	punct

1	The	the	DT	_	2	det
2	findings	finding	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	11	mark
5	the	the	DT	_	6	det
6	dosage	dosage	NN	_	11	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reduced	reduce	VBN	_	3	ccomp
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	receiving	receive	VBG	_	13	acl
15	drug2	drug2	NN	_	14	dobj
16	.	.	.	_	3	punct

1	Interaction	interaction	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	different	different	JJ	_	6	amod
6	drug2	drug2	NN	_	1	nmod
7	is	be	VBZ	_	8	cop
8	antagonistic	antagonistic	JJ	_	0	ROOT
9	in	in	IN	_	10	case
10	breast	breast	NN	_	8	nmod
11	but	but	CC	_	10	cc
12	not	not	RB	_	16	neg
13	in	in	IN	_	16	case
14	other	other	JJ	_	16	amod
15	cancer	cancer	NN	_	16	compound
16	cells	cell	NNS	_	10	conj
17	.	.	.	_	8	punct

1	drug1	drug1	NN	_	10	nsubjpass
2	,	,	,	_	1	punct
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	1	appos
5	of	of	IN	_	6	case
6	cyclooxygenase-2	cyclooxygenase-2	NN	_	4	nmod
7	,	,	,	_	1	punct
8	is	be	VBZ	_	10	aux
9	being	be	VBG	_	10	auxpass
10	investigated	investigate	VBN	_	0	ROOT
11	for	for	IN	_	12	case
12	enhancement	enhancement	NN	_	10	nmod
13	of	of	IN	_	15	case
14	chemotherapy	chemotherapy	NN	_	15	compound
15	efficacy	efficacy	NN	_	12	nmod
16	in	in	IN	_	19	case
17	cancer	cancer	NN	_	19	compound
18	clinical	clinical	JJ	_	19	amod
19	trials	trial	NNS	_	12	nmod
20	.	.	.	_	10	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	investigates	investigate	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	ability	ability	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	to	to	TO	_	9	mark
9	sensitize	sensitize	VB	_	5	acl
10	cells	cell	NNS	_	9	dobj
11	from	from	IN	_	13	case
12	different	different	JJ	_	13	amod
13	origins	origin	NNS	_	9	nmod
14	to	to	TO	_	16	case
15	several	several	JJ	_	16	amod
16	drug2	drug2	NN	_	9	nmod
17	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	16	nsubjpass
3	of	of	IN	_	7	case
4	the	the	DT	_	5	det
5	drug	drug	NN	_	7	nmod:poss
6	's	's	POS	_	5	case
7	mechanism	mechanism	NN	_	2	nmod
8	of	of	IN	_	9	case
9	action	action	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	sequence	sequence	NN	_	9	conj
12	of	of	IN	_	13	case
13	administration	administration	NN	_	9	nmod
14	are	be	VBP	_	16	auxpass
15	also	also	RB	_	16	advmod
16	investigated	investigate	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	sensitivity	sensitivity	NN	_	42	nsubjpass
3	,	,	,	_	2	punct
4	cell	cell	NN	_	5	compound
5	cycle	cycle	NN	_	2	conj
6	,	,	,	_	2	punct
7	apoptosis	apoptosis	NN	_	2	conj
8	and	and	CC	_	2	cc
9	DNA	dna	NN	_	10	compound
10	damage	damage	NN	_	2	conj
11	of	of	IN	_	16	case
12	five	five	CD	_	16	nummod
13	different	different	JJ	_	16	amod
14	cancer	cancer	NN	_	16	compound
15	cell	cell	NN	_	16	compound
16	lines	line	NNS	_	2	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	HeLa	hela	NN	_	16	dep
19	,	,	,	_	18	punct
20	HCT116	hct116	NN	_	18	conj
21	,	,	,	_	18	punct
22	HepG2	hepg2	NN	_	18	conj
23	,	,	,	_	18	punct
24	MCF7	mcf7	NN	_	18	conj
25	and	and	CC	_	18	cc
26	U251	u251	NN	_	18	conj
27	-RRB-	-rrb-	-RRB-	_	18	punct
28	to	to	TO	_	29	case
29	drug1	drug1	NN	_	2	nmod
30	,	,	,	_	29	punct
31	drug2	drug2	NN	_	29	conj
32	,	,	,	_	29	punct
33	drug3	drug3	NN	_	29	conj
34	and	and	CC	_	29	cc
35	drug4	drug4	NN	_	36	compound
36	drug5	drug5	NN	_	29	conj
37	following	follow	VBG	_	40	case
38	different	different	JJ	_	40	amod
39	incubation	incubation	NN	_	40	compound
40	schedules	schedule	NNS	_	2	nmod
41	were	be	VBD	_	42	auxpass
42	analyzed	analyze	VBN	_	0	ROOT
43	.	.	.	_	42	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	antagonism	antagonism	NN	_	2	dobj
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	the	the	DT	_	9	det
8	four	four	CD	_	9	nummod
9	drugs	drug	NNS	_	5	conj
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	breast	breast	NN	_	14	compound
13	cancer	cancer	NN	_	14	compound
14	cells	cell	NNS	_	9	nmod
15	MCF7	mcf7	NN	_	5	dep
16	following	follow	VBG	_	19	case
17	all	all	DT	_	19	det
18	incubation	incubation	NN	_	19	compound
19	schedules	schedule	NNS	_	2	nmod
20	and	and	CC	_	19	cc
21	between	between	IN	_	22	case
22	drug2	drug2	NN	_	19	conj
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	in	in	IN	_	28	case
26	all	all	DT	_	28	det
27	cell	cell	NN	_	28	compound
28	lines	line	NNS	_	22	nmod
29	except	except	IN	_	32	case
30	for	for	IN	_	32	case
31	two	two	CD	_	32	nummod
32	combinations	combination	NNS	_	2	nmod
33	in	in	IN	_	35	case
34	HCT116	hct116	NN	_	35	compound
35	cells	cell	NNS	_	32	nmod
36	.	.	.	_	2	punct

1	drug1	drug1	NN	_	13	nsubj
2	with	with	IN	_	6	case
3	the	the	DT	_	6	det
4	other	other	JJ	_	6	amod
5	three	three	CD	_	6	nummod
6	drugs	drug	NNS	_	1	nmod
7	in	in	IN	_	12	case
8	the	the	DT	_	12	det
9	remaining	remain	VBG	_	12	amod
10	four	four	CD	_	12	nummod
11	cell	cell	NN	_	12	compound
12	lines	line	NNS	_	6	nmod
13	resulted	result	VBD	_	0	ROOT
14	in	in	IN	_	16	case
15	variable	variable	JJ	_	16	amod
16	interactions	interaction	NNS	_	13	nmod
17	.	.	.	_	13	punct

1	Mechanistic	mechanistic	JJ	_	2	amod
2	investigations	investigation	NNS	_	3	nsubj
3	revealed	reveal	VBD	_	0	ROOT
4	that	that	IN	_	6	mark
5	drug1	drug1	NN	_	6	nsubj
6	exerts	exert	VBZ	_	3	ccomp
7	different	different	JJ	_	9	amod
8	molecular	molecular	JJ	_	9	amod
9	effects	effect	NNS	_	6	dobj
10	in	in	IN	_	12	case
11	different	different	JJ	_	12	amod
12	cells	cell	NNS	_	6	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	lines	line	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	it	it	PRP	_	6	nsubj
6	abrogates	abrogate	VBZ	_	0	ROOT
7	the	the	DT	_	10	det
8	drug-induced	drug-induced	JJ	_	10	amod
9	G2/M	g2/m	NN	_	10	compound
10	arrest	arrest	NN	_	6	dobj
11	enhancing	enhance	VBG	_	10	acl
12	pre-mature	pre-mature	JJ	_	13	amod
13	entry	entry	NN	_	11	dobj
14	into	into	IN	_	15	case
15	mitosis	mitosis	NN	_	13	nmod
16	with	with	IN	_	18	case
17	damaged	damaged	JJ	_	18	amod
18	DNA	dna	NN	_	13	nmod
19	thus	thus	RB	_	20	advmod
20	increasing	increase	VBG	_	6	dep
21	apoptosis	apoptosis	NN	_	20	dobj
22	and	and	CC	_	20	cc
23	resulting	result	VBG	_	20	conj
24	in	in	IN	_	25	case
25	synergism	synergism	NN	_	23	nmod
26	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	other	other	JJ	_	3	amod
3	cells	cell	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	it	it	PRP	_	6	nsubj
6	enhances	enhance	VBZ	_	0	ROOT
7	drug-induced	drug-induced	JJ	_	9	amod
8	G2/M	g2/m	NN	_	9	compound
9	arrest	arrest	NN	_	6	dobj
10	allowing	allow	VBG	_	9	acl
11	time	time	NN	_	10	dobj
12	to	to	TO	_	13	mark
13	repair	repair	VB	_	10	xcomp
14	drug-induced	drug-induced	JJ	_	16	amod
15	DNA	dna	NN	_	16	compound
16	damage	damage	NN	_	13	dobj
17	before	before	IN	_	18	case
18	entry	entry	NN	_	13	nmod
19	into	into	IN	_	20	case
20	mitosis	mitosis	NN	_	18	nmod
21	and	and	CC	_	13	cc
22	decreasing	decrease	VBG	_	24	amod
23	cell	cell	NN	_	24	compound
24	death	death	NN	_	13	conj
25	resulting	result	VBG	_	24	acl
26	in	in	IN	_	27	case
27	antagonism	antagonism	NN	_	25	nmod
28	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	some	some	DT	_	4	det
3	synergistic	synergistic	JJ	_	4	amod
4	combinations	combination	NNS	_	13	nmod
5	,	,	,	_	13	punct
6	celecoxib-induced	celecoxib-induced	JJ	_	7	amod
7	abrogation	abrogation	NN	_	13	nsubjpass
8	of	of	IN	_	10	case
9	G2/M	g2/m	NN	_	10	compound
10	arrest	arrest	NN	_	7	nmod
11	was	be	VBD	_	13	auxpass
12	not	not	RB	_	13	neg
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	15	case
15	apoptosis	apoptosis	NN	_	13	nmod
16	but	but	CC	_	15	cc
17	permanent	permanent	JJ	_	18	amod
18	arrest	arrest	NN	_	15	conj
19	in	in	IN	_	21	case
20	G1	g1	NN	_	21	compound
21	phase	phase	NN	_	18	nmod
22	.	.	.	_	13	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	8	nsubj
3	,	,	,	_	8	punct
4	if	if	IN	_	5	mark
5	confirmed	confirm	VBN	_	8	advcl
6	in-vivo	in-vivo	JJ	_	5	xcomp
7	,	,	,	_	8	punct
8	indicate	indicate	VBP	_	0	ROOT
9	that	that	IN	_	15	mark
10	drug1	drug1	NN	_	15	nsubj
11	is	be	VBZ	_	15	cop
12	not	not	RB	_	15	neg
13	a	a	DT	_	15	det
14	suitable	suitable	JJ	_	15	amod
15	chemosensitizer	chemosensitizer	NN	_	8	ccomp
16	for	for	IN	_	18	case
17	breast	breast	NN	_	18	compound
18	cancer	cancer	NN	_	15	nmod
19	or	or	CC	_	18	cc
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	18	conj
22	for	for	IN	_	24	case
23	other	other	JJ	_	24	amod
24	cancers	cancer	NNS	_	21	nmod
25	.	.	.	_	8	punct

1	Moreover	moreover	RB	_	11	advmod
2	,	,	,	_	11	punct
3	combination	combination	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	tailored	tailor	VBN	_	0	ROOT
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	tumor	tumor	NN	_	15	compound
15	type	type	NN	_	11	nmod
16	,	,	,	_	15	punct
17	drug	drug	NN	_	15	conj
18	and	and	CC	_	15	cc
19	administration	administration	NN	_	20	compound
20	schedule	schedule	NN	_	15	conj
21	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	interaction	interaction	NN	_	1	dep
5	and	and	CC	_	4	cc
6	associated	associate	VBN	_	9	amod
7	gastrointestinal	gastrointestinal	JJ	_	9	amod
8	bleeding	bleeding	NN	_	9	compound
9	risk	risk	NN	_	4	conj
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	case-control	case-control	JJ	_	13	amod
13	study	study	NN	_	1	nmod
14	.	.	.	_	1	punct

1	Bleeding	bleeding	NN	_	9	nsubj
2	is	be	VBZ	_	9	cop
3	the	the	DT	_	9	det
4	most	most	RBS	_	5	advmod
5	common	common	JJ	_	9	amod
6	and	and	CC	_	5	cc
7	worrisome	worrisome	JJ	_	5	conj
8	adverse	adverse	JJ	_	9	amod
9	effect	effect	NN	_	0	ROOT
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	9	nmod
13	.	.	.	_	9	punct

1	One	one	CD	_	11	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	factors	factor	NNS	_	1	nmod
5	that	that	WDT	_	7	nsubj
6	might	might	MD	_	7	aux
7	increase	increase	VB	_	4	acl:relcl
8	bleeding	bleeding	JJ	_	9	amod
9	risk	risk	NN	_	7	dobj
10	is	be	VBZ	_	11	cop
11	initiation	initiation	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	interacting	interact	VBG	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	that	that	WDT	_	16	nsubj
16	potentiate	potentiate	VBP	_	14	acl:relcl
17	drug1	drug1	NN	_	16	dobj
18	.	.	.	_	11	punct

1	We	we	PRP	_	2	nsubj
2	sought	seek	VBD	_	0	ROOT
3	to	to	TO	_	4	mark
4	evaluate	evaluate	VB	_	2	xcomp
5	whether	whether	IN	_	10	mark
6	initiation	initiation	NN	_	10	nsubj
7	of	of	IN	_	9	case
8	an	a	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	increases	increase	VBZ	_	4	ccomp
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	14	case
14	hospitalization	hospitalization	NN	_	12	nmod
15	for	for	IN	_	17	case
16	gastrointestinal	gastrointestinal	JJ	_	17	amod
17	bleeding	bleeding	NN	_	12	nmod
18	in	in	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	users	user	NNS	_	17	nmod
21	.	.	.	_	2	punct

1	Medicaid	Medicaid	NNP	_	2	nsubj
2	claims	claim	VBZ	_	0	ROOT
3	data	datum	NNS	_	8	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	1999-2005	1999-2005	CD	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	were	be	VBD	_	8	auxpass
8	used	use	VBN	_	2	ccomp
9	to	to	TO	_	10	mark
10	perform	perform	VB	_	8	xcomp
11	an	a	DT	_	14	det
12	observational	observational	JJ	_	14	amod
13	case-control	case-control	JJ	_	14	amod
14	study	study	NN	_	10	dobj
15	nested	nested	JJ	_	14	amod
16	within	within	IN	_	17	case
17	person-time	person-time	JJ	_	15	nmod
18	exposed	expose	VBN	_	17	acl
19	to	to	TO	_	20	mark
20	drug1	drug1	VB	_	18	xcomp
21	in	in	IN	_	24	case
22	those	those	DT	_	24	det
23	18	18	CD	_	24	nummod
24	years	year	NNS	_	20	nmod
25	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	total	total	NN	_	7	nmod
3	,	,	,	_	7	punct
4	430,455	430,455	CD	_	6	nummod
5	drug1	drug1	NN	_	6	compound
6	users	user	NNS	_	7	nsubj
7	contributed	contribute	VBD	_	0	ROOT
8	407,370	407,370	CD	_	9	nummod
9	person-years	person-year	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	use	use	NN	_	9	nmod
13	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	incidence	incidence	NN	_	3	compound
3	rate	rate	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	hospitalization	hospitalization	NN	_	3	nmod
6	for	for	IN	_	8	case
7	GI	gi	NN	_	8	compound
8	bleeding	bleeding	NN	_	3	nmod
9	among	among	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	users	user	NNS	_	8	nmod
12	was	be	VBD	_	3	dep
13	4.48	4.48	CD	_	12	nsubj
14	per	per	IN	_	16	case
15	100	100	CD	_	16	nummod
16	person-years	person-year	NNS	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	95	95	CD	_	19	compound
19	%	%	NN	_	20	amod
20	CI	ci	NN	_	16	dep
21	,	,	,	_	20	punct
22	4.42-4	4.42-4	CD	_	23	nummod
23	.55	.55	CD	_	20	appos
24	-RRB-	-rrb-	-RRB-	_	20	punct
25	.	.	.	_	3	punct

1	Each	each	DT	_	4	det
2	gastrointestinal	gastrointestinal	JJ	_	4	amod
3	bleeding	bleeding	NN	_	4	compound
4	cases	case	NNS	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	matched	match	VBN	_	0	ROOT
7	to	to	TO	_	9	case
8	50	50	CD	_	9	nummod
9	controls	control	NNS	_	6	nmod
10	based	base	VBN	_	13	case
11	on	on	IN	_	13	case
12	index	index	NN	_	13	compound
13	date	date	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	state	state	NN	_	13	conj
16	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	compound
2	users	user	NNS	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	an	a	DT	_	7	det
5	increased	increase	VBN	_	7	amod
6	odds	odds	NNS	_	7	compound
7	ratio	ratio	NN	_	3	dobj
8	of	of	IN	_	10	case
9	gastrointestinal	gastrointestinal	JJ	_	10	amod
10	bleeding	bleeding	NN	_	7	nmod
11	upon	upon	IN	_	12	case
12	initiation	initiation	NN	_	3	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	OR	or	NN	_	3	dep
17	=	=	JJ	_	16	amod
18	1.73	1.73	CD	_	22	nummod
19	-LSB-	-lsb-	-LRB-	_	22	punct
20	95	95	CD	_	21	compound
21	%	%	NN	_	22	amod
22	CI	ci	NN	_	17	dep
23	,	,	,	_	16	punct
24	1.25-2	1.25-2	CD	_	25	compound
25	.38	.38	CD	_	16	nummod
26	-RSB-	-rsb-	-RRB-	_	16	punct
27	-RRB-	-rrb-	-RRB-	_	16	punct
28	,	,	,	_	3	punct
29	drug3	drug3	NN	_	3	dep
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	OR	or	NN	_	29	appos
32	=	=	JJ	_	31	amod
33	1.63	1.63	CD	_	37	nummod
34	-LSB-	-lsb-	-LRB-	_	37	punct
35	95	95	CD	_	36	compound
36	%	%	NN	_	37	amod
37	CI	ci	NN	_	32	dep
38	,	,	,	_	31	punct
39	1.11-2	1.11-2	CD	_	40	compound
40	.38	.38	CD	_	31	nummod
41	-RSB-	-rsb-	-RRB-	_	31	punct
42	-RRB-	-rrb-	-RRB-	_	31	punct
43	,	,	,	_	29	punct
44	drug4	drug4	NN	_	29	conj
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	OR	or	NN	_	44	appos
47	=	=	JJ	_	46	amod
48	1.64	1.64	CD	_	52	nummod
49	-LSB-	-lsb-	-LRB-	_	52	punct
50	95	95	CD	_	51	compound
51	%	%	NN	_	52	amod
52	CI	ci	NN	_	47	dep
53	,	,	,	_	46	punct
54	1.27-2	1.27-2	CD	_	55	compound
55	.12	.12	CD	_	46	nummod
56	-RSB-	-rsb-	-RRB-	_	46	punct
57	-RRB-	-rrb-	-RRB-	_	46	punct
58	,	,	,	_	29	punct
59	drug5	drug5	NN	_	29	appos
60	-LRB-	-lrb-	-LRB-	_	61	punct
61	OR	or	NN	_	59	dep
62	=	=	JJ	_	61	amod
63	1.47	1.47	CD	_	67	nummod
64	-LSB-	-lsb-	-LRB-	_	67	punct
65	95	95	CD	_	66	compound
66	%	%	NN	_	67	amod
67	CI	ci	NN	_	62	dep
68	,	,	,	_	61	punct
69	1.02-2	1.02-2	CD	_	70	nummod
70	.11	.11	CD	_	61	appos
71	-RSB-	-rsb-	-RRB-	_	61	punct
72	-RRB-	-rrb-	-RRB-	_	29	punct
73	.	.	.	_	3	punct

1	Also	also	RB	_	2	advmod
2	drug1	drug1	NN	_	13	nsubj
3	,	,	,	_	2	punct
4	which	which	WDT	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	believed	believe	VBN	_	2	acl:relcl
8	to	to	TO	_	9	mark
9	interact	interact	VB	_	7	xcomp
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	2	punct
13	increased	increase	VBD	_	0	ROOT
14	the	the	DT	_	15	det
15	risk	risk	NN	_	13	dobj
16	of	of	IN	_	18	case
17	GI	gi	NN	_	18	compound
18	bleeding	bleeding	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	OR	or	NN	_	21	nsubj
21	=	=	JJ	_	13	parataxis
22	1.75	1.75	CD	_	21	dobj
23	-LSB-	-lsb-	-LRB-	_	26	punct
24	95	95	CD	_	25	compound
25	%	%	NN	_	26	amod
26	CI	ci	NN	_	21	dep
27	,	,	,	_	26	punct
28	1.30-2	1.30-2	CD	_	29	nummod
29	.35	.35	CD	_	26	appos
30	-RSB-	-rsb-	-RRB-	_	26	punct
31	-RRB-	-rrb-	-RRB-	_	21	punct
32	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	compound
2	users	user	NNS	_	15	nsubj
3	who	who	WP	_	4	nsubj
4	initiated	initiate	VBD	_	2	acl:relcl
5	drug2	drug2	NN	_	4	dobj
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug5	drug5	NN	_	5	conj
12	,	,	,	_	5	punct
13	or	or	CC	_	5	cc
14	drug6	drug6	NN	_	5	conj
15	had	have	VBD	_	0	ROOT
16	an	a	DT	_	18	det
17	increased	increase	VBN	_	18	amod
18	risk	risk	NN	_	15	dobj
19	of	of	IN	_	20	case
20	hospitalization	hospitalization	NN	_	18	nmod
21	for	for	IN	_	23	case
22	gastrointestinal	gastrointestinal	JJ	_	23	amod
23	bleeding	bleeding	NN	_	18	nmod
24	.	.	.	_	15	punct

1	However	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	the	the	DT	_	5	det
4	elevated	elevated	JJ	_	5	amod
5	risk	risk	NN	_	8	nsubj
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	suggests	suggest	VBZ	_	0	ROOT
9	that	that	IN	_	17	mark
10	a	a	DT	_	12	det
11	drug-drug	drug-drug	JJ	_	12	amod
12	interaction	interaction	NN	_	17	nsubj
13	may	may	MD	_	17	aux
14	not	not	RB	_	17	neg
15	have	have	VB	_	17	aux
16	been	be	VBN	_	17	cop
17	responsible	responsible	JJ	_	8	ccomp
18	for	for	IN	_	19	case
19	all	all	DT	_	17	nmod
20	of	of	IN	_	22	case
21	the	the	DT	_	22	det
22	observed	observe	VBN	_	19	nmod
23	increased	increase	VBD	_	24	amod
24	risk	risk	NN	_	17	dep
25	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	enhances	enhance	VBZ	_	0	ROOT
3	the	the	DT	_	5	det
4	antinociceptive	antinociceptive	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	in	in	IN	_	9	case
9	mice	mouse	NNS	_	5	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	11	nsubjpass
2	,	,	,	_	1	punct
3	a	a	DT	_	7	det
4	highly	highly	RB	_	5	advmod
5	selective	selective	JJ	_	7	amod
6	alpha-2-adrenoceptor	alpha-2-adrenoceptor	NN	_	7	compound
7	agonist	agonist	NN	_	1	appos
8	,	,	,	_	1	punct
9	was	be	VBD	_	11	auxpass
10	recently	recently	RB	_	11	advmod
11	introduced	introduce	VBN	_	0	ROOT
12	into	into	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	practice	practice	NN	_	11	nmod
15	for	for	IN	_	17	case
16	its	its	PRP$	_	17	nmod:poss
17	sedative	sedative	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	analgesic	analgesic	JJ	_	20	amod
20	properties	property	NNS	_	17	conj
21	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	purpose	purpose	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	whether	whether	IN	_	14	mark
10	the	the	DT	_	13	det
11	psychostimulant	psychostimulant	NN	_	13	compound
12	drug	drug	NN	_	13	compound
13	drug1	drug1	NN	_	14	nsubj
14	has	have	VBZ	_	8	ccomp
15	any	any	DT	_	16	det
16	effect	effect	NN	_	14	dobj
17	on	on	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	-	-	:	_	8	punct
20	induced	induce	VBN	_	21	amod
21	antinociception	antinociception	NN	_	8	dep
22	and	and	CC	_	21	cc
23	locomotor	locomotor	NN	_	25	compound
24	inhibitor	inhibitor	NN	_	25	compound
25	activity	activity	NN	_	21	conj
26	in	in	IN	_	27	case
27	mice	mouse	NNS	_	21	nmod
28	in	in	IN	_	30	case
29	acute	acute	JJ	_	30	amod
30	application	application	NN	_	21	nmod
31	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	both	both	DT	_	3	det
3	sexes	sex	NNS	_	0	ROOT
4	of	of	IN	_	7	case
5	swiss	swiss	JJ	_	7	amod
6	albino	albino	NN	_	7	compound
7	mice	mouse	NNS	_	3	nmod
8	;	;	:	_	3	punct

1	antinociception	antinociception	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	assessed	assess	VBN	_	14	csubjpass
4	with	with	IN	_	6	case
5	hot-plate	hot-plate	JJ	_	6	amod
6	test	test	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	the	the	DT	_	9	det
9	locomotor	locomotor	NN	_	6	conj
10	,	,	,	_	6	punct
11	exploratory	exploratory	JJ	_	12	amod
12	activities	activity	NNS	_	6	conj
13	were	be	VBD	_	14	auxpass
14	assessed	assess	VBN	_	0	ROOT
15	with	with	IN	_	19	case
16	holed	hole	VBN	_	19	amod
17	open	open	JJ	_	19	amod
18	field	field	NN	_	19	compound
19	test	test	NN	_	14	nmod
20	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	animals	animal	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	received	receive	VBN	_	0	ROOT
5	;	;	:	_	4	punct

1	saline	saline	NN	_	0	ROOT
2	+	+	CC	_	1	cc
3	saline	saline	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug1	drug1	NN	_	1	conj
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	10	10	CD	_	8	nummod
8	mg/kg	mg/kg	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	+	+	CC	_	1	cc
11	saline	saline	NN	_	1	conj
12	,	,	,	_	1	punct
13	saline	saline	NN	_	1	conj
14	+	+	CC	_	1	cc
15	drug2	drug2	NN	_	1	conj
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	15	15	CD	_	18	nummod
18	g/kg	g/kg	NN	_	15	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	and	and	CC	_	1	cc
21	drug3	drug3	NN	_	1	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	10	10	CD	_	24	nummod
24	mg/kg	mg/kg	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	+	+	CC	_	21	cc
27	drug4	drug4	NN	_	21	conj
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	15	15	CD	_	30	nummod
30	g/kg	g/kg	NN	_	27	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	,	,	,	_	1	punct
33	intraperitoneally	intraperitoneally	RB	_	1	dep
34	,	,	,	_	33	punct
35	30	30	CD	_	36	nummod
36	min	min	NN	_	34	root
37	before	before	IN	_	39	case
38	hot	hot	JJ	_	39	amod
39	plate	plate	NN	_	36	nmod
40	or	or	CC	_	36	cc
41	holed	hole	VBD	_	36	conj
42	open	open	JJ	_	44	amod
43	field	field	NN	_	44	compound
44	tests	test	NNS	_	41	dobj
45	.	.	.	_	36	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	det
3	hot	hot	JJ	_	5	amod
4	plate	plate	NN	_	5	compound
5	test	test	NN	_	21	nmod
6	in	in	IN	_	7	case
7	mice	mouse	NNS	_	5	nmod
8	,	,	,	_	21	punct
9	co-administration	co-administration	NN	_	21	nsubj
10	of	of	IN	_	13	case
11	15	15	CD	_	13	nummod
12	g/kg	g/kg	NN	_	13	compound
13	drug1	drug1	NN	_	9	nmod
14	with	with	IN	_	17	case
15	10	10	CD	_	17	nummod
16	mg/kg	mg/kg	NN	_	17	compound
17	drug2	drug2	NN	_	9	nmod
18	intraperitoneally	intraperitoneally	RB	_	21	advmod
19	not	not	RB	_	20	neg
20	only	only	RB	_	21	cc:preconj
21	enhanced	enhance	VBN	_	0	ROOT
22	,	,	,	_	21	punct
23	but	but	CC	_	21	cc
24	also	also	RB	_	25	advmod
25	prolonged	prolong	VBD	_	21	conj
26	the	the	DT	_	27	det
27	duration	duration	NN	_	25	dobj
28	of	of	IN	_	29	case
29	antinociception	antinociception	NN	_	27	nmod
30	induced	induce	VBN	_	29	acl
31	by	by	IN	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	.	.	.	_	21	punct

1	At	at	IN	_	4	case
2	the	the	DT	_	4	det
3	same	same	JJ	_	4	amod
4	time	time	NN	_	13	nmod
5	,	,	,	_	13	punct
6	the	the	DT	_	9	det
7	locomotor	locomotor	NN	_	9	compound
8	inhibitory	inhibitory	JJ	_	9	amod
9	effect	effect	NN	_	13	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	was	be	VBD	_	13	auxpass
13	counteracted	counteract	VBN	_	0	ROOT
14	by	by	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	13	punct

1	We	we	PRP	_	2	nsubj
2	concluded	conclude	VBD	_	0	ROOT
3	that	that	IN	_	12	mark
4	the	the	DT	_	6	det
5	combined	combined	JJ	_	6	amod
6	administration	administration	NN	_	12	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	may	may	MD	_	12	aux
12	have	have	VB	_	2	ccomp
13	beneficial	beneficial	JJ	_	14	amod
14	effects	effect	NNS	_	12	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	treatment	treatment	NN	_	12	nmod
18	of	of	IN	_	19	case
19	pain	pain	NN	_	17	nmod
20	without	without	IN	_	21	mark
21	causing	cause	VBG	_	12	advcl
22	sedation	sedation	NN	_	21	dobj
23	,	,	,	_	22	punct
24	which	which	WDT	_	25	nsubj
25	limits	limit	VBZ	_	22	acl:relcl
26	the	the	DT	_	27	det
27	use	use	NN	_	25	dobj
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	as	as	IN	_	32	case
31	an	a	DT	_	32	det
32	drug4	drug4	NN	_	25	nmod
33	in	in	IN	_	34	case
34	humans	human	NNS	_	32	nmod
35	.	.	.	_	2	punct

1	Interaction	interaction	NN	_	2	compound
2	study	study	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	with	with	IN	_	9	case
8	co-administered	co-administered	JJ	_	9	amod
9	drugs	drug	NNS	_	2	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	are	be	VBP	_	5	cop
5	drug3	drug3	NN	_	0	ROOT
6	used	use	VBN	_	5	acl
7	in	in	IN	_	8	mark
8	treating	treat	VBG	_	6	advcl
9	urinary	urinary	JJ	_	13	amod
10	and	and	CC	_	9	cc
11	respiratory	respiratory	JJ	_	9	conj
12	tract	tract	NN	_	13	compound
13	infections	infection	NNS	_	8	dobj
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	have	have	VB	_	3	xcomp
6	interactions	interaction	NNS	_	5	dobj
7	with	with	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	that	that	WDT	_	11	nsubj
10	are	be	VBP	_	11	cop
11	active	active	JJ	_	8	acl:relcl
12	in	in	IN	_	15	case
13	gastro	gastro	NN	_	15	compound
14	intestinal	intestinal	JJ	_	15	amod
15	tract	tract	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Being	be	VBG	_	0	ROOT
2	drug1	drug1	NN	_	8	compound
3	and	and	CC	_	2	cc
4	lomefloxacin	lomefloxacin	NN	_	2	conj
5	drug2	drug2	NN	_	8	compound
6	the	the	DT	_	8	det
7	interaction	interaction	NN	_	8	compound
8	study	study	NN	_	1	dobj
9	of	of	IN	_	11	mark
10	was	be	VBD	_	11	auxpass
11	carried	carry	VBN	_	8	acl
12	out	out	RP	_	11	compound:prt
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	,	,	,	_	14	punct
16	drug4	drug4	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug5	drug5	NN	_	14	conj
19	and	and	CC	_	14	cc
20	drug6	drug6	NN	_	14	conj
21	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	at	at	IN	_	11	case
6	neutral	neutral	JJ	_	11	amod
7	,	,	,	_	6	punct
8	acidic	acidic	JJ	_	6	conj
9	and	and	CC	_	6	cc
10	basic	basic	JJ	_	6	conj
11	conditions	condition	NNS	_	4	nmod
12	both	both	CC	_	15	cc:preconj
13	at	at	IN	_	15	case
14	room	room	NN	_	15	compound
15	temperature	temperature	NN	_	11	nmod
16	and	and	CC	_	15	cc
17	37	37	CD	_	18	nummod
18	C	c	NN	_	15	conj
19	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	16	nsubjpass
3	of	of	IN	_	5	case
4	dissolution	dissolution	NN	_	5	compound
5	medium	medium	NN	_	2	nmod
6	simulating	simulate	VBG	_	5	acl
7	various	various	JJ	_	9	amod
8	body	body	NN	_	9	compound
9	environments	environment	NNS	_	6	dobj
10	with	with	IN	_	11	case
11	response	response	NN	_	6	nmod
12	to	to	TO	_	13	case
13	pH	ph	NN	_	11	nmod
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	examined	examine	VBN	_	0	ROOT
17	in	in	IN	_	20	mark
18	order	order	NN	_	17	mwe
19	to	to	TO	_	20	mark
20	elucidate	elucidate	VB	_	16	advcl
21	the	the	DT	_	22	det
22	interactions	interaction	NNS	_	20	dobj
23	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	response	response	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	after	after	IN	_	8	case
8	interaction	interaction	NN	_	2	nmod
9	with	with	IN	_	11	case
10	co-administered	co-administered	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	at	at	IN	_	14	case
13	different	different	JJ	_	14	amod
14	conditions	condition	NNS	_	8	nmod
15	and	and	CC	_	14	cc
16	temperature	temperature	NN	_	14	conj
17	were	be	VBD	_	18	auxpass
18	noted	note	VBN	_	0	ROOT
19	using	use	VBG	_	18	xcomp
20	a	a	DT	_	23	det
21	Shimadzu	Shimadzu	NNP	_	23	compound
22	HPLC	hplc	NN	_	23	compound
23	system	system	NN	_	19	dobj
24	with	with	IN	_	26	case
25	PDA	pda	NN	_	26	compound
26	detector	detector	NN	_	23	nmod
27	.	.	.	_	18	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	seen	see	VBN	_	0	ROOT
4	that	that	IN	_	13	mark
5	interaction	interaction	NN	_	13	nsubj
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	drug1	drug1	NN	_	5	nmod
9	was	be	VBD	_	13	cop
10	more	more	RBR	_	13	advmod
11	at	at	IN	_	13	case
12	37	37	CD	_	13	nummod
13	C	c	NN	_	3	ccomp
14	than	than	IN	_	17	case
15	at	at	IN	_	17	case
16	room	room	NN	_	17	compound
17	temperature	temperature	NN	_	13	nmod
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	reacts	react	VBZ	_	0	ROOT
5	faster	faster	RBR	_	4	advmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	drug4	drug4	NN	_	7	conj
10	in	in	IN	_	12	case
11	acidic	acidic	JJ	_	12	amod
12	media	media	NNS	_	7	nmod
13	whereas	whereas	IN	_	4	dep
14	with	with	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	in	in	IN	_	18	case
17	basic	basic	JJ	_	18	amod
18	media	media	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	drug6	drug6	NN	_	18	conj
21	in	in	IN	_	23	case
22	neutral	neutral	JJ	_	23	amod
23	media	media	NNS	_	18	nmod
24	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	ensures	ensure	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	interaction	interaction	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	10	case
9	selected	select	VBN	_	10	amod
10	class	class	NN	_	5	nmod
11	of	of	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	achieve	achieve	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	effective	effective	JJ	_	8	amod
7	therapeutic	therapeutic	JJ	_	8	amod
8	effect	effect	NN	_	4	dobj
9	appropriate	appropriate	JJ	_	11	amod
10	time	time	NN	_	11	compound
11	intervals	interval	NNS	_	17	nsubj
12	between	between	IN	_	13	case
13	administrations	administration	NNS	_	11	nmod
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	is	be	VBZ	_	17	cop
17	essential	essential	JJ	_	8	acl:relcl
18	.	.	.	_	4	punct

